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ABSTRACT OF THE DISSERTATION 
 
Microfluidics for the analysis and synthesis of radiopharmaceuticals 
 
by 
 
Noel Ha 
Doctor of Philosophy in Bioengineering 
University of California, Los Angeles, 2018 
Professor Robert Michael van Dam, Chair 
 
Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-
emitting isotopes are injected into patients just prior to performing a positron emission 
tomography (PET) or single photon emission computed tomography (SPECT) scan. 
These imaging modalities are widely used in clinical care, as well as in the development 
and evaluation of new therapies via clinical trials. Unlike ordinary pharmaceuticals, the 
short lifetime of radiopharmaceuticals requires that they be produced in relatively small 
batches close to the geographical location where the patient is scanned.  
Since PET tracers are classified as drugs by regulatory agencies, they must pass 
stringent quality control (QC) tests after their production to ensure patient safety prior to 
injection. Performing and documenting these tests is cumbersome and time-consuming, 
and requires an array of expensive analytical chemistry equipment and significant 
 iii 
dedicated lab space, and there is considerable interest in the development of 
automated and lower-cost approaches.  
 By replacing conventional techniques with lab-on-a-chip technologies, it may be 
possible to achieve further reductions in the size, cost, and complexity of automated QC 
testing platforms. While some advances have been made for some of the many QC 
tests, high-resolution miniaturized methods suitable for assessment of chemical or 
radiochemical identity and purity are notably missing. We have been exploring 
microchip capillary electrophoresis (MCE) as a potential means to fill this gap. We have 
shown the potential to perform chemical identity and purity analysis by successful 
separation of the PET tracer [18F]FLT from all of its side products, with comparable limit 
of detection as HPLC. More recently, we demonstrated first-in-field work to add 
radiation detection to the MCE system, using a high-resolution positron detector to 
perform the radiochemical identity analysis of PET tracers.  
Microfluidic systems are also useful for the synthesis of radiopharmaceuticals 
such as radiolabeled peptides and antibody fragments, which provide a means to image 
disease-specific targets with extremely high specificity. To substantially reduce the high 
cost of radiolabeling, we have explored the feasibility of using a microdroplet reactor 
approach. As an example, a thiol-containing RGD peptide was labeled with fluorine-18 
in a site-specific manner via the maleimide-based prosthetic group, [18F]FBEM on a 
microfluidic chip. We have also explored the site-specific radiofluorination of engineered 
antibody fragments (diabody) for ImmunoPET imaging via this microfluidic approach. 
These studies, and other work on small-molecule synthesis, have shown that 
there are advantages in performing radiochemistry in microdroplets. Active means of 
 iv 
manipulating microdroplets, such as electrowetting-on-dielectric (EWOD) provides more 
flexibility of reaction implementation than passive methods, but EWOD devices are well 
known to suffer from a charging effect and the dielectric and hydrophobic layers have 
been found to suffer defects during harsh chemical reactions. Therefore, a novel droplet 
actuation mechanism, electro-dewetting, has been developed to address these 
challenges. Electro-dewetting uses an electric field formed inside a droplet to 
manipulate the adsorption of ionic surfactant molecules on the solid surface to change 
the contact angle. The underlying mechanism of this pheromone has been elucidated.   
We believe that all the work described here shows the potential for dramatic 
miniaturization of the complete PET tracer production process, and ultimately increasing 
the availability of diverse PET tracers for research use, further development, and clinical 
translation via lowering the cost and complexity of tracer production. 
 v 
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1. Chapter 1: Introduction 
 Positron emission tomography (PET) 
Positron emission tomography (PET) and single photon emission tomography 
(SPECT) are real-time, 3D imaging techniques that have unparalleled specificity and 
sensitivity for visualizing biochemical processes in living subjects [1], [2]. The 
information from a PET or SPECT scan is used clinically in disease diagnosis, 
prediction of response to therapy, and monitoring of response to therapy [1], [3]–[7]. 
PET is also an indispensable research tool for uncovering mechanisms of disease 
initiation and progression, developing new therapies, measuring and optimizing the 
pharmacokinetic properties of new therapeutic compounds, and evaluating new 
therapies in clinical trials [8].  PET and SPECT both rely on the injection of a 
radioisotope-labelled compound, known as a radiotracer or radiopharmaceutical, into 
the patient that targets specific receptors, enzymes, or proteins and allows their location 
and density/activity to be measured via radiation detectors during a PET or SPECT 
scan. PET employs radiotracers labelled with positron (β+)-emitting isotopes (e.g. F-18, 
C-11, O-15, N-13, Ga-68, Cu-64, Zr-89, etc.), which release positrons upon decay. 
These positrons rapidly annihilate with nearby electrons to form two anti-parallel gamma 
(γ) rays (511 keV each) that are detected by a ring of detectors [2]. SPECT typically 
utilizes radioisotopes that directly emit γ rays (e.g. Tc-99m, I-123, In-111, etc.) which 
are detected using a collimator and gamma camera [9]. In both cases, many decay 
events are detected to enable reconstruction of the three-dimensional radiotracer 
distribution in the body. Due to the short half-life of PET and SPECT radioisotopes, 
labeled tracers must be manufactured just prior to imaging (Figure 1-1).  
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 PET tracer production; Radiochemistry 
Among many radioisotopes, fluorine-18 (F-18) is the most commonly used 
radioisotope in clinical PET. This is in part due to its relatively low positron emission 
energy (maximum 635 keV) and thus short positron linear range in the tissue, resulting 
in higher resolution than other isotopes. Its half-life (109.8 min) is long enough to allow 
production, purification, testing, and delivery of radiolabeled tracers, as well as to give 
access to relatively extended imaging protocols [10], [11]. In addition, the strong 
covalent bond it forms with carbon atoms results in tracers with good in vivo stability 
[13]. 
Figure 1-1. Workflow of PET and SPECT tracer production 
Production of positron emission tomography (PET)/single photon emission tomography (SPECT) 
radiotracers for clinical imaging involves generation of the radioisotope (via cyclotron or 
generator), radiosynthesis, purification (via HPLC or solid-phase extraction), formulation (via 
evaporative or solid-phase extraction methods), followed by quality control (QC) testing to ensure 
safety of the formulated radiotracer prior to injection. 
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Numerous methods have been developed for efficient incorporation of F-18 into a 
variety of structurally diverse compounds. Most methods rely on nucleophilic aliphatic or 
nucleophilic aromatic substitution reactions starting from [18F]fluoride [14]. In the case of 
PET, the majority of scans are currently performed using the glucose analog 2-
[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) as a wide range of conditions can be detected 
via altered metabolism [5], [11], [15], but there is a growing interest in visualizing more 
diverse biological processes and biomarkers using other tracers [16], [17]. Not all 
tumors show high [18F]FDG uptake. Also, tumors near brain or heart can be difficult to 
see due to high uptake of  [18F]FDG. In addition, inflammatory processes can cause 
false-positive FDG-PET scans [18]. On top of that, [18F]FDG uptake reveals little about 
the molecular phenotype of the tumor requiring additional approaches [19]. 
 In combination with other tracers, PET can provide even more specific 
diagnoses based on the detection of specific underlying molecular alterations 
associated with many health conditions. PET also provides tremendous benefit in the 
process of developing new targeted drugs and companion diagnostics for precision 
medicine, as well as in the development of novel gene- and cell-based therapies [20]. 
Routine access to tracers other than [18F]FDG could accelerate progress in all of these 
areas. 
 Microfluidics in PET tracer production 
PET tracer production requires specialized equipment, infrastructure, technology, 
and expert personnel, resulting in the high cost and complexity of the production [21]. 
Currently, PET tracers for clinical PET service are produced in a centralized manner by 
commercial PET radiopharmacies. Most universities operate in a similar, centralized 
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manner with a core radiochemistry facility to produce PET tracers for research 
laboratories [21]. By spreading the significant costs over many customers in the 
production of one tracer, commercial radiopharmacies have significantly lower the cost 
of [18F]FDG for clinical and research use.  
Although many other PET tracers are being used in preclinical settings and some 
in clinical trials, the cost of these tracers compared to [18F]FDG is prohibitive, especially 
for non-clinical studies, and cannot be provided at a reasonable price due to relatively 
low demand and thus inability to coordinate schedules for shared production [22], [23].  
To increase the diversity of PET tracers available at low cost will require a 
fundamental reduction in the production cost, and this requires new technologies.   
One approach is miniaturized radiosynthesizers, which have the potential to 
dramatically reduce the cost of the synthesizer itself, as well as the amount of radiation 
shielding infrastructure needed for operation. Other emerging technologies, such as 
automated and microscale quality control testing, will further reduce equipment, 
personnel, and documentation costs and simplify production.  
A key technology driving miniaturization is the use of microfluidics. It has been 
well established that microfluidic devices offers many advantages for the synthesis of 
radiopharmaceuticals [24]–[26]. In particular, the small dimensions enable improved 
control of reaction conditions that can lead to faster and higher yield production, and  
reduce the reagent consumption and overall cost of the system.  
The emerging technology of digital microfluidics is opening the possibility of 
performing radiochemistry and analyzing radiopharmaceuticals at the microliter scale. In 
digital microfluidic devices, reagent droplets are controlled electronically, providing high 
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reliability, a compact control system, and flexibility for diverse syntheses with a single-
chip design. Keng et al. has demonstrated the successful synthesis of several PET 
tracers using a digital microfluidic device based on the digital manipulation of droplets 
between two parallel plates (electrowetting-on-dielectric device) [27]. 
More recently, a large number of microfluidic systems have been introduced for 
various steps in PET tracer production including radiosynthesis [23],[28]–[30], 
radioisotope concentration [31], tracer formulation and concentration [32], and quality 
control of tracers [33]. 
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2. Chapter 2: Microfluidic Quality Control Testing of Radiopharmaceuticals 
 Quality control testing of PET tracers 
Since PET tracer is injected into humans and defined as drug, there are strict 
regulatory requirements for performing quality control (QC) testing of the purified, 
formulated product of each batch that is produced, to ensure safety before they can be 
released for clinical use [34], [35]. Specific procedures and requirements for these tests 
are described in regulatory documents published in each country or region (e.g. U.S. 
Pharmacopeia (USP) General Chapter <823> [36, p. 823] and U.S. Food and Drug 
Administration (FDA) 21 CFR Part 212 [37]; European Pharmacopoeia (EP) [38]). 
Procedures specific to the PET tracer [18F]FDG have been discussed in detail in several 
review articles [39], [40]. In general, pharmaceutical tests (e.g., pH, color and clarity, 
chemical purity, residual solvents, pyrogenicity, sterility) are required to ensure 
physiological compatibility of the final preparation and the absence of microbiological, 
pyrogenic, chemical or particulate contamination. In addition, radioactive tests (e.g., 
radiochemical identity, radiochemical purity, radioisotope identity, radioisotope purity, 
and radioactivity concentration) are required to ensure there are no radioactive or 
radionuclidic impurities that could interfere with the biodistribution or imaging protocol 
and to ensure the proper patient dose [41]. 
Performing and documenting these required QC tests is cumbersome and time-
consuming, and requires an array of expensive analytical chemistry equipment and 
significant dedicated lab space. In addition, for most tests, manual handling, loading, 
and/or visual assessment of samples leads to significant radiation exposure to 
personnel and operator-induced variability in the results. In particular Ferguson et al. 
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found that QC personnel received significant radiation exposure, especially due to 
performing sterility (filter integrity), pH, and chemical/radiochemical purity and identity 
testing [42]. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-
lived PET radiopharmaceuticals has to be manufactured and tested within a short 
period of time to prevent significant losses due to radioactive decay [41]. 
Several companies, including QC-1 (Munster, Germany) [43], Trace-ability 
(Culver City, CA USA) [44], and ABT Molecular Imaging Inc. (Louisville, TN USA) [45], 
[46], have been developing QC systems that automatically perform the tests and also 
handle the majority of the needed equipment calibrations, performance testing, and 
report generation. After further development and appropriate validation, such automated 
QC testing systems have the potential to significantly alleviate the labor burden and 
decrease radiation exposure.   
More recently, there have been efforts to miniaturize the instrumentation for QC 
testing by using microfluidics, much like the efforts to miniaturize other stages of 
radiotracer production (radioisotope concentration, radiosynthesis, purification, and 
formulation) [20], [24], [32], [47], [48]. Microfluidic QC systems could lead to significantly 
lower instrumentation cost and reduction of needed laboratory space. Microfluidic 
techniques in general also offer many other important advantages over their 
conventional counterparts, including vastly reduced sample and reagent consumption, 
shorter analysis times, higher detection sensitivity, and increased multiplexing or 
parallelism [20], [49]. Furthermore, the fabrication and material cost of many techniques 
used in microfluidic QC systems can be very low, potentially enabling tests to be 
implemented with a disposable fluid path. These advantages could be especially helpful 
 8 
in conjunction with emerging technologies that produce smaller batches of PET/SPECT 
tracers at a time (each requiring QC testing), including dose-on-demand approaches 
[28].  
While the field is still far from achieving a fully-integrated microscale QC testing 
platform, we highlight in this review the significant progress that has been made in 
developing microscale implementations suitable for several of the required QC tests for 
radiopharmaceuticals and pharmaceuticals.  
 Miniaturization of quality control (QC) tests 
Testing of PET and SPECT radiopharmaceuticals involves several specific 
measurements to ensure product purity, identity, and biological safety for human 
subjects [36], [38].  The detailed criteria for passing each test depend on the particular 
radiopharmaceutical and method of preparation, but in many cases the tests are similar 
or identical across a broad range of radiotracers. Below, we describe each of the 
required tests and the conventional method(s) for performing them, and then describe 
current efforts to directly miniaturize each test or discuss examples from the field of 
microfluidics that could be implemented to miniaturize the test. 
 pH test 
pH must be controlled to ensure both the stability of the formulated 
radiopharmaceutical (to ensure it does not degrade between manufacturing and 
injection) and its physiological compatibility with the patient.  Due to the high buffer 
capacity of the blood and the relatively small injection volume (typically 1-10 mL), a 
relatively wide pH range (typically 4.5 – 8.5) is considered to be acceptable from a 
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physiological point of view [41]. The requirement for stability often shrinks the 
acceptable range. The pH of the formulated radiotracer is most commonly measured 
using a calibrated electronic pH meter or pH indicator strips.  
While there are a myriad of approaches and technologies developed for the 
measurement of pH, to the best of our knowledge, there is only one report (aside from a 
brief mention in a patent [50]) on application of a microscale approach to pH 
measurement of radiopharmaceuticals. Tarn et al. described a simple, 3-layer, glass 
microfluidic device, in which the sample is first combined with a universal pH indicator in 
an on-chip mixer, and the optical absorbance of the mixture is measured with a 
spectrometer connected via optical fibers to an extended flow-cell in the chip (Figure 
2-1A)  [51]. The absorption spectrum of the indicator shifts as a function of pH, and a 
calibration was created using reference standards to relate the pH value to the 
absorbance at that wavelength. With this device, the pH of small samples (<2 µL) of 
[18F]FDG solutions could be determined (in the pH range 1 – 13) within a few minutes. A 
second analysis method was also reported, where the absorbance was monitored at 
multiple wavelengths to obtain a “fingerprint” of the sample, which could be “matched” 
with fingerprints of standards. The flow cell is an important part of the implementation as 
the small dimensions of microchannels can lead to low optical path lengths (OPL) and 
thus low absorbance values and low detection sensitivity. A variety of detection cell 
designs have been reported in the literature that incorporate (i) an extended optical path 
to increase absorbance by the sample, (ii) multiple passes of the illumination light 
through the sample to increase absorbance, or (iii) or an optical resonator that is filled 
with the sample. These approaches were reviewed by Rushworth et al. [52]. 
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A wide variety of other microfluidic methods for measuring sample pH have been 
reported [53].  These include miniaturized approaches based on traditional pH 
indicators or electrochemical cells, as well as approaches based on detection of 
physical or optical changes in pH-responsive coatings. Many of these approaches could 
presumably be applied to pH analysis of radiopharmaceuticals, provided they have a 
sufficiently wide working pH range and fast analysis time.  A few examples of these 
approaches are discussed below. 
Maruyama et al. used gel microbeads impregnated with pH indicator to measure 
local pH in the sample immediately surrounding the bead (Figure 2-1B) [54]. The gel 
microbeads, positioned with optical tweezers, changed color within a few seconds when 
in contact with sample solution indicating the local pH over the range 5.8 – 9.0. Maclin 
et al. reported a similar approach in which the indicator was contained in nanocapsules 
immobilized in high-porosity polyvinyl alcohol matrix [55], and demonstrated analysis of 
30 µL sample volumes within 2 min spanning a pH range of 2.7 to 12.6.  An advantage 
of these approaches is more accurate measurements (since they avoid adding the 
indicator into solution, which, in high quantities, can affect the pH being measured). 
Furthermore, because mixing is not required, the implementation can be simpler. 
Other approaches for pH measurement are based on detectable changes in a 
pH-sensitive coating.  For example, Mela et al. reported the detection of pH by 
modifying the internal surface of a microfluidic channel with the pH-sensitive fluorescent 
dye Oregon Green 514 (Figure 2-1C) [56]. By monitoring fluorescent emission intensity, 
pH in the range 2-10 could be measured in real time as an aqueous sample flowed 
through a 20 x 2 µm channel inside a PDMS/glass chip. Florea et al. described a device 
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in which the surface of a microchannel was coated with polyanaline [57]. pH of the 
sample flowing through the device affects the optical properties of the polymer coating 
resulting from a reversible protonation/deprotonation reaction. Response could be 
detected over the pH range 2 – 12 in real time (Figure 2-1D). 
In addition to optical changes, pH can induce changes in density, volume, and 
stiffness of coatings such as hydrogels that can be detected as changes in refractive 
index, electrical resistance, natural frequency of mechanical oscillation, etc. These 
approaches have been described in a comprehensive review [58]. In one example of 
these approaches, Trinh et al. reported a hydrogel-based piezoresistive pH sensor, in 
which a hydrogel was placed between a stiff, porous grate and a piezoresistive bending 
plate transducer [59]. pH-induced swelling of the hydrogel deflected the plate and 
caused a detectable resistance change, allowing detection of pH values in the range 5.5 
– 11 within 12 min.  
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Examples of microfluidic pH measurement systems. (A) (Left) Microfluidic device to mix a sample 
with a universal pH indicator and then measure optical absorbance in a 3.1 mm long detection 
cell. (Right) Representative absorbance measurements at 551 nm as a function of sample pH. 
Adapted with permission from [51] Copyright © 2014 The Chemical and Biological Microsystems 
Society. (B) (Top) pH-sensing polymer microbeads are prepared by introducing the pH indicator 
during the cross-linking process. (Bottom) The beads are immobilized using optical tweezers or 
tethered to the surface, and the color of each bead reflects the pH of the local environment. 
Adapted from [54] with permission of The Royal Society of Chemistry. (C) Microfluidic device with 
internal channel surface coated with pH-sensitive fluorescent molecules (Oregon Green 514). The 
fluorescence intensity is correlated with pH. Adapted from [56] with permission of The Royal 
Society of Chemistry. (D) (Left) PDMS microfluidic channel with polyaniline coating that changes 
color in response to pH. The zoomed in image shows the response to a pH gradient along the 
channel.  Inset SEM image shows the structure of the coating layer. (Right) Absorbance spectra 
of the polyaniline coating when exposed to solutions of different pH. Adapted from [57] with 
permission of The Royal Society of Chemistry. (E) Micro-cantilever undergoes deflection in 
response to pH-dependent swelling of a hydrogel polymer coating. Deflection is monitored with a 
laser beam. Adapted with permission from [60] Copyright © 2003 Springer. (F) Thin-film 
electrodes integrated into a PDMS chip allow pH to be measured based on potential between 
working and reference electrodes. Adapted with permission from [61] Copyright © 2006 Elsevier. 
(G) Flow-based microfluidic pH measurement system using ion-sensitive field-effect transistor 
(ISFET) sensors, one acting as a reference and one as a working electrode. Modulation of flow 
Figure 2-1. Examples of microfluidic pH measurement systems.  
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rates moves the liquid junction and allows measurement of the sample solution (SS) after an 
initialization process using a baseline solution (BLS).  Adapted from [62] with permission from 
MDPI AG. 
 
In a similar approach, Hilt et al. [60] reported the use of a hydrogel coating on a 
micro-cantilever that could respond to changes in environmental pH resulting in a 
surface stress that deflected the cantilever (Figure 2-1E). By measuring the deflection 
with a laser beam reflecting from the cantilever surface, pH measurements in the range 
2.8 – 6.8 were reported.   
pH can also be detected via electrochemical reactions, in which the electrical 
potential is sensitive to the pH of the sample solution in the electrochemical cell. A wide 
variety of implementations of electrochemical cells have been reviewed [33,40] and a 
few examples of microscale cells reported for pH measurement are given below. Lin et 
al. developed a microfluidic continuous-flow pH measurement chip by integrating thin-
film pH-sensing electrochemical electrodes into in a PDMS chip (Figure 2-1F) [61]. The 
free hydrogen atoms of the sample react with the sensing electrodes (fabricated by 
sputtering layers of SiO2–Li O2–BaO–Ti O2–La2O3 (SLBTLO) on platinum (Pt) 
electrodes) inducing a detectable change in potential with respect to the reference 
electrode (Ag electrode with thin coating of AgCl). pH measurements in the range pH 2 
to 10 could be made using only ~0.5 µL sample volume and 200 s duration. Yamada 
and Suzuki developed a flow-based microfluidic pH measurement system using ion-
sensitive field-effect transistor (ISFET) sensors for measurement of the proton 
concentration (Figure 2-1G) [62]. Two ISFET sensors and an Ag/AgCl pseudo 
reference electrode are fitted into a microfluidic Y-junction such that the reference 
ISFET and reference electrode are always immersed in a stream of baseline solution 
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and the measurement ISFET is immersed in baseline solution or the sample, depending 
on a switchable flow. Under a continuous flow, sample solution could be measured in 
<120 s with a wide detection range (pH 1.68–10.0). Though the authors reported 2.0 mL 
sample consumption per measurement due to filling and flushing the external tubing 
and syringe pumps, the dimensions of the microfluidic chip suggest the detection 
volume was < 14 µL, a value that can be compared with other papers. 
 Appearance test (Optical clarity test) 
In general, only a clear and colorless, particulate-free solution should be used for 
injection. Formulated PET and SPECT tracers are generally colorless due to the lack of 
appreciable absorbance by the tiny amounts of tracer used (e.g. pmol to nmol for a 
~370 MBq (10 mCi) single patient dose of a 18F-labeled PET tracer, or nmol to µmol for 
a >37GBq (>1 Ci) multi-dose batch). Any coloration would indicate a significant quantity 
of an impurity. Generally, the test is performed manually, via qualitative visual 
inspection, resulting in variability in the readout. 
Using the same microfluidic device as described above for pH testing, Tarn et al. 
reported automation of a quantitative optical clarity test for [18F]FDG [51]. A non-clear 
sample could be detected when the absorbance exceeded that of a reference solution 
(water). Though this appears to be the only microfluidic implementation of the 
appearance test applied specifically to the analysis of radiopharmaceuticals, it is likely 
that any of the other strategies described above based on optical absorbance could also 
be used to implement a miniature optical clarity test based on the same principle. 
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 Sterility test 
According to the FDA document “current good manufacturing practice for PET 
drugs” [63], even if care is taken to minimize microbiological contamination during 
synthesis, a drug is considered to be nonsterile until it is passed through a sterilizing 
grade filter. Generally, radiopharmaceutical production can use commercially available, 
pre-sterilized filters, provided that the vendor has been shown to be reliable and the 
filter meets certain specifications. Conventionally, sterility is assessed by inoculating the 
filtered sample into two types of culture media (soybean-casein digest medium (SCDM) 
to culture aerobic bacteria and fungi, and fluid thioglycollate medium (FTM) to culture 
anaerobic bacteria), incubating for ≥14 days, and then looking for formation of colonies 
[64]. However, because this timeframe is much longer than the half-life of SPECT and 
PET radioisotopes, the FDA allows a quick, short-term test to be used to enable early 
release of the radiotracer (though the culture test must still be completed). In the short-
term test, the integrity of the filter membrane is assessed (typically via a bubble point 
test) after completing sterile filtration. In this test, compressed gas is applied to the inlet 
of the wetted filter and pressure is increased until bubbling appears at the outlet (i.e., 
the bubble point). If the bubble point exceeds a threshold pressure, then it can be 
assured that the membrane is intact and pores do not exceed the specified size. A 
drawback of this test is that the operator has to manually handle the filter membrane 
and it has been reported that this test results in the largest radiation dose to QC 
personnel [42].  
Although not yet demonstrated specifically for the analysis of 
radiopharmaceuticals, microfluidics may provide a way to directly assess sterility in a 
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much shorter time than 14 days, and potentially obviate the need for the bubble point 
test. In the conventional culture test, the long duration is essentially needed for 
amplification, i.e. to allow many cycles of growth, such that any bacterial colonies could 
be detected visually. This growth amplification step could be omitted for high-sensitivity 
microfluidic approaches that enable direct detection of individual microorganisms in 
liquids [65]. 
A large number of reports (reviewed in [65]–[68]) have demonstrated the 
detection of small numbers of bacteria (even single cells). Some strategies rely on PCR 
amplification of specific DNA sequences, or sensitive assays of specific surface 
antigens or metabolites. In one example, Jung et al. reported an integrated microfluidic 
device capable of detection and identification of as few as 1 colony-forming unit (CFU) 
in a 10 µL sample via a sandwich-type assay within 30 min [69]. In the assay, bacteria 
are bound by two types of particles functionalized with antibodies that target the 
bacteria. The magnetic particles allow the bacteria to be immobilized using a magnetic 
field while unbound particles were washed away, and then “barcode” DNA was released 
from the other particle for analysis by an electrophoretic separation and detection unit.  
Despite impressive sensitivity and operation speed, such methods may not be suitable 
for QC testing of radiopharmaceuticals because they detect only the specifically-
targeted pathogens rather than all pathogens.  
 This can be partially addressed by incorporating certain types of “universal” PCR 
primers or bacterial stains that target broad classes of pathogens. For example, Lantz et 
al. reported a high-sensitivity microfluidic device capable of detecting diverse bacteria 
and fungi down to the single cell level [70]. The sample was stained with the dye 
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BacLight Green, then a series of plugs (sample, buffer, and “blocking agent”) were 
injected into a capillary/channel causing aggregation of cells when electrophoretic 
potential was applied (Figure 2-2A). The concentration process, combined with 
fluorescence measurement over a 10 min integration time resulted in high detection 
sensitivity. 
Rather than relying on specific biochemical markers, other rapid approaches for 
bacterial detection have been reported that are based on detection of physical 
properties such as electrical impedance of single cells (reviewed in  [71], [72]). In 
impedance-based flow cytometry, the sample solution is focused down into a narrow 
channel containing a detector such that at most only one cell at a time flows over a 
region with detection electrodes. When there is a cell within the detection region, the 
impedance differs from that of the buffer due to capacitance of the cell membrane and 
possibly differing resistance of the cell contents. Haandbæk et al. reported a resonance-
enhanced microfluidic impedance cytometer for detection of single bacteria (Figure 
2-2B) [73]. After focusing cells to the center of the channel via DEP, bacterial cells 
passing over downstream electrodes were detected and characterized by frequency 
and phase shifts an electrical resonator. With the sample flowing at a speed of 0.5 
µL/min, the system was able to detect single particles as small as 0.9 µm in diameter, 
as well as distinguishing different sizes and types (bacteria or polymer bead) of 
particles.  
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Though extensive validation and other work would be needed, it seems that 
microfluidic approaches like impedance cytometry might be capable of performing a 
rapid sterility test by counting the number of bacterial cells in a sample if throughput can 
be increased to measure a sufficiently large representative sample (e.g., 100 µL) of the 
radiopharmaceutical formulation without compromising detection sensitivity. If such a 
technique could be realized, there would potentially be no need for the filter integrity 
test.  
 Bacterial Endotoxin test 
Bacterial endotoxins, lipopolysaccharides (LPS), are toxic components of the 
outer membrane of gram-negative bacteria that can cause fever and possibly 
leukopenia in immunosuppressed patients [41]. Because endotoxins can contaminate a 
solution even if the bacteria have been thoroughly removed via sterile filtration, it is 
necessary to test radiopharmaceutical formulations for their presence. According to the 
USP Bacterial Endotoxins Test (General Chapter <85>) [74], the maximum allowable 
Figure 2-2.  Microfluidic methods for detection of bacteria. 
(A) A microbial sample with “universal” fluorescent stain is concentrated by capillary 
electrophoresis to improve detection sensitivity. (BA = “blocking agent”). Adapted with permission 
from [50] Copyright © 2007 American Chemical Society (B) Impedance-based bacterial detection 
chip. Cells are first focused via dielectrophoresis (DEP) to the center of channel for downstream 
detection. A detectable shift in resonant frequency and phase occur when a single cell or particle 
passes through the measurement area due to a change in the channel impedance. Adapted from 
[53] with permission of The Royal Society of Chemistry. 
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endotoxin level in radiopharmaceutical injections is 175 EU/V, where V is the maximum 
volume (mL) of drug administered at the time of expiration (1 EU = 100 pg of 
Escherichia coli LPS). The conventional test for bacterial endotoxins is based on a 
multi-step biochemical pathway leading to activation of a clotting enzyme that occurs 
when bacterial endotoxins are mixed with Limulus amebocyte lysate (LAL) derived from 
blood cells of horseshoe crabs (Limulus polyphemus or Tachypleus tridentatus) [75]. 
The enzyme acts on a coagulogen to create a “clot” in the test sample (“gel clot 
method”) or to increase its turbidity which can be optically detected (“turbidimetric 
method”). Alternatively, if a chromogenic substrate is added, a color change can be 
detected (“chromogenic method”). The timescale of clotting, turbidity increase, or color 
change is related to the endotoxin concentration. Several commercial reagent kits and 
test instruments are currently available and are routinely used in QC testing of 
radiopharmaceuticals [75]. 
One of these commercial systems (EndoSafe, Charles River Laboratories, 
Wilmington, MA, USA), already in widespread use in testing of radiopharmaceutical 
formulations, performs a small-scale version of the chromogenic assay in 15 min using 
disposable ~25 mm x 75 mm microfluidic cartridges pre-loaded with reagents (Figure 
2-3A) [76]. In this system, a 25 µL sample is loaded on the cartridge, mixed with the 
LAL reagent and then combined with the chromogenic substrate, incubated, and finally 
the color intensity is measured over time via a small handheld spectrophotometer-based 
reader. This system can detect down to 0.005 – 10 EU/mL. Though not specifically 
applied to radiopharmaceutical analysis, one group demonstrated a similar assay in a 
microfluidic chip (18 mm W x 62 mm L)  made of PDMS (Figure 2-3B)  [77]. After 
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mixing the sample with reagents outside the chip, a 4 µL sample was injected and result 
could be obtained after 10 min. To match the capabilities of the EndoSafe device, the 
PDMS chip would have to be modified to include analysis of a replicate as well as 
positive controls.  
Miao et al. reported an electrochemical approach that replaced the optical 
readout of the standard gel clot assay with an electrical readout [78]. Millimeter-sized 
screen-printed electrodes were inserted in a small volume of a mixture of the sample 
and LAL reagent (270 µL) at 37 °C and the electrical current was monitored over time 
(Figure 2-3C). Onset of gel clotting resulted in a rapid drop in current, the timing of 
which could be correlated with endoxtoxin concentration. Response time was fast (< 
100 s) and a detection limit of 0.03 EU/mL was reported. 
In addition to miniaturized versions of the standard LAL assay, there has been 
considerable development of new approaches, including modifications to the standard 
assay to improve sensitivity, as well as miniature biosensors that detect endotoxins 
based on binding with surface-immobilized biomolecules (recently reviewed in [75]).  
For example, Noda et al. a reported a modified LAL assay in which the 
coagulogen was replaced with a luciferin-modified peptide (benzoyl-Leu-Gly-Arg-
aminoluciferin) [79]. When this substrate becomes activated by the LAL cascade (i.e. in 
the presence of endotoxin), the reaction with luciferase produces luminescence, 
allowing very sensitive detection. A detection limit of 0.0005 EU/mL was reported in an 
assay time of 15 min. Though such high sensitivity is not strictly necessary, it may 
provide the capability to use a smaller sample volume.  
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Sensor-based methods rely on detection of endotoxin binding, and can produce 
a signal via fluorescence or luminescence assays, electrical impedance, 
electrochemical reactions, or mechanical resonators. Though many of the approaches 
require lengthy procedures to modify/derivatize the LPS prior to detection or have poor 
sensitivity, there are a few approaches that appear sufficiently fast and sensitive for QC 
testing of radiopharmacuticals. For example, Su et al. demonstrated an impedance-
based readout with a detection limit of 0.05 EU/mL within 10 min [80]. The 
electrochemical biosensor comprised a gold electrode functionalized with an LPS-
specific single stranded DNA (ssDNA) aptamer as a probe (Figure 2-3D). A good linear 
relationship between charge-transfer resistance and logarithm of LPS concentration 
was demonstrated over a wide dynamic range (0.01 – 10 EU/mL). As surface binding 
sensors are often prone to fouling, non-specific binding, or sensitivity to sample matrix, 
a thorough characterization of these factors and validation of the testing method would 
be required.  
Finally, detection of endotoxins has also been reported using miniaturized 
chromatography methods. Makszin et al. used microchip electrophoresis (MCE) to 
separate and detect S-and R-type endotoxin components conjugated with fluorescence 
dyes. Separation took ~1 min and the limits of detection were 2.6 and 6.9 ng for the S- 
and R-type endotoxins [81]. Despite sensitive quantitation, the method required 
significant off-chip processing to perform the conjugation step. 
To summarize, there already exist miniaturized methods validated for performing 
endotoxin testing of radiopharmaceutical formulations. Many other approaches have 
also been developed for endotoxin testing in other applications, which may offer 
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advantages of speed, reagent cost, or convenience of readout if applied to 
radiopharmaceutical samples. 
 Chemical purity and identity 
Chemical purity refers to absence of non-radioactive impurities in the formulated 
PET or SPECT tracer, including side products as well as residues of other components 
Figure 2-3. Examples of microfluidic devices for bacterial endotoxin test. 
(A) Commercial LAL assay system (Endosafe®, Charles River Laboratories, Inc.) comprising 
a portable, hand-held spectrometer (left) and ~25 mm x 75 mm disposable microfluidic 
cartridge (right). Adapted from [56]. (B) Photograph of microfluidic LAL test chip (left) and block 
diagram illustrating detection method (right). Sample mixed with chromogenic substrate is 
loaded into the microchannel and optical detection is performed in the middle of channel. 
Photograph adapted with permission from [57] Copyright © 2004 Springer. (C) Screen-printed 
electrodes for electrical-impedance monitoring of standard gel clot LAL assay. Adapted with 
permission from [58] Copyright © 2013 Elsevier (D) Biosensor comprising a gold electrode 
functionalized with endotoxin-specific aptamer.  Binding of endotoxin is detected via impedance 
spectroscopy. Adapted with permission from [60] Copyright © 2012 Elsevier. 
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used in the production process. The purpose of testing is to ensure that the purification 
process has reduced residual amounts of impurities to safe levels (i.e. below allowed 
limits). The required chemical purity tests for radiopharmaceuticals depends on 
particular synthesis method and only needs to assess reagents added and byproducts 
expected for the particular synthesis route and conditions.  
Though, in rare cases, a specific impurity can be determined via a simplified test 
(e.g., see Kryptofix test, Section 2.6), impurities are typically determined by 
chromatographic techniques, i.e. by performing chemical separation prior to detection. 
For some SPECT and PET radiopharmaceuticals that are labeled by a chelation 
reaction, the most significant impurity is unlabeled radioisotope, which can be detected 
via radio-TLC to determine (see Section 2.10). In other cases, impurities are typically 
quantified using HPLC combined with UV absorbance detection (HPLC/UV) or 
sometimes other modalities such as pulsed amperometric detection. Recently, analysis 
of radio-pharmaceuticals has also been performed using ultra-high performance liquid 
chromatography (UHPLC or UPLC), offering the advantages of faster separation times 
and more compact separation columns [82], [83]. The identity of each peak in the 
detected chromatogram is determined by comparison of retention time with reference 
standards, and the quantity is generally determined from the peak area. For known 
impurities, the amount present in the sample is compared with allowed regulatory limits. 
For unknown impurities, so long as the impurities are below the limit of observed 
adverse effects in preclinical toxicology studies, they may be safe for injection. More 
specifically, it is not required to identify all impurities if microdosing criteria are met, i.e. 
their total mass is <100 μg and if the injected dose contains <1% of the 
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pharmacologically active dose (determined using the same formulation as used in 
preclinical studies). 
Miniaturization of HPLC is one approach that could potentially be used for 
microscale implementation of the chemical purity test, though it has not yet been 
demonstrated for radiopharmaceuticals. In “microchip HPLC”, the HPLC column, and 
often elements of the injection valve, are integrated into a microfluidic chip. One 
implementation uses trapped cylindrical plugs of polymer monolith (formed by in situ 
polymerization) that slide within cylindrical glass microchannels to inject samples into 
the on-chip polymer monolith column [84] (Figure 2-4A). Another implementation that 
has been commercialized (HPLC-chip, Agilent, Santa Clarita, CA, USA) includes an 
integrated micro-rotary injection valve with sample enrichment column serving as the 
injection loop. In this setup samples are injected into an integrated column, flowing to a 
downstream electrospray emitter to nebulize and transfer the sample to a mass 
spectrometric detector [85]  (Figure 2-4B). A recent review discusses the wide range of 
available microchip HPLC systems [86]. With chip-based HPLC, sample volume and 
separation time are significantly reduced (usually nL to µL), as is the physical size of the 
separation medium. However, chip-based HPLC systems still rely on bulky instruments 
that house the high-pressure pumping system, injection valve actuator, and detection 
modules, though efforts are underway to shrink these other components as well [86], 
[87] 
Capillary electrophoresis (CE) is another separation method in which a sample is 
driven through a separation medium by application of an electric field. Species are 
separated based on electrophoretic mobility in the separation buffer, and sometimes 
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based on additional interactions with functionalized particles within the capillary 
(capillary electrochromatography, CEC) or by partitioning of analytes between micelles 
and surrounding buffer (micellar electrokinetic chromatography, MEKC). Unlike HPLC,  
CE can readily be miniaturized into microfluidic chips that are simple to fabricate and 
operate without the need for high-pressure pumps [ 68–70]. Additionally, CE exhibits 
high separation resolution and can achieve high detection sensitivity, and has been 
employed in diverse applications such as protein separation and pharmaceutical 
analysis [91]–[93]. By replacing conventional HPLC methods with microchip 
electrophoresis (MCE), there is much potential to significantly reduce the size, cost, and 
complexity of chemical purity testing systems in the future. Furthermore, sample volume 
is generally reduced by orders of magnitude, and very short analysis times (seconds) 
have been reported [88], [94], [95].  
While there are numerous examples of MCE employed for pharmaceutical 
analysis [93], [96], there have been very few examples of CE methods, and no 
examples of MCE methods, applied to the analysis of radiopharmaceuticals. Separation 
and detection of 99mTc-labeled SPECT compounds has been performed with capillary 
zone electrophoresis and isotachophoresis [97]–[101], and use of CE has been 
suggested for analysis of PET tracers in a patent application [50]. Recently, using the 
PET tracers [18F]FLT and [18F]FAC as model systems, our group explored the feasibility 
of using micellar electrokinetic chromatography (MEKC) to separate neutral tracers from 
neutral impurities, and showed comparable separation and limit of detection as 
HPLC/UV [102]. We further showed that the system could be implemented as a hybrid 
MCE device (unpublished work), and that baseline separation of FLT from its known 
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impurities and very repeatable injections could be achieved using only 4 nL of sample 
(Figure 2-4C)  [94].  
While our work has focused on detection via UV absorbance as a proof of 
concept, additional modes of detection can be implemented using techniques reported 
Figure 2-4 Examples of miniature chromatography systems. 
(A) Microfluidic HPLC system. A sliding fluoropolymer element is used to create a high-pressure 
valve for sample injection. When the element is in the left position, sample can be loaded via the 
sample input port. When the HPLC pump is activated, the flowing buffer closes the valve (slides 
the element to the right) and sweeps the injected sample through the integrated monolith column 
for separation. Adapted with permission from [64] Copyright © 2005 American Chemical Society. 
(B) Commercial HPLC-chip (Agilent)) includes an integrated micro-rotary injection valve with 
sample enrichment column serving as the injection loop, for injecting samples into the integrated 
LC column and downstream electrospray emitter to nebulize and transfer the sample to a mass 
spectrometric detector. Adapted from [65]. (C) Microchip electrophoresis setup with a volumetric 
sample injection chip, a separation capillary, and an optical detection chip. Inset shows 
representative electropherogram showing baseline separation of a mixture of 4 compounds. 
Adapted with permission from [74] Copyright © 2017 Elsevier.  
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in the literature for pulsed amperometric detection [103], capacitively coupled 
contactless conductivity detection (C4D) [104]–[106] , refractive index detection [107], or 
mass spectrometry [108], [109]. For analysis of certain radiopharmaceuticals or 
impurities (e.g. with low UV absorbance), such alternative detection modes may be 
essential. 
Efforts to miniaturize chemical purity testing for radiopharmaceuticals are just 
beginning, but chip-HPLC or MCE could provide a means to analyze a wide variety of 
PET and SPECT tracers with high sensitivity and separation resolution. 
 Kryptofix 2.2.2 (K222) 
2,2,2-Cryptand or 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo [8.8.8]hexacosane, 
also known by its commercial name Kryptofix 2.2.2 (K222), is frequently used as a 
phase transfer catalyst in the manufacture of 18F-labeled PET tracers. 
Radiopharmaceutical formulations must be analyzed for residual amounts of K222 
before human application due to its toxicity. The limit specified in the US 
Pharmacopoeia (USP) is <50 µg/mL and EP limit is 2.2 mg/V (i.e. per patient). Most 
commonly, residual K222 is assessed qualitatively via a TLC method in which the size 
and intensity of spot of K222 from the sample solution should not exceed (by visual 
observation) that of a spotted reference solution [110]. Another method uses a spot test 
in conjunction with iodoplatinate indicator, and can be completed in 5 min (compared to 
30 min for the TLC test) [111]. As with any colorimetric test, there is some risk of non-
specific interactions that could interfere with the test result. For example, the spot test is 
sensitive to tertiary amines, which may be present in the radiotracer itself or impurities, 
potentially leading to false positives. To avoid such issues, K222 is sometimes analyzed 
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after chromatographic separation. Reports have shown that K222 can be detected via 
gas chromatography (GC) with a nitrogen detector [112], liquid chromatography with 
mass spectrometric (MS) detector (LC/MS [113], [114] or UPLC/MS [115]) or HPLC with 
a UV detector (HPLC/UV) with post-column and pre-column derivatization [116].  
Efforts to miniaturize indicator-based tests for radiopharmaceuticals in 
microfluidic chips have been reported. For example, Charles reported the on-chip 
optical absorbance-based detection of K222 by first mixing the sample with 
iodoplatinate reagent then loading the sample into a microchannel [117]. The limit of 
detection was within range of the allowed limits of K222, though the reported data 
suggest that further optimization of the test is warranted. Presumably this approach 
could be combined with an on-chip mixer, and could leverage approaches for high-
sensitivity optical detection systems (see Section 2.1) to further improve sensitivity. 
Other colorimetric K222 indicator chemistries can likely be used in microfluidic 
devices as well. Anzellotti et al. reported an evaluation of the I2/I- indicator for testing 
PET radiopharmaceuticals and suggested that it could be used to test sample volumes 
as low as 2 – 25 µL [118]. Experiments showed that the color change occurred within 1-
2 s, and that the indicator was unaffected by the presence of several salts or amine-
containing PET tracers in the formulation.  
Alternatively, the K222 test could potentially be implemented in miniaturized form 
using microscale chromatographic approaches. For example, we have shown, using 
capillary electrophoresis, that K222 could be separated from FLT and several impurities 
and identified and quantified in <2 min [102], though miniaturized detection in an MCE 
device has not yet been demonstrated. 
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Although initial efforts have been made to miniaturize the K222 test for 
radiopharmaceuticals, further development is needed to demonstrate reliability and 
ease of use for implementation in a radiopharmaceutical QC facility. 
 Residual organic solvents 
Residual solvents in the final formulation could exhibit a variety of toxic effects 
and the remaining amounts of all solvents used during the synthesis and purification 
process must be monitored to ensure residual amounts are below safe limits. Typically 
this test is needed for PET tracers, but often can be omitted for SPECT tracers when 
produced under aqueous reaction conditions. There is clear guidance on the limits for 
many possible solvents [119]. For the commonly used class 2 solvents acetonitrile 
(MeCN), dichloromethane (DCM), and N,N-dimethylformamide (DMF), the allowed limits 
are 4.1 mg/day (410 ppm), 6 mg/day (600 ppm) and 8.8 mg/day (880 ppm), 
respectively. Class 3 solvents such as ethanol (EtOH) and dimethylsulfoxide (DMSO) 
have much lower toxicity, and up to 50 mg/day (5000 ppm, 50mg/V) is allowed for each. 
Typically, residual solvents are assessed using gas chromatography (GC) in 
conjunction with a flame ionization detector. Testing can also be performed via HPLC in 
conjunction with a refractive index detector  [45], [120]  
For the particular application of radiopharmaceutical analysis, a recent 
preliminary study suggests that residual solvent impurities might be quantified via raman 
spectroscopy in a glass microfluidic flow cell [29], though details of the method and its 
performance have not yet been published. A patent application also mentions the 
possibility to detect solvents in radiopharmaceuticals via a gas sensor microarray 
(“electronic nose”) [121] MEMS device, though details are not described [122]. While, in 
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principle, it seems possible that residual solvents could also be assessed via chip-HPLC 
systems [86], [87]  (e.g. with RI detection) or microscale GC systems [123], [124], these 
approaches have not yet been demonstrated.  
Further development is therefore needed to implement a reliable microfluidic 
detection method for organic solvents with the required performance for testing of 
radiopharmaceuticals. 
 Radioactivity measurement (Radioactivity concentration) 
The concentration of radioactivity in every batch of the final drug preparation at 
the end of synthesis (EOS) must be measured [34]. This value is needed to determine 
how much volume to dispense for each individual patient dose (decay-corrected to the 
expected time of injection). The total amount of radioactivity in the vial containing the 
final drug preparation is usually measured using a calibrated dose calibrator. In order to 
determine the concentration, a known volume of the final drug preparation is withdrawn 
into a syringe, the activity of the syringe is measured, and the concentration then 
calculated. 
To miniaturize this test, the sample can be loaded into a microfluidic channel 
placed in close proximity to a compact radiation detector. Taggart et al. have shown that 
a small array of silicon photomultipliers (SiPMs) could measure the radioactivity in a 
sample of PET or SPECT radiotracers ([18F]FDG, [68Ga]gallium citrate, 
[99mTc]pertechnetate) contained in an adjacent 40 µL serpentine microchannel after 
stopping the flow (Figure 2-5A) [125]. The effect of different microfluidic chip materials 
and substrate thicknesses were investigated. In their optimized device, good linearity 
was observed for the PET tracers over a range of ~0.01 to 100 MBq total activity, 
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though upper and lower limits were not reported. The signal for the SPECT tracer 
required longer integration time to obtain a reliable reading.  Convert et al. have 
demonstrated a miniaturized device for a slightly different application: measuring the 
radioactivity concentration in the blood of a rodent model for pharmacokinetic analysis 
of PET and SPECT radiotracers [126]. To maximize detection efficiency, a polymeric 
microfluidic device with a 0.7 µL microchannel was bonded directly on top of a 
commercial unpackaged 300 µm thick silicon PIN photodiode, with only 9 µm separation 
between the sample and detector (Figure 2-5B). Limits of detection were not reported, 
but absolute detection efficiency of the microfluidic geometry was significantly higher 
compared to a capillary-based setup, and detection efficiencies were close to the 
theoretical maximum for 11C- and 18F-decay events (47% and 39%, respectively, 
compared to 50% theoretical maximum), due to the high efficiency of direct positron 
detection. Dooraghi et al. reported radiation measurement of [18F]fluoride and [18F]FDG 
solutions in capillary tubing or a microchannel to calibrate an automated aliquoting / 
dose-dispensing system [127]. The detector comprised two 3 mm x 30 mm silicon PIN 
diodes at different distances from the sample such that the closest detector was 
sensitive primarily to positron interactions, while the further detector allowed 
measurement and subtraction of background gamma interactions (Figure 2-5C). The 
dynamic range of detectable activity was measured to be 0.74 – 4400  kBq/µL (0.02 – 
120 µCi/µL) and 0.01 – 105  MBq/µL (0.3 – 2830 µCi/µL)  for the high- and low-gain 
electronics configurations, respectively.  
 Additional compact radiation detection methods have been reported for 
applications that require a higher degree of spatial information about the radioactivity 
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distribution of positron-emitting samples, but presumably these could be adapted to 
measure the radioactivity concentration in sample of a formulated PET 
radiopharmaceutical. 
Cho et al. reported a system in which a scintillator was placed in close proximity 
to a PDMS microfluidic chip and scintillation light from positron interactions was 
detected with a CCD camera [128], [129] (Figure 2-5D) Preliminary studies showed that 
this imaging device is capable of discerning line pairs of printed [18F]FDG solution with 
separation as low as 300 - 500 µm and quantifying the activity concentration reliably 
down to 1.48 Bq/mm2 (40 pCi/mm2) or 13.32 Bq/mm2  (360 pCi/mm2) in 5 min with the 
use of CsI or plastic scintillators, respectively. Pratx et al. reported a different 
scintillation-based approach known as radioluminescence microscopy [130] in which the 
sample was placed on a thin scintillator plate, and light produced by positron decay 
events was measured using a high-sensitivity microscope (Figure 2-5E). The spatial 
resolution, measured using a dried droplet of [18F]FDG (370MBq), was estimated to be 
5 µm FWHM, and the minimum detectable activity density was 150 Bq/mm2 (4 
nCi/mm2). The high sensitivity allowed detection of [18F]FDG uptake in single cells. The 
maximum detectable activity was not specified. 
Cho et al. demonstrated an additional measurement technique in collaboration 
with our group: a sensitive CCD camera was used to detect the Cerenkov radiation 
emitted as energetic positrons from the sample travel through the surrounding medium 
[131], [132] (Figure 2-5F). Using solutions of [18F]fluoride and [18F]FDG, the system 
dynamic range was found to be 7.03 – 2740 kBq/mm2  (0.19 -742 μCi/mm2) for 5 min 
acquisitions , though the upper end of the dynamic range could be further improved by 
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using a shorter camera acquisition time and a smaller lens aperture setting, if 
necessary. The spatial resolution of Cerenkov image was found to be ~200 µm. 
Dooraghi et al. developed a system based on direct positron detection using a 
position-sensitive avalanche photodiode (PSAPD) (Figure 2-5G) [133]. In a PSAPD, the 
interaction of a positron creates an electron-hole pair that is amplified by an avalanche 
affect due to an applied bias across the device, allowing positron interactions to be 
easily distinguished from thermal noise. Furthermore, a 4-point detector allows 
localization of the detection event across the substrate. The sample is contained in a 
chamber on a PDMS microfluidic chip with 50 µm thick PDMS substrate separating the 
fluid from the detector. For 18F-containing solutions, the lower detection limit was 
measured to be 0.5 Bq/mm2 (~14 pCi/mm2) for a 1 min acquisition and 62 × 62 μm pixel 
size. The same device has been used to quantify activity in single cells [134] The upper 
count rate limit was 21 ,000cps (~46 kBq). The spatial resolution ranged from 0.4 mm 
FWHM at the center of the field of view (FOV), and 1 mm at a distance of 5 mm away 
from center. 
Tarn et al. have demonstrated the use of the commercially available miniaturized 
positron sensor array (Medipix2, Medipix Collaboration) with a pixel size of 55 µm x 55 
µm and overall detector size of 14 mm x 14 mm (65k pixels) to measure activity of 
[68Ga]Ga-citrate solutions in Tygon tubing (709 nL detection volume, 254 µm sample to 
detector distance). Upper and lower detection limits were not reported but a linear 
response was observed over the range tested (0.05 – 100 MBq/mL). The detector was 
also used to measure the activity passing through a silica monolith (Figure 2-5H) [135] 
as described in Section 2.10. Maneuski et al. reported the use of a similar detector 
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(Timepix) for measurement of activity in an adjacent tubing designed to measure the 
output of a UPLC system [136]. Though complete details of geometry were not 
provided, if the tubing is assumed to have a standard 1.6 mm (1/16”) outer diameter, 
then the distance from sample to detector is ~400 µm. Injected samples with 
concentration as low as 1 kBq/mL could be detected. Sensitivity was found to be much 
greater than several scintillation-based detetors. 
Mapelli et al. have reported an interesting detector comprising a serpentine 
microfluidic channel filled with liquid scintillation material [137], [138]  (Figure 2-5I). 
Each path of the serpentine channel acts as an independent detector to convert 
radiation into light in one portion of the channel (via the liquid scintillator), and also as a 
liquid waveguide to guide this light to a distant photodetector in a non-irradiated portion 
of the device. The idea was to provide improved detector resolution and increased 
radiation resistance, while achieving efficient optical coupling throughout the system 
and potentially enable fabrication of low-cost, high-resolution detectors. The 
photoelectric yield of the chip was measured by exciting the liquid scintillator with 
electrons from an external collimated 90Sr source and found to be in the order of 1.65 
photoelectrons per minimum ionizing particles (MIP) for 200 µm deep microchannels. 
Presumably this device could be used to measure the activity of radiopharmaceutical 
samples loaded into an adjacent microfluidic chip. 
Another technique that has been used to analyze compounds labeled with C-11, 
Ga-68, or F-18 in microfluidic channels is autoradiography (Figure 2-5J) [139], [140]. 
Laven et al. did not report the detection limit but reported good linearity in the range of 
~10 – 180 Bq. The need to first expose then image the phosphorimaging plates could 
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make this approach too slow and impractical for an automated QC testing system, and 
too bulky for microscale implementation. 
 (A) (Left) Setup of microfluidic chip and silicon photomultiplier (SiPM) array for measurement of 
radioactivity and half-life of a sample.  (Right) Photograph of the final chip setup on the SiPM 
array. Adapted from [125] with permission of the Royal Society of Chemistry. (B) Device for 
positron detection from blood samples in a microchannel bonded to a silicon PIN photodiode.  
Adapted from [126] with permission of the Royal Society of Chemistry. (C) Dual silicon PIN 
photodiode detection of a sample in a channel or tubing. Photodiode 1 responds to both positrons 
Figure 2-5. Examples of radiation detection methods 
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and gamma rays, while photodiode 2 responds only to gamma radiation, allowing subtraction of 
the background gamma signal. Adapted with permission from [127]. Copyright © 2016 Springer. 
(D) Scintillator based detection. A scintillator was placed in close proximity to a PDMS microfluidic 
chip and scintillation light from positron interactions was detected with a CCD camera. Adapted 
with permission from [128] Copyright © 2007 IEEE. (E) Radioluminescence imaging. Scintillator 
light output is observed via sensitive microscope as radioactive decays occur in sample. Adapted 
with permission from [141] Copyright © 2015 John Wiley & Sons, Inc. (F) Cerenkov imaging. (Left) 
Cerenkov radiation is emitted as energetic particles travel through the liquid or chip material. 
(Right) Bright-field and Cerenkov images of 200 µm-wide microchannel filled with [18F]FDG 
solution. Adapted from [131] with permission of IOP PUBLISHING, Ltd. (G) Beta-box imaging. 
(Top left) Microfluidic chip containing multiple sample chambers is placed on the detector; (Bottom 
left) Photograph of position sensitive avalanche photodiode (PSAPD) detector; (Right) Resulting 
image when sample chambers are filled with varying concentrations of [18F]fluoride. Adapted from 
[133] with permission of IOP PUBLISHING, Ltd. (H) System for measuring radioactivity in a silica-
based monolith column placed above a Medipix sensor. Adapted from [135] with permission of 
the Royal Society of Chemistry. (I) Microfluidic channel filled with liquid scintillator that acts an 
array of scintillation detectors connected by liquid waveguides to photodetectors. Adapted with 
permission from [137] Copyright © 2010 Elsevier. (J) Autoradiography (phosphor imaging 
system). (Left) Autoradiography image of adsorbed radiolabeled peptide on the channel surfaces 
of a plastic microfluidic chip. Adapted from [139] with permission of The Royal Society of 
Chemistry. (Right) Autoradiography image of [18F]fluoride trapped in the serpentine channel of an 
electrochemical cell. Adapted with permission from [140] Copyright © 2013 Elsevier. 
 
The examples described here represent a wide variety of detection approaches 
that may be suitable for measuring radioactivity in microchannels. With further 
development, it is likely that several of these approaches could provide a compact 
means to perform radioactivity measurements for the radioactivity test (as well as some 
of the tests below). 
 Radionuclidic purity and identity 
The radionuclidic purity is the ratio of the desired radionuclide activity to the total 
activity. The purpose of testing is to ensure that the radiopharmaceutical is not 
contaminated with other radionuclides, that could make the resulting PET/SPECT 
images difficult to interpret, or, in the case of long-lived isotopes, could cause harm to 
the patient. For example, SPECT and PET tracers labeled with generator-produced 
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radionuclides can contain contamination by radioactive parent compounds. In general, 
the radionuclidic identity can be confirmed by measuring the half-life of the product, and 
the radionuclidic purity can be measured by a gamma spectrometer with a multichannel 
analyzer (e.g. based on sodium iodide scintillation detector or high-purity germanium 
detector). The half-life is determined by taking at least 3 radioactivity measurements of 
a sample using a dose calibrator (with the same geometry for each measurement), and 
then calculating half-life via a non-linear fit to the radioactivity decay equation [41]. For 
highest accuracy, the measurements should be carried out as far apart in time as 
practical. The radionuclidic purity is determined by obtaining a gamma spectrum of the 
sample, and matching this spectrum (after background spectrum is subtracted) to the 
expected energy spectrum. Each radionuclide has a characteristic gamma spectrum; for 
example, positron-emitting isotopes in PET tracers have a peak at 0.511 MeV due to 
positron annihilation, plus additional peaks corresponding to other decay modes, if 
applicable.  Since some positron emitters have a very short half-life, the USP and EP 
allow PET radiopharmaceuticals to be released before the radionuclidic identity test is 
completed on each batch, in which case periodic tests of samples prepared in the same 
way would be necessary.  
The half-life test can be miniaturized using an integrated radiation detector to 
measure the radioactivity of a sample in a microchannel in a consistent geometry 
multiple times. Taggart et al. used their SiPM array platform to measure not only the 
radioactivity concentration as described above but also the half-life of microfluidic 
samples [125]. Accurate half-life measurements were achieved for [18F]fluoride and 
[18F]FDG solutions based on 5 min measurements taken over a time period of several 
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hours, but reliable values could not be obtained for calculations based on shorter 
measurements (e.g. 30-60 s) taken over a more realistic 20 min timespan without 
constraining the exponential fit. It is possible that performance could be improved with 
further optimization.  In addition, any of the microscale radiation detection approaches 
described in Section 2.8, depending on activity level and geometry of the sample, could 
be considered for microscale implementation of the half-life test. 
To the best of our knowledge, a microscale implementation of the radiouclidic 
purity test has not yet been demonstrated, though perhaps a microscale gamma 
spectrometer could be implemented using similar technologies to those discussed in 
Section 2.8, provided the radiation detector has adequate energy resolution.  
 Radiochemical purity and identity 
The radiochemical identity of a positron-emitting radiopharmaceutical is generally 
determined after chromatographic separation by determining the retention time (radio-
HPLC), retardation factor (radio-TLC), or migration time (radio-CE) of the main 
radioactivity peak (corresponding to the radioactive product), and comparing to that of a 
reference standard to confirm structural identity of the radiopharmaceutical. 
In addition to confirming the identity of the product, it is also necessary to ensure 
the absence of radioactive impurities. Radiochemical purity is defined as the ratio of the 
activity of the radionuclide concerned, which is present in the desired chemical form, to 
the total activity of that radionuclide present in the radiopharmaceutical preparation. Any 
radiochemical impurity can potentially affect the biodistribution of the 
radiopharmaceutical giving a misleading imaging result. In general, the radiochemical 
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purity should be >95%, though in the case of [18F]FDG, USP specifies >90% as 
acceptable. 
Typically, radiochemical identity and purity are determined via HPLC with a 
radiation detector positioned at the end of the column (radio-HPLC). While the same 
instrumentation can be used for the chemical purity test, the radiochemical identity and 
purity tests are often run on a sample that is spiked with a non-radioactive reference 
standard, while the chemical purity test is carried out on an unadulterated sample. The 
standard is used to confirm the radiochemical identity by matching retention times of the 
radiation and UV absorbance peaks in the chromatogram. In addition to radio-HPLC, 
analysis by radio-TLC may also be necessary for accurate determination of 
radiochemical purity since certain radioactive species such as [18F]fluoride can be 
under-represented in HPLC [142]. In the case of some PET and SPECT tracers labeled 
via chelation reactions, where only the product and non-chelated radionuclide are 
expected in the final formulation, radio-TLC may be sufficient (without radio-HPLC) for 
determination of purity.  
Similar to the corresponding non-radioactive tests, there is interest in developing 
miniaturized versions of the radiochemical identity and purity tests due to the bulkiness 
of radio-HPLC, radio-TLC, and radio-CE systems. As discussed in Section 2.5, HPLC 
and CE can be miniaturized into chip-HPLC or MCE format, and potentially these 
techniques could be integrated with one of the compact radiation detection approaches 
described in Section 2.8 to measure the output of the separation column or separation 
channel, respectively. To the best of our knowledge, such integration has not yet been 
reported. 
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Some efforts have been made to replace traditional HPLC/UPLC radiation 
detectors with more compact detectors, which could be a step in this direction. For 
example, the Timepix detector reported by Maneuski et al. [136] was suitable for 
measurements at the output of a UPLC system and showed a wider dynamic range and 
improved sensitivity compared to a PMT detector with either CsF or BGO scintillator.  
Tarn et al. have used a Medipix detector to detect radioactivity within a porous 
silica monolith embedded in tubing with the goal of real-time imaging of separation 
processes. The detected signal was higher for a sample of [68Ga]Ga-citrate passing 
through the monolith than the signal observed with a traditional radio-HPLC detector 
(NaI scintillator / PMT) positioned downstream in the tubing. In addition, the 
accumulation of activity could be measured as [68Ga]Ga3+ was trapped on the monolith, 
as could the reduction in activity when the monolith was eluted. Maneuski et al. also 
demonstrated the spatial imaging capabilities of the Timepix detector in the context of 
radiochemical separations. The radioactivity distribution along a conventional radio-TLC 
plate containing an unspecified 18F-labeled sample was measured with sub-mm 
resolution by placing it adjacent the detector [136]. Imaging of three parallel 18F-
solution-containing tubes was also demonstrated, perhaps in anticipation of performing 
chromatographic separations in channels in the future. Spatially-resolved radiation 
detection was also mentioned in a patent by Hansteen et al. [50] to monitor separation 
of radiopharmaceuticals in a capillary to determine radiochemical purity, though details 
were not provided. 
While some steps have been taken toward miniaturized implementation of 
radiochemical identity and purity tests, much development is still needed in this regard. 
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 Molar activity 
Molar activity (often called “specific activity”) is a measure of the amount of 
radioactivity per molar amount of the radiopharmaceutical [3]. For certain 
radiopharmaceuticals, such as [18F]FDG, radiolabeled amino acids, or fatty acids that 
visualize metabolic processes, molar activity determination is not crucial since these 
radiotracers have natural physiologically abundant levels of nonradioactive counterparts 
in vivo, especially in circulation. However, for receptor-binding radiotracers, radiolabeled 
mAbs, and peptide hormone analogs, a relatively high molar activity is crucial. 
Conventionally, for most organic radiopharmaceuticals, the concentration (total number 
of moles per volume) is determined based on analytical HPLC after creating a 
calibration curve using known concentrations of an ultra-pure reference standard. If 
radioactivity concentration is also known, then molar activity can easily be calculated.  
Though it has not been demonstrated, molar activity measurement can likely be 
miniaturized by combining aforementioned techniques for measuring concentration 
(chemical purity test, Section 2.5) and radioactivity concentration (radioactivity test, 
Section 2.8). High-sensitivity and accuracy will be needed to measure the 
concentration, as the molar amounts can be very small (e.g. pmol to nmol for 18F-
labeled PET tracers). 
 Outlook 
We have reviewed various microfluidic implementations of the QC tests for PET 
and SPECT radiopharmaceuticals, or techniques that could potentially be implemented 
to perform these tests (summarized in Table 2-1). It is encouraging that viable 
approaches for ultra-compact implementation of many of the required tests have been 
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demonstrated at least as a proof of concept. In some cases, the desired performance 
has already been demonstrated, and/or significant reductions in sample consumption 
have been reported. 
However, in most cases, considerable development and optimization efforts will 
be needed to increase reliability, speed, sensitivity or other measures of performance 
up to the rigorous requirements of clinical testing. In addition, in cases where the 
method of detection is fundamentally changed (e.g. sterility testing based on counting of 
individual bacterial, assessment of chemical/radiochemical purity via new 
chromatographic approaches such as MCE, and detection of residual solvents via 
Raman spectroscopy or an “electronic nose”), extra efforts may be required to 
demonstrate equivalence (or superiority) to currently-accepted test methods. 
Once individual tests have been perfected, efforts will be needed to integrate 
them into a unified system that performs all tests, data collection, and report generation 
in a fully-automated manner. Integrated systems with some degree of microfluidic 
elements have been suggested in patents and patent applications [50], [122]. One 
approach would be to integrate all sample channels and detectors into a single lab-on-
a-chip device, and develop a means to aliquot the original sample and distribute 
portions to each testing area. A challenge in splitting the sample and delivering aliquots 
to various detection systems via fixed fluid pathways is the possibility of cross-
contamination from one sample to the next, which may require extensive cleaning 
protocols and cleaning validation. One advantage of microfluidics is that many of the 
fabrication methods and materials used can be very low cost, enabling tests to be 
implemented in disposable fluid paths. Leveraging such features could eliminate the 
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need for cleaning, and could reduce the required maintenance, further simplifying the 
testing process and overall QC testing platform. 
If realized, integration of microscale QC tests on an automated platform would 
allow for unified QC system validation, eliminate operator-induced variation, significantly 
reduce radiation exposure to personnel, and streamline the overall workflow. As 
increasing numbers of the thousands of known tracers [16], [17] move into the clinic, 
and as new technologies such as microfluidic systems enable more widespread 
production of tracers on demand [21], [23], [48], [143], it will become increasingly 
important to have an integrate QC testing platform that simplifies and reduces the cost 
of QC testing. 
Though we have focused on the special needs of radiopharmaceutical analysis, 
where sample volume and total duration are extremely limited, the methods described 
here could likely also be applied to the analysis of non-radioactive pharmaceuticals, and 
may offer significant advantages in terms of speed and cost. 
 
Table 2-1. Summary of required QC tests, the conventional method(s) used, and 
typical specifications.  
In addition, examples of microfluidic approaches to perform each test are listed. Note we have 
indicated in italics approaches that have not been demonstrated/proven, but may be possible in 
principle. Abbreviations: HPLC/UV = HPLC with UV absorbance detector, HPLC/RI = HPLC with 
refractive index detector, etc. 
QC Test Conventional 
method(s) 
Typical acceptance 
criteria 
  Examples of microfluidic suitable approaches 
pH pH indicator 
strips; electronic 
pH meter 
4.5 < pH < 8.5 UV absorbance of sample + indicator   [51], [54], [55] 
UV absorbance of pH-sensitive surface [57] 
Fluorescence emission from pH-sensitive 
dye/surface [56]  
Hydrogel-based pH sensing (physical or electrical 
change) [58]–[60] 
Electrochemical cell [61], [62] 
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Appearance (color 
/ clarity) 
Visual Clear, colorless, 
particulate-free 
UV absorbance of sample [51] 
Sterility Short term: filter 
integrity test 
(e.g. bubble 
point test); Long 
term: Bacterial 
culture 
Long term: no 
bacterial growth 
observed 
Fluorescent detection of “universal” dye that binds to 
bacteria [70] 
Electrical impedance detection of individual bacteria 
[71]–[73] 
Bacterial 
endotoxin 
LAL test 175 EU/V Variations of LAL assay (UV absorbance detection 
[76], [77], electrical impedance detection [78], 
bioluminescence detection [79]) 
Detection of endotoxin binding to surface [75], [80]  
MCE/fluorescence [81] 
Chemical identity/ 
purity 
HPLC/UV Varies MCE/UV [94] 
Chip-HPLC/UV  
Kryptofix 2.2.2 Color spot test <50 µg/mL (USP); 
2.2 mg/V(EP) 
UV absorbance of sample + indicator [117], [118] 
MCE/UV 
Chip-HPLC/UV 
Residual organic 
solvents 
Gas 
chromatography
; HPLC/RI 
 
Varies (e.g., MeCN 
4.1 mg/day, EtOH 
50 mg/day, DMSO 
50 mg/day, DCM 6 
mg/day, DMF8.8 
mg/day) 
MCE/RI 
Micro-GC 
Electronic nose [121] 
Radioactivity 
concentration 
Dose calibrator Varies  Solid-state detectors (SiPM [125], PIN diode [126], 
[127], PSAPD-based detector [133], [144], 
Medipix/Timepix detector [135], [136]) 
Cerenkov imaging [131], [132] 
Scintillator-based detectors (CCD imaging [128], 
[129], radioluminescence microscopy [130], [141], 
liquid scintillator with photodetector [137]) 
Radionuclidic 
identity  
Half-life 
measurement 
with dose 
calibrator  
Varies 
(e.g. 105-115 min 
for 18F-labled 
tracers) 
Radiation detector (half-life measurement) [125] 
Potentially some of radiation detectors listed under 
“Radioactivity concentration” can be used 
Radionuclidic 
purity 
Gamma 
spectrometer 
Match expected 
energy spectrum 
Potentially some of radiation detectors listed under 
“Radioactivity concentration” can be used 
Radiochemical 
identity and purity 
Radio-HPLC; 
radio-TLC 
>95%; (>90% for 
[18F]FDG) 
Porous silica monolith with Medipix positron detector 
array [135] 
TLC plate with Timepix positron detector array [136] 
 MCE / positron detector Chip-HPLC / positron 
detector 
Specific 
activity 
Radio-HPLC 
and dose 
calibrator 
Varies MCE/UV and radioactivity measurement 
Chip-HPLC/UV and radioactivity measurement 
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3. Chapter 3: Development of microchip electrophoresis for analysis of 
radiopharmaceuticals 
 
 Background: Capillary electrophoresis (CE) 
 Capillary electrophoresis  
Capillary electrophoresis (CE) is a powerful separation technique with high 
separation efficiency, flexibility in separation mechanism, low consumption of sample 
and reagents, and simple instrumentation [145], [146]. CE is employed in diverse 
applications including DNA and protein separation [92], [93], [147], detection of disease 
biomarkers [148], [149], environment monitoring on earth and other planets [150], [151], 
food (e.g. wine) analysis [152], and pharmaceutical analysis [153]–[155]. Unlike other 
separation methods such as high-performance liquid chromatography (HPLC), CE can 
more readily be miniaturized using microfluidic chip technology, microchip 
electrophoresis (MCE) [88]–[90], [156]. This is especially important for applications 
where compactness, portability, and/or low cost are needed. Miniaturization confers 
even further advantages, including lower sample consumption, improved resolution, 
shorter separation times, improved reproducibility (e.g. from improved temperature 
control), and increased sensitivity and diversity of detection methods [157]–[159]. 
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 Introduction: MCE for analysis of PET tracers 
Microscale capillary-electrophoresis (CE)-based devices are increasingly being 
used for high-resolution separations where portability, ease of integration, or small 
sample size are of particular importance. Recent examples include environmental 
analysis [160], biomolecular separations [161], [162], and mobile heath diagnostics 
[163].   
Another field that can benefit from the advantages of MCE devices is nuclear 
medicine, particularly in assessing patient safety of freshly-prepared batches of short-
lived radiolabeled imaging tracers for positron-emission tomography (PET) or single 
photon emission computed tomography (SPECT). PET and SPECT are real-time, 3D 
medical imaging techniques with exquisite specificity and sensitivity for visualizing 
particular biological/biochemical processes depending on the tracer used.  
Since PET tracers are classified as drug products by regulatory agencies, they 
must pass stringent quality control (QC) tests after their production for safety of the 
patient prior to injection (see 2.2 Miniaturization of quality control (QC) tests). 
Performing and documenting the tests is cumbersome and time-consuming, and 
requires an array of expensive analytical chemistry equipment and significant dedicated 
lab space, and there is considerable interest in the development of automated and 
lower-cost approaches.  
By replacing conventional analysis techniques with lab-on-a-chip technologies, it 
may be possible to achieve significant reductions in the size, cost, and complexity of 
automated QC testing platforms, and potentially to increase sensitivity [161], [164]. 
Commercial microscale devices already exist for testing of endotoxins [76], and there 
 47 
have been recent efforts to miniaturize some of the other tests, including radioactivity 
measurement [125], radioisotope identity (half-life) test [125], pH test [51], color and 
clarity test [51], and Kryptofix 2.2.2 test [117]. While these results represent an 
impressive step forward, high-resolution miniaturized chromatographic methods, 
suitable for assessment of chemical or radiochemical identity and purity across a wide 
range of tracers, are notably missing. Due to the potential presence of several impurities 
in each batch of PET tracer, and due to the wide variety of tracers and synthesis 
methods, performing these tests will likely require some kind of chromatographic 
separation followed by a radiation detector (e.g. gamma rays or positrons) and 
additional detectors for non-radioactive species (e.g. UV absorbance, refractive index, 
or pulsed amperometric detectors) to quantify each compound and ensure it is below 
permitted limits. The identity of each peak can be determined by matching the retention 
time to a reference standard (or by co-injection of the standard), or, in rare cases, via a 
mass detector. 
Here we focus on the development of a microscale CE-based device to replace 
the gold standard approach of high-performance liquid chromatography (HPLC) for this 
critical and challenging component of QC testing. We have been exploring CE methods 
due to the possibility of microchip implementation and corresponding reductions in size, 
cost, and complexity of the overall QC system. Microchip electrophoresis (MCE) has 
been shown capable of separating a vast range of analytes including large biomolecules 
(e.g. nucleic acids, proteins), peptides, and inorganic ions and chiral molecules [157], 
[165] simply by tuning the separation conditions. The versatility and separation power of 
CE have been noted to be equal to HPLC, or even better in some applications [96]. CE 
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also avoids the use of high pressures, which simplifies the interface with other system 
components and eliminates the need for bulky and expensive high-pressure valves, 
pumps and fittings. Additional advantages of CE are the ability to miniaturize the QC 
system into a microfluidic chip measuring 25 mm x 75 mm or smaller that is operated 
via a compact electronic control system and power supply, and the extremely tiny 
sample consumption (typically nanoliters). 
Conventional-scale CE separation of several 99mTc-labeled SPECT species from 
impurities has been reported [101], and we recently showed that two 18F-labeled PET 
tracers, namely 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) and 1-(2’-deoxy-2’-
[18F]fluoro-β-D-arabinofuranosyl) cytosine ([18F]FAC) can be readily separated from 
impurities, including Kryptofix 2.2.2 (K222), using MEKC [166]. Compared to traditional 
HPLC/UV, we observed similar separation resolution and limits of detection (LOD), but 
reduction in analysis time in some cases, and several orders of magnitude reduction in 
buffer and sample consumption. (In typical HPLC analysis of radiopharmaceuticals, 
sample volume is on the order of 10-100 µL, the flow rate is 1-2 mL/min, and the 
analysis time may be 5-30 min, consuming 5 – 60 mL of mobile phase. On the other 
hand, in MCE, the buffer consumption can be as low as 100 µL and sample injection 
volume is typically in the nL range or lower.) However, to the best of our knowledge, 
there have been no reports on the miniaturization of these approaches to analyze 
chemical species relevant to the testing of radiopharmaceuticals. Here we describe a 
proof-of-concept hybrid microfluidic CE device consisting of a hydrodynamic injection 
chip, a separation capillary, and a microfluidic optical absorbance detection chip to 
perform chemical identity and purity analysis of FLT and its known impurities. 
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Potentially, with integration of a radiation detector in the future, this approach could also 
be used for radiochemical identity and purity tests. In addition, this approach could 
enable the fluid path to be inexpensive and disposable, reducing maintenance and 
eliminating the need for cleaning, further simplifying the testing process. 
 Materials and Methods 
 Miniaturized Capillary Electrophoresis system 
We combined the three key components (injection, separation, and detection) 
into a hybrid MCE system (Figure 3-1). One microfluidic chip, used for sample injection 
and containing the anode, was connected to the upstream side of a 60 cm long, Teflon-
coated fused silica capillary (75 µm I.D., 375 µm O.D; Polymicro, Phoenix, AZ, USA). A 
second microfluidic chip, used for sample detection and containing the cathode, was 
connected to the downstream side of the separation capillary. The capillary was 
connected to each chip via a port perpendicular to the channels within the chip. 
All electronic components were connected to a digital acquisition (DAQ) module 
(USB 6211, National Instruments Corporation, Austin, TX, USA). A custom-written 
LabVIEW program (National Instruments Corporation, Austin, TX, USA) was used to 
coordinate the timing of all functions. 
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Figure 3-1. Schematic of complete hybrid MCE device setup. 
The system includes PDMS optical detection chip, PDMS injection chip, and glass capillary 
separation channel. The solenoid valves are used to control the on-chip microvalves. 
 
 Injection chip 
Though the commonly used technique of electrokinetic injection provides a very 
convenient means to inject samples in CE and MCE, this technique suffers from 
injection bias, i.e. solutes with higher electrophoretic mobilities are preferentially 
introduced, resulting in a difference between the composition of the original sample and 
that injected into the separation channel, as well as changing of the sample composition 
over time which interferes with repeat measurements [167], [168]. This bias, and other 
sensitivities of this technique (to voltage, sample conductivity, sample pH, electrolysis, 
and the possibility of complex formation) [168] could prevent accurate assessment of 
diverse impurities in PET tracer samples. Thus, pressure-driven injection [168], which 
avoids the above injection bias was used. 
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The design of the microfluidic injection chip, shown in Figure 3-2A, was adapted 
from the report of Li et al. [169]. The chip was fabricated from poly(dimethylsiloxane) 
(PDMS) using multilayer soft lithography [170]. The chip enables a controlled amount of 
sample to be loaded from the sample inlet port into the separation channel by 
momentarily opening a microvalve (v3) for a fixed time. An additional microvalve (v2) 
enables priming of the sample inlet to eliminate air. The sample was contained in a 
septum-sealed vial (Fisherbrand™ 2 mL screw thread autosampler vial, Thermo Fisher 
Scientific, Waltham, MA, USA). Pressurized nitrogen gas was supplied to the vial 
through an electronic pressure regulator (ITV0010-3BL, SMC Corporation of America, 
Noblesville, IN, USA). The vial also contained an outlet tubing (#30 PTFE tubing, Cole-
Parmer, IL, USA) connected to the sample inlet port of the injector chip. In addition to 
the sample inlet, the chip also contained an inlet for buffer solution, which was similarly 
connected to a pressurized vial of the separation buffer (SDS-PB) and controlled via 
microvalve v1. 
The detailed steps to perform sample injection are illustrated in Figure 3-2B. 
Before use, the chip was first primed with buffer by closing v3, opening v1, and 
pressurizing the buffer vial (6.0 psi) until buffer started flow out of all the buffer wells 
(and also out the buffer waste well of the detection chip connected to the other end of 
the capillary). Next, the sample vial was pressurized (1.5 psi) and the sample inlet was 
primed by closing v1 and v3 and then opening v2 until sample was seen entering the 
sample waste vial. To load the sample, valve v3 was then opened for a fixed time to 
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allow sample to fill part of the main channel in the chip.  After the sample is loaded all 
valves were closed and electrophoretic potential was applied to separate the sample. 
On-chip microvalves were each controlled by the common port of an electronic 
solenoid valve (S070B-5DG, SMC Corporation), connected to the chip via #30 PTFE 
tubing. The solenoid valves switched between two states: (i) supplying pressurized 
Figure 3-2. Design of PDMS injection chip and sample injection method. 
(A) Design of multi-layer PDMS chip for timed hydrodynamic sample injection. (Left) 
Schematic; (Right) 3D representation. (B) Schematic view of steps involved in injection 
process. First, the channel is primed with buffer (step 1). Next, the sample is loaded and 
primed (steps 2-3). The sample is then injected (steps 4-5), and the separation potential is 
applied along the separation channel (step 6). Solid red boxes indicate closed microvalves 
and hollow black boxes indicate open microvalves. Arrows indicate direction of fluid flow. 
Channels filled with buffer are shown in blue while those filled with sample are shown in 
orange. The capillary and waste well are connected for all steps but for clarity are only depicted 
in the final step when the separation voltage is applied. Diagrams not to scale. 
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nitrogen (35 psi) to close the on-chip microvalve, and (ii) venting to atmosphere to allow 
the on-chip microvalve to open via elastic restoration of the PDMS. To avoid the 
generation of air bubbles inside the sample-containing channels of the chip, the valve 
control channels were filled with water prior to use as previously described [94].  
3.3.2.1 Fabrication details of microfluidic injector 
The injection chip was fabricated from two patterned layers of 
poly(dimethylsiloxane) (PDMS) and a PDMS substrate using multilayer soft lithography. 
When the layers are aligned and bonded together two planar networks of sealed 
channels are formed: an upper layer in which the sample and buffer flow (flow layer), 
and a lower layer that contains microvalve control channels (control layer). The control 
layer channel is 15 µm deep and 75 µm wide and were rectangular in cross section. 
The flow layer channels were 20 µm deep and 75 µm wide and were rounded in cross 
section to enable complete channel sealing using the on-chip pneumatic valves [170].  
The control layer mold was fabricated from a 4” silicon wafer (Silicon Valley 
Microelectronics, Santa Clara, CA USA). The wafer was first cleaned with oxygen 
plasma using a Matrix 105 – Downstream Asher (Allwin21, Morgan Hill, CA, USA), and 
baked at 150°C for 10 min. ~4 mL of SU-8 2010 negative photoresist (MicroChem, 
Newton, MA USA) was poured onto the wafer and spun at the following 3 step spin 
setting: 500:200:5, 1500:500:30, 0:500:0 (speed:acceleration:duration; units are 
RPM:RPM:s). After soft baking at 95°C for 3 min, the wafer was exposed to 140 mJ/cm2 
of UV light through the control layer transparency mask using a Karl Suss MA150 Mask 
Aligner (Karl Suss American Inc., Williston, Vermont, USA), followed by post-baking at 
95°C for 4 min. Next, the wafer was developed by immersion in SU-8 Developer 
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(MicroChem, Newton, MA USA) for 3 min, followed by cleaning with methanol and 
drying with compressed nitrogen gas.  Finally, the mold was hard baked at 175°C for 15 
min and then 100°C for 5 min. The height of the inverse channel was measured using a 
Veeco Dektak 150 Surface Profilometer (Bruker, Tustin, AZ, USA) to be 15 μm. 
The flow layer mold was made from a 4” silicon wafer, cleaned as described 
above. ~6 mL of the adhesion promoter hexamethydisilazane (HMDS) (Sigma-Aldrich, 
St. Louis, MO USA) was poured onto the wafer and spun at the following setting 3 step 
spin setting: 400:200:18, 1000:500:45, 0:500:0.  Next, ~6 mL of SPR 220-7.0 positive 
photoresist (MicroChem, Newton, MA USA) was spun onto the wafer using the following 
setting 3 step spin setting: 400:200:30, 1000:500:80, 0:500:0.  The coated wafer was 
then soft baked at 105°C for 6 min, and then exposed with 720 mJ/cm2 through the flow 
layer transparency mask. After exposure, the coated wafer was set aside for rehydration 
for 3 h, post-baked at 110°C for 5 min, and again rehydrated at room temperature for 45 
min. The wafer was then developed by immersing in CD-26 (MicroChem, Newton, MA 
USA) for 30 min, rinsed with DI water, and dried with compressed nitrogen gas.  Once 
developed, a reflow process (to achieved rounded channel profile) was performed.  This 
was accomplished by placing the wafer on a 65°C hot plate, ramping up to 140°C and 
holding for 40 min. Finally, a hard bake step was performed by placing the wafer on a 
135°C hot plate, ramping up to 190°C, and holding for 3 h (channel features become 
blackened). The height of the inverse channel feature was then measured to be 20 µm 
using a profilometer. 
Each microfluidic chip was made as follows. ~45 g of a 20:1 mass ratio of 
RTV615 A:B (Momentive, New Smyrna Beach, FL, USA) was prepared, thoroughly 
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mixed, and then placed into a vacuum desiccator for 2 h to remove air bubbles. The 
degassed mixture was poured onto the control mold and spun at 2500 RPM 
(acceleration: 1000 RPM/s) for 1 min.  ~50 g of a 5:1 mass ratio of RTV615 A:B was 
also prepared in a similar fashion. This mixture was poured to ~5mm thickness on the 
flow layer mold, which had been placed in a foil lined Pyrex petri dish (140 mm ID) 
(Product#3160101BO, Corning Inc., Corning, NY, USA). Both layers were then baked in 
an oven at 80°C for 20 min. The flow layer was then removed from the wafer mold, 
trimmed to the size of the chip, and aligned onto the control layer with the assistance of 
alignment marks and a stereo zoom microscope. Scotch tape was used to keep the 
surface of the chip clean before alignment (810 Scotch Tape, 3M, Saint Paul, MN, 
USA). The layers were placed in contact so that there were no air bubbles between 
them, and then baked at 80°C oven for at least 2 h to facilitate bonding. The bonded 
chip was then removed from the control wafer mold. A Schmidt manual press (Press 
Type 3/6, Schmidt, Cranberry Twp., PA, USA) equipped with metal punches was used 
to create a buffer well, ports for fluidic and control lines, and a port for a fused silica 
capillary.  The buffer well was formed using a 4.75 mm ID catheter punch 
(HS1871730P1183S, Syneo, West Palm Beach, FL).  A 720 µm ID catheter punch 
(CR0350255N20R4, Syneo) was used for all other ports except the capillary port, which 
used a 330 µm ID punch ID punch (CR0180115N26R4, Syneo).  A 60 cm long, 75 µm 
I.D., 375 µm O.D. Teflon coated fused-silica capillary (Polymicro, Phoenix, AZ, USA) 
was then inserted into the capillary port with one end of the capillary end not quite flush 
with the bottom surface (i.e. ~1 mm retracted from the surface) of the PDMS chip. The 
combined chip (fluid and control layers) was then bonded to a flat PDMS substrate 
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using a Corona Discharge bonder (LM4816-11MS-MSA, Enercon Industries). (To create 
this PDMS substrate, ~50 g of a 10:1 mass ratio of RTV615 A:B was prepared, 
degassed, and poured to a ~5 mm thickness on a blank silicon wafer, and then cured at 
80°C for 2 h.) The completed chip was then baked at 80°C for at least 2 h. The 
thickness of the valve membrane between the control and flow channels was 
determined via profilometry to be ~15 µm (total thickness of PDMS control layer of 30 
µm minus the 15 µm height of the channel feature on the mold). 
 
 Detection chip 
In typical radio-HPLC systems used in the field of radiochemistry, the flow cell 
has a path length of ~10 mm (10,000 μm). In the case of capillary electrophoresis in 
capillaries or microchannels, the optical path length (OPL) is much shorter (e.g. 30-100 
μm) if light is directed, via a window, perpendicular to the flow through the capillary of 
microchannel. Because this short optical path reduces the absorbance ‘signal’, it 
typically results in a relatively poor LOD in CE systems compared to HPLC. This 
problem can be addressed by leveraging the ability to precisely control fluid geometry in 
microfluidic devices and implementing an increased optical path length. An in-plane Z-
shaped detection cell design [171] was selected, due to the simplicity of chip fabrication 
and interfacing of the illumination and detection optical fibers. 
The chip was fabricated from a single patterned layer of PDMS bonded to a 
PDMS substrate. The design (Figure 3-3) includes fiber alignment channels to ensure 
accurate collinear alignment of both the optical fibers (i.e. to provide illumination via the 
external light source and detection via the external spectrometer) with a ‘jog’ in the 
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sample channel representing the extended optical path within the chip [172]. Due to the 
elastic property of PDMS, the 125 µm OD optical fibers (ThorLabs, Newton, New 
Jersey, USA) are held stably in these channels by friction forces. The flat ends of the 
fibers sit flush against the flat end of the fiber channels, providing efficient optical 
coupling to the sample channel. Since PDMS absorbs strongly in the UV range [173], it 
was desirable to minimize the thickness of PDMS membrane between the end of the 
fiber and the sample within the channel. A thickness of 100 µm was chosen as it 
provides good optical transmission (>85% transmission for wavelengths > 220 nm), 
sufficient mechanical resistance to deformation, and high electrical breakdown voltage 
(~2000V [174], sufficient to sustain the CE potential at this point in the separation 
channel). In addition to the portion of each fiber alignment channel that is collinear with 
the optical path, there is a continuation that allows the air initially in the channel to be 
vented. All channels were 125 µm deep and 125 µm wide. Using the same depth for the 
fiber-aligning channels as for the fluid-containing channels simplifies the chip 
fabrication, requiring a single thickness of photoresist. 
The performance of the detection chip was compared with two combinations of 
light sources and detectors, one with lower performance and one with higher 
performance. Detector 1 comprised a PX-2 pulsed xenon light source (Ocean Optics, 
Dunedun, FL, USA) and USB-4000 spectrometer (Ocean Optics) and Detector 2 
consisted of a DH-2000-BAL continuous deuterium light source (Ocean Optics) and QE-
Pro spectrometer (Ocean Optics). The PX-2 is ~5x cheaper than the DH-2000-BAL; 
however, it has significant noise, which adversely affects LOD. The pulse-to-pulse 
variation in light intensity is in the range 3-12% depending on pulse frequency [175], 
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compared to an intensity drift of <0.01% per hour [176] for the DH-20000-BAL. Similarly, 
the USB4000 is ~20x cheaper than the QE-Pro, but has a lower signal-to-noise ratio 
(275:1 compared to 1000:1) and lower dynamic range. 
While the current work serves as proof of concept for miniaturized analysis of 
PET radiopharmaceuticals, ultimately it will be necessary to incorporate a radiation 
detector with good spatial resolution to enable assessment of radiochemical identity and 
purity in addition to chemical purity. We are currently in the process of developing such 
an integrated detector for the detection chip and will publish these findings in the future. 
 
 
Figure 3-3. PDMS detection chip. 
(A) Schematic of the PDMS detection chip with the extended optical path. (B) Micrograph of the 
region of the chip outlined by the dotted red line in A. (C) 3D representation of the PDMS detection 
chip with connected capillary and optical fibers for absorbance measurement. 
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3.3.3.1 Fabrication details of PDMS detection chip 
The detection chip was fabricated from a single layer of patterned PDMS bonded 
to a PDMS substrate. The channel mold was created from a cleaned 4” silicon wafer. ~4 
mL of SU-8 2150 negative photoresist (MicroChem) was poured and spun at the 
following 3 step spin setting: 500:200:5, 1500:500:30, 0:500:0. After soft-baking at 65°C 
for 5 min and then 95°C for 25 min, the wafer was exposed to 240 mJ/cm2 of UV light 
through the transparency mask. The exposed wafer was then post baked at 65°C for 5 
min and 95°C for 11 min. The wafer was developed in SU-8 Developer for 15 min, 
cleaned with methanol, and dried with compressed nitrogen gas.  Finally, the mold was 
hard baked at 175°C for 15 min and at 100°C for 5 min. The height of the inverse 
channel features was determined to be 125 µm using a profilometer.  To prepare the 
chip, a ~50 g amount of 10:1 mass ratio RTV615 A:B was mixed and degassed and 
then poured onto the mold (~5 mm thickness) and baked at 80°C overnight. Once 
completely cured, the PDMS chips were peeled away from the mold and a 4.75 mm 
inlet well and 330 µm capillary port were made with metal punches. Next, the other end 
of the capillary (connected to the injection chip) was inserted in a similar fashion through 
the capillary port of the detection chip. Finally, the chip was bonded to a PDMS 
substrate using corona discharge bonding and baked at 80°C for at least 2 hr 
conditioning. 
After fabrication and assembly of the hybrid chip, it was conditioned prior to use. 
First, the chips and capillary were filled with water via the buffer inlet port at 10 psi for 
30 min to ensure all air was purged from the system. The both ends of the chips were 
placed in a Petri dish containing a damp Kimwipe and wrapped with parafilm. Next, this 
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procedure was repeated with 1M NaOH to form hydroxyl groups [177] on the inner 
surfaces of the capillary and PDMS microchannels. The NaOH was removed during the 
buffer priming step of the sample injection process. 
 Separation and detection of analytes 
The separation voltage was provided by a 0-30 kV high voltage DC power supply 
(HV350, Information Unlimited, Amherst, NH, USA). The tip of the high voltage 
electrode wire was submerged in the separation buffer well of the injection chip and that 
of the ground electrode wire was submerged in the waste well of the detection chip. 
Electrodes were held in place by electrically-insulated clamps mounted on a retort 
stand. 12 kV was supplied to achieve a field of ~200 V/cm along the separation channel. 
The total length of the separation path from the buffer well to the waste well was 62 cm. 
The effective separation length, i.e. injection point to the detector, was 61 cm. CE 
voltage was turned on or off using a solid-state relay in series with the high-voltage side 
of the circuit. During operation, DC current was monitored in real-time via a digital 
multimeter (Model 2831E, BK precision, Yorba Linda, CA, USA) to detect any abnormal 
behavior of the chip. For example, any air/gas bubble formation can lead to interruption 
of the current with intermittent electrical arcing; if this occurred, the high voltage was 
immediately interrupted, and the fluidic system was reconditioned for ~2 min to purge 
any bubbles and to re-equilibrate the inner surfaces. 
 Micellar Electrokinetic Capillary chromatography (MEKC) 
 In CE, the migration of analyte depends on the electroosmotic flow (EOF), bulk 
flow, and on the charge of analytes. If all analytes are neutral, they cannot be 
separated.  
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Micellar electrokinetic capillary electrophoresis (MECE) is a type of capillary 
electrophoresis where a surfactant (e.g., sodium dodecyl sulfate, SDS) is added to the 
running buffer to form micelles to assist with separation of neutral analytes [178].  
Micelles are formed when surfactants with long hydrophobic tails and polar heads self-
organize into spherical aggregates, which occurs above a specific surfactant 
concentration known as the critical micelle concentration (CMC; 8mM for SDS).   
Anionic (negatively charged) surfactants, such as SDS used in our study, form micelles 
with net negative charge and migrate towards the anode, which is the opposite direction 
of EOF. Since the EOF is typically faster than the migration velocity of the micelles, the 
net movement will still occur in the same direction of the EOF. When micelles are 
formed, neutral analytes with differing hydrophobicity distribute differently between the 
hydrophobic inner core of the micelles and the hydrophilic exterior. Thus, the species 
that are more hydrophobic will be slowed down due to more interaction with the micelles 
compared to those that are less hydrophobic and have less interaction with the micelles. 
This variation in analyte/micelle affinity produces different migration velocities for neutral 
analytes, resulting in separation.   
 Reagents 
Sodium phosphate monobasic (NaH2PO4), sodium phosphate dibasic dihydrate 
(Na2HPO4), boric acid, sodium dodecyl sulfate (SDS), ammonium acetate, ethanol, 
sodium chloride (NaCl), sodium hydroxide (NaOH), thymine, thymidine, furfuryl alcohol 
(FA), 2',3'-didehydro-3'-deoxythymidine (stavudine), and 3' deoxy-3'-fluorothymidine 
(FLT) were purchased from Sigma–Aldrich (Milwaukee, WI, USA). Zidovudine impurity 
B (chlorothymidine, CLT) was purchased from LGC Standards (Wesel, Germany). 
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Kryptofix2.2.2 (K222), 3-N-Boc-5'-Odimethoxytrityl-3'-O-nosyl-thymidine (Boc-FLT) were 
purchased from ABX (Radeberg, Germany). 
All samples were prepared with 18 MΩ deionized water using a Milli-Q® Integral 
Water Purification system (EMD Millipore, Billerica, MA, USA). 30 mM phosphate buffer 
(PB) was prepared via titration 100 mM solutions of NaH2PO4 and Na2HPO4 and 
monitored with a pH meter (Mettler, Toledo, Easy five, Columbus, OH, USA). 100 mM 
SDS in 30 mM phosphate buffer (SDS-PB) was prepared by dissolving SDS in 30 mM 
PB. All buffers were degassed prior to use. 
 UV absorbance measurements 
Before the light source was turned on, the detector reading (i.e. dark noise) was 
recorded. Next, the optical path was filled with the buffer solution (SDS-PB), a blank 
(reference) signal was recorded as a function of wavelength, to enable removal of 
effects of the capillary wall / flow cell, buffer solution, etc. on the measurement. 
The light transmission percentage (%T) at a given wavelength is equal to the 
intensity of light that passed through the sample, I, divided by the initial light intensity I0. 
This can be calculated by taking the ratio of the sample signal (S) minus dark noise (D) 
over the reference signal (R) minus the dark noise: 
%𝑇 =
𝐼
𝐼0
∗ 100 =
𝑆 − 𝐷
𝑅 − 𝐷
∗ 100          (Equation S1) 
The absorbance, A, is then computed as follows: 
𝐴 = 2 − log10 %𝑇             (Equation S2) 
To create an electropherogram, spectrometer output was measured at a rate of 
10 samples/s and converted to absorbance, starting at the time of injection. 
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Each electropherogram was analyzed using OriginPro 8.5 (OriginLab, 
Northampton, MA, USA) to determine peak migration times (tm, taken at peak center), 
peak widths (w1/2, full width at half maximum), as well as other values such as peak 
areas based on a Gaussian fit to each peak. Peaks were identified based on retention 
times determined by injecting standard compounds individually. 
 
 CE System characterization 
 Characterization of injection chip 
For the purposes of characterizing the injector, the detection chip was not used; 
rather, detection of analytes was performed directly in the capillary using a 4-way 
junction (PEEK Cross, P-729, Idex Health & Science, Oak Harbor, WA, USA) positioned 
7 cm away from the downstream end of capillary. A small portion of capillary was 
covered with a 1/16" OD tubing sleeve (Idex Health & Science, Oak Harbor, WA, USA) 
and secured via two opposite ports of the junction. The illumination and detection optical 
fibers were secured in the two perpendicular ports. Note that the effective separation 
length in this case was 54 cm. The total separation length between the buffer well of the 
injection chip and the waste vial was 61 cm and the separation voltage applied was +12 
kV. 
To assess the sample injection repeatibility, successive injections of 5mM 
thymidine were performed with a valve opening time of 800 ms. 
 Characterization of detection chip 
Chemical purity tests are performed on radiopharmaceutical preparations to 
confirm the absence of impurities after the purification and formulation processes. For 
some impurities (e.g. Kryptofix K222, etc.), there are well-established limits based on 
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toxicity studies that can safely be injected into patients. Unstudied impurities, provided 
they pose negligible risk of carcinogenicity, are typically limited to 1.5 µg per patient per 
day (5 nmol for a compound with molar mass of 300 g/mol). A typical 
radiopharmaceutical preparation has a volume of 1-10 mL (or larger) and contains 
sufficient material for 1 or more patient scans. In the conservative case (1 mL volume, 1 
patient), this gives an upper permitted limit of 5 µM. To establish whether these levels 
can be detected in our setup, we have characterized the sensitivity of detection chip by 
measuring the limit of detection (LOD) and limit of quantitation (LOQ) for varying 
conditions, including varying optical detection path length and varying optical systems).  
To characterize the detection chip, the capillary was connected but the injection 
chip was not used. Instead, UV absorbance was measured when the detection chip was 
fully filled with several concentrations of each analyte. The absorbance was measured 
for each sample at the desired wavelength(s) for ~ 1 min, and then averaged to obtain 
one data point. This procedure was repeated 3 times while flushing the optical path 
length with blank solution between each measurement.  The three data points were 
then averaged to obtain an overall absorbance value for the particular concentration of 
the particular analyte. To minimize the impact of cross-contamination, the most dilute 
samples were measured prior to more concentrated samples. After performing a linear 
fit of absorbance versus concentration (i.e. Beer’s Law), the LOD and LOQ were 
determined by calculating the concentration that corresponds to 3x and 10x, 
respectively, the standard deviation in background absorbance noise. UV absorbance 
was measured at 256 nm or 224 nm, corresponding to the wavelengths of maximum 
absorbance for the model compounds used. 
 65 
 Evaluating separation efficiency 
To evaluate separation efficiency, we chose as a model system the PET tracer 
[18F]3’-fluoro-3’-deoxythimidine ([18F]FLT), for which the impurity profile is well known 
[179]. The synthesis scheme and the structurally-similar side-products are shown in 
Figure 3-4. A mixture of FLT and by-products (5 mM thymidine, 2 mM thymine, 2.5 mM 
furfuryl alcohol, 5 mM stavudine, 2.6 mM FLT, and 1.4 mM CLT) was injected to assess 
separation efficiency. Separation was performed with micellar electrokinetic 
chromatography (MEKC) since the compounds are all neutral. 
 
Samples were injected via injection chip using a valve opening time of 400 ms. 
For each peak in the resulting electropherogram, the number of theoretical plates, N, 
was calculated as follows [180], [181]: 
𝑁 = 5.54 (
𝑡𝑚
𝑤1/2
)
2
    (1). 
 
 Benchmark comparisons to conventional method 
Performance was compared to separations on an analytical HPLC system as 
previously described [166]: Knauer Smartline HPLC system using a C18 Luna reverse 
Figure 3-4. Radiosynthesis of [18F]FLT showing side-product formation.  
A mixture of FLT and side-products was used as a model system in this work. Figure 
adapted from [45], copyright © 2012, with permission of Elsevier. 
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phase column (4.6 mm × 250 mm, 5 µm; Phenomenex, Torrance, CA, USA). Detection 
was performed at 224 and 254 nm with an inline UV detector (model 2500, Knauer, 
Berlin, Germany). The HPLC mobile phase for FLT separations was 10% ethanol in 
water (v/v), at flow rate of 1 mL/min. All chromatograms were collected by a GinaStar 
analog to digital converter (Raytest USA Inc., Wilmington, NC, USA) and GinaStar 
software (Raytest USA Inc., Wilmington, NC, USA). Comparisons were also made to 
previously reported results using a commercial (macroscale) CE system (PA800, 
Beckman Coulter, CA, USA) [166]. 
 Results and Discussion 
 Sample injection 
Injection repeatability of the PDMS injection chip was assessed by determining 
the consistency of peak area resulting from successive injections of single compound. 
The relative standard deviation (RSD) of peak area of successive injections of thymidine 
was 3.9% (n=8). Since this performance was sufficient for remaining experiments to 
assess the feasibility of the hybrid MCE for chemical purity analysis, further optimization 
was not performed at the time, and remaining results are performed with this injector. 
However, peak area RSD <2% is generally desired for quantitative analysis 
[182].  Li et al. reported a peak area RSD as low as 1.77% (n=15) [169], using a similar 
PDMS injection chip, but with an integrated separation channel rather than external 
capillary as used here. We suspect that dead volume at the chip to capillary junction in 
our MCE setup (see discussion below) may be causing the variability. 
 67 
Another way to improve performance may be to switch injection methods since 
the method can have a large impact on the peak area RSD. In HPLC, the amount of 
sample is measured volumetrically (by the injection loop), resulting in very high injection 
repeatability. Recently, we explored a novel volumetric injection technique for MCE and 
showed that a peak area RSD as low as 1.04% (n=4) [94] could be achieved (see 
Chapter 4: Novel volumetric method for highly repeatable injection in microchip 
electrophoresis), even using an external capillary for separation. We are thus confident 
that a next-generation device incorporating a PDMS-based injector will achieve 
sufficient repeatability for radiopharmaceutical analysis. 
 Sample detection in MCE device 
Initially, we attempted UV detection directly in the capillary. The LOD and LOQ 
for several analytes, using both combinations of light source and detector are shown in 
Table 3-1. Even when the higher performance setup (Detector 2) was used for the in-
capillary detection, LODs were all higher than 20 µM, and significantly worse than 
values previously measured for HPLC [166]. This is likely due to the much shorter 
optical path through the sample in the capillary (i.e. ~75 µm, the inner diameter of the 
capillary) compared to the 10000 µm flow cell in the HPLC system. The values were 
also significantly worse than those previously measured in a commercial CE system (5 
– 11 µM; Beckman Coulter PA800) [166], likely due to differences in the optical system, 
capillary environment (i.e. temperature-controlled in the commercial CE system), and 
signal processing. 
To improve the LOD, a PDMS detection chip with a Z-shaped extended optical 
path (500 µm) was implemented. In combination with the higher performance light 
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source and detector pair (Detector 2), LODs ranged from 2 - 3 µM for the set of 
compounds with similar chromophore (thymidine, thymine, stavudine, FLT, and CLT), 
and 7 µM for furfuryl alcohol. Thus, the LOD values of the MCE setup are comparable to 
the performance of HPLC (i.e., 2 µM for stavudine and FLT, 35 µM for furfuryl alcohol) 
[166], and are below the typical permitted limit of impurities found in 
radiopharmaceuticals. Detection performance is summarized in Table 3-1 for all system 
configurations. Since the desired performance was achieved, the 500 µm OPL was 
used in subsequent experiments. For a 500 µm OPL detection chip and Detector 
Configuration 2, we found the linear range of the various species to be: 2 µM – 5 mM 
(thymidine), 2 µM – 5 mM (thymine), 7 µM – 3 mM (furfuryl alcohol), 3 µM - 5mM 
(stavudine), 3 µM – 5 mM (CLT), and 2 µM – 5 mM (FLT). 
 
Table 3-1. Limits of detection (LODs) and quantitation (LOQs) for all setups for 
FLT and its impurities. 
 Blank entries indicate conditions that were not measured. By combining a higher performance 
light source and detector with 500 µm OPL (bold entries), the sensitivity of the MCE setup was 
comparable to HPLC (bold entries). 
Experimental Setup 
 
Compound 
Thymidine Thymine FA Stavudine FLT CLT K222 
MCE 
detection chip 
(with 500µm OPL)                    
 Wavelength (nm) 256 256 224 256 256 256   
Detector 1 
(lower 
performance) 
LOD 8  30      
LOQ 30  96      
Detector 2 
(higher 
performance) 
LOD 2 3 7 3 2 3   
LOQ 8 10 23 10 8 9   
In-capillary 
detection 
 Wavelength (nm) 256 256 224 256 256 256   
Detector 1 
(lower 
performance) 
LOD (µM) 210 260 790 310 300 1100   
LOQ (µM) 750 850 2600 1000 1000 3500   
Detector 2 
(higher 
performance) 
LOD (µM) 22 21 54 27 25 75   
LOQ (µM) 72 69 180 91 84 250   
HPLC 
Wavelength (nm)   224 254 254  * * 
LOD (µM)   35 2 2  Not detected 
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LOQ (µM)   116 4 5  Not detected 
Commercial CE 
Wavelength (nm) 254 254 218 254 254 254 218 205 
LOD (µM) 5 5 11 7 6 6 180 120 
LOQ (µM) 13 14 36 15 20 15 570 390 
*Measurements were attempted at various wavelengths (205, 218, 224, 236, 254, and 267 nm) but K222 could not be 
detecteda 
 
We also explored the possibility to achieve similar performance with the lower-
performance (and lower cost) light source and detector (Detector 1) by fabricating 
additional detection chips with different OPL. The LOD and LOQ values for thymidine 
and furfuryl alcohol in detection chips with different OPL are summarized in Table 3-2. 
To more clearly see the effect of OPL, we note that LOD is defined as the concentration 
of analyte where the absorbance equals 3x the standard deviation of noise (N). 
Substituting into Beer’s law, we can write LOD = 3N/ε/OPL, where ε is the molar 
absorbtivity. Thus, LOD is inversely proportional to the OPL and the data in Figure 3-5 
were thus fit to this function to extrapolate the OPL necessary to match the performance 
of HPLC. To achieve LOD = 2 µM for thymidine (and FLT and stavudine, which have an 
identical chromophore and thus similar absorbance), an OPL of 2500 µm would be 
required. Similarly, to achieve LOD = 35 µM for furfuryl alcohol, an OPL of 420 µm 
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would be required. Thus, the PDMS detection chip with Detector 1 could match/surpass 
the detection sensitivity of HPLC by extending the optical path length to 2500 µm.  
 
Table 3-2. Performance of PDMS detection chip with varying optical path lengths.  
Limit of detection (LOD) and quantitation (LOQ) are indicated for thymidine (256 nm) and furfuryl 
alcohol (224 nm). Measurements were performed with the lower performance light source and 
detector (Detector 1). 
 Thymidine (256 nm) Furfuryl alcohol (224 nm) 
OPL (µm) LOD (µM) LOQ (µM) LOD (µM) LOQ (µM) 
125 40 130 130 430 
250 18 56 56 190 
375 11 36 36 120 
500 8 30 30 96 
1000 5 16 16 54 
 
 Separation of samples 
Previously we showed that mixtures of FLT and its structurally-similar byproducts 
(thymidine, thymine, furfuryl alcohol, stavudine, and CLT) could be separated by HPLC 
and by a conventional CE instrument with baseline resolution [102]. We analyzed 
similar samples to demonstrate the feasibility of injecting, separating, and detecting 
samples in the hybrid microfluidic system.  
Figure 3-5. Dependence of LOD on the OPL of the PDMS detection chip. 
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First, we started with the simplest geometry that resembles the commercial CE 
instrument, i.e., a capillary-only (“0-junction”) system without any microchips connected 
(Figure 3-6A). For this method, the injection was performed electrokinetically, by 
inserting the upstream side of the capillary in the sample vial (2 mL, C4013-15A, 
Thermo Scientific), applying +12 kV for 5 s, then moving the capillary back to the buffer 
vial prior to separation. Successful baseline separation of the sample mixture (FLT and 
five impurities) was achieved (Figure 3-7A). 
Next, the injection microchip was added to the capillary to form a “1-junction” 
system (Figure 3-6B). Even though baseline separation was observed for most peaks, 
the first two peaks were not completely resolved (Figure 3-7B). Finally, we tested an 
integrated microfluidic system with injection chip, silica capillary and detection chip 
(Figure 3-6C). An electropherogram is shown in Figure 3-7C. While all expected peaks 
are discernable, baseline separation was not achieved among the three fastest eluting 
compounds (thymidine, thymine, and furfuryl alcohol). Qualitatively, it is clear that the 
peak width using the hybrid MCE device was greater than that for the 0-junction setup, 
leading to the reduced separation efficiency. This was confirmed by computing the 
number of theoretical plates, N, for each setup (Table 3-3): it was found that N is 
significantly lower for the hybrid MCE device compared to the 0-junction setup. 
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Figure 3-6. Schematic of system configurations with different numbers of 
capillary-chip junctions.  
(A) Setup with the capillary only (0-junction configuration). Sample was introduced via 
electrokinetic injection, and detection occurred in a capillary detection cell. (B) Setup with the 
PDMS injection chip and capillary (1-junction configuration). Detection occurred in a capillary 
detection cell. This setup was used for evaluation of the injection performance. (C) Hybrid MCE 
device with PDMS injection chip, capillary, and PDMS detection chip. Red dotted circles highlight 
capillary junctions. Diagrams not to scale. 
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To determine where improvements can be made, we analyzed another measure 
of efficiency: the plate height, H=L/N, where L is the effective separation length. Lower 
H values indicate more theoretical plates within the separation length meaning a higher 
Figure 3-7. Separation performance of 3 different system configurations.  
(A) Electropherogram from separation in a capillary-only (0-junction) setup. Peaks: 6 mM 
thymidine (peak 1), 3 mM thymine (peak 2), 5 mM furfuryl alcohol (peak 3), 6 mM stavudine 
(peak 4), 3 mM FLT (peak 5), 3 mM CLT (peak 6). (B) Electropherogram from separation in a 
1-junction setup (i.e., injection chip with a capillary). Peaks: 5 mM thymidine (peak 1), 2 mM 
thymine (peak 2), 2.5 mM furfuryl alcohol (peak 3), 5 mM stavudine (peak 4), 2.6 mM FLT (peak 
5), and 1.4 mM CLT (peak 6). (C) Electropherogram of sample mixture injected, separated, and 
detected with the hybrid MCE device (i.e. with 2 capillary-chip junctions). Peaks: 5 mM thymidine 
(peak 1), 2 mM thymine (peak 2), 2.5 mM furfuryl alcohol (peak 3), 5 mM stavudine (peak 4), 
2.6 mM FLT (peak 5), and 1.4 mM CLT (peak 6). 
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separation efficiency. Conveniently, H can be expressed as a sum of contributing 
factors (injection, detection, diffusion, and geometry) [183]: 
𝐻 =
𝐿
𝑁
= 𝐻𝑖𝑛𝑗 + 𝐻𝑑𝑒𝑡 + 𝐻𝑑𝑖𝑓𝑓 + 𝐻𝑔𝑒𝑜    (2) 
The injection and detection components are determined from the length of the 
injection plug (linj) and the length of the detection cell (i.e. OPL) (ldet), respectively [183]: 
𝐻𝑖𝑛𝑗 =
𝑙𝑖𝑛𝑗
2
12𝐿
    (3) 
𝐻𝑑𝑒𝑡 =
𝑙𝑑𝑒𝑡
2
12𝐿
    (4) 
where L is the effective separation length. 
The contribution of axial diffusion [181], [183] is given by:  
𝐻𝑑𝑖𝑓𝑓 =
2𝐷𝑎
𝜈
    (5) 
where Da is the diffusion coefficient of the analyte and ν is the linear velocity of 
the analyte. 
The contribution due to the geometry is the most complex [183], [184]: 
𝐻𝑔𝑒𝑜 = 𝑛
(𝜔𝜃)2
12𝐿
+
𝜎𝑛𝑖
2
𝐿
+
𝜎𝑑𝑣
2
𝐿
    (6) 
The first term can be ignored since our system does not currently use a 
separation channel with a serpentine pattern (n is the number of turns, ω is the width at 
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the top of the channel (peak of the turn), θ is the turn angle). σni represents band 
broadening from non-ideal behavior of injected sample and Joule heating, and σdv 
represents the broadening due to dead volume.  Both σni and σdv are of unknown form 
that depends of geometric shape of the channel, channel material, and electric field 
gradients [184]. 
Based on electropherograms, values of N, H, Hinj, and Hdet were computed and 
are summarized in Table 3-3. These results show that the contribution to peak 
broadening due to the detector (Hdet) in the hybrid MCE (2-junction) device is negligible 
and broadening due to the injector (Hinj) is ~1% for stavudine and <1% for CLT. Thus, 
the major contributors to the broadening of peak width are Hdiff or Hgeo.  
For the 0-junction CE system, H (total) was low, i.e. 6.41 µm and 6.38 µm for 
thymidine and CLT, respectively. Based on the well-defined computed values of Hinj and 
Hdet, and ignoring Hgeo for the moment, maximum upper bounds on Hdiff for the 0-
junction system can be estimated as ~3.5 µm and ~5.2 µm for thymidine and CLT, 
respectively. It is expected that broadening due to diffusion (Hdiff) would have a similar 
value for the 1- and 2-junction (hybrid MCE) systems. This is because the analytes, 
buffer, and temperature were consistent across these systems and thus Da was 
constant. In addition, the elution velocities were very similar (e.g. for CLT, 0-junction 
velocity was 0.054 cm/s, 1-junction velocity was 0.038 cm/s, and 2-junction velocity was 
0.045 cm/s). Thus, we expect Hdiff to have an upper bound of only a few µm for the 1- 
and 2-junction cases, and we can deduce that Hgeo must be the dominant factor for 
both.  
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Comparing the CLT peak from the 0- and 1-junction cases, there was a large 
increase in H (i.e. from 6.4 to 39), and comparing the 1- and 2-junction cases, there was 
another large increase (i.e. from 39 to 121). Since there are only minor expected 
differences in the injection, detection, or diffusion components of plate height, these 
increases must be due to geometric factors. Because of the strong increase in H as the 
number of junctions increases, the band broadening is likely occurring due to the 
geometry (e.g. dead volume) at each capillary-to-chip junction. 
Table 3-3. Separation performance for the CE setups with different numbers capillary-
chip junctions.  
Migration time (tm), peak full width at half maximum (w1/2), number of theoretical plates (N), plate 
height (H), injection component of plate height (Hinj), and detection component of plate height 
(Hdet) are shown for each. Values were calculated for the fastest and slowest eluting analytes, 
i.e. stavudine and CLT for 1- and 2-junction cases and for thymidine and CLT for the 0-junction 
case. 
Analytica
l Method MCE 
No. Cap 
junction 0 1 2 
Compou
nds 
Thymidine Thymine FA Stavudi
ne 
FLT CLT FA Stavudine FLT CLT Stavudine FLT CLT 
tm(s) 610 630 670 690 750 980 920 970 1070 1400 970 1050 1360 
W1/2(s) 5 5 5 7 7 8 15 17 21 28 22 30 45 
N 
82400 88100 99200 54200 6360
0 
82800 21000 18100 14300 13900 10700 6780 5060 
H (µm) 6.43 6.01 5.34 9.78 8.33 6.40 26 30 38 39 57 90 121 
Hinj (µm) 2.96 2.78 2.47 2.30 1.96 1.15 0.65 0.58 0.48 0.28 0.67 0.42 0.25 
Hdet 
(µm) 
9.01E-04 9.01E-04 9.01E-04 9.01E-
04 
9.01
E-04 
9.01E-
04 
2.93E-
03 
2.93E-03 2.93E
-03 
2.93E
-03 
0.034 0.034 0.034 
number 
of 
repeats 
(n) 
3 3 3 3 3 3 4 4 4 4 3 3 3 
 
The dead-volume could be reduced by various approaches such as precise 
drilling [184] or molding  the capillary port [185], or by tapering the capillary to fit directly 
in an in-plane microchannel [94], [186].The geometry issue could also be addressed by 
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integration of the separation channel directly into the chip (instead of using a capillary); 
this would eliminate the junctions altogether and simplify the overall setup, enabling a 
single integrated microfluidic device for injection, separation, and detection. Separation 
in PDMS channels has been reported by several groups [187], [188], though some have 
reported challenges in maintaining stable surface conditioning [189], [190]. An 
alternative may be to perform separation using an embedded capillary [191], [192]. With 
an optimized chip, one could expect the total plate height H to be similar to the 0-
junction case. Indeed, the elimination of 1 junction shows significant improvement in 
separation (Figure 3-7B), and elimination of both junctions shows further improvement 
(Figure 3-7A), achieving baseline separation of FLT and five impurities. An optimized 
hybrid (2-junction) MCE system with improved capillary junction is therefore expected to 
be capable of similar baseline separation. 
In addition to addressing the dead-volume at the capillary junctions in this 
manner, optimization of other parameters could also be explored to maximize 
separation efficiency. For example, applied electrical field can be increased to increase 
the velocity of analytes, which would reduce diffusive broadening, and either allow 
reduced separation times or enable the use of increased separation length. 
 Conclusions 
The use of miniaturization to reduce the equipment size and shielding needed for 
the chemical purity analysis of PET tracers is expected to be a key part of streamlining 
the QC testing process, and ultimately the overall tracer production process. In this 
work, we have demonstrated the first proof-of-concept experiments to show the 
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feasibility of microfluidic implementation of chemical identity and purity tests of 
radiopharmaceuticals.  
The novel hybrid MCE device consists of a PDMS injection chip, a silica capillary, 
and a PDMS detection chip. Sample injection was based on hydrodynamic injection 
using microvalves to achieve satisfactory reproducibility while avoiding the known 
injection bias of conventional electrokinetic injection. The detection chip enabled 
adjustment of the optical path length to tune the limit of detection. Though an extended 
path length of 500 µm resulted in LOD comparable to HPLC when the higher 
performance light source/detector pair was used, we showed that further extension of 
the optical path (e.g. OPL ~2500 µm) could enable similar sensitivity even with the 
lower performance light source and detector, without significantly compromising the 
separation performance. In the integrated hybrid device, mixtures of FLT and impurities 
were successfully injected, separated, and detected. Even though FLT was successfully 
separated from all impurities, several impurity peaks were not fully resolved with 
baseline resolution. While the separation performance of the integrated device was 
lower than desired, a detailed analysis identified the capillary-chip junctions as the 
problem. Extrapolating from the performance when junctions are eliminated, we argue 
that a device with optimized junctions [94] could achieve the requisite performance.  
Furthermore, the optimized MCE device would be very much smaller than an HPLC 
system. 
Unlike simple colorimetric tests that have been developed for determination of 
certain individual impurities (e.g. Kryptofix 2.2.2, a phase transfer catalyst frequently 
used in the synthesis of 18F-labeled PET tracers), MCE-based testing provides a flexible 
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way to assess different and multiple impurities, possibly by tuning separation conditions 
and/or adding detectors (e.g. electrochemical, pulsed amperometric, etc.) for detection 
of species with low UV absorbance. Furthermore, separation prior to detection greatly 
reduces the chance of false negatives or positives due to non-specific interactions that 
can occur in colorimetric tests. Due to the flexibility of a chromatographic approach, it is 
expected that this device could easily be applied to the evaluation of PET tracers other 
than FLT. Furthermore, integration of a radiation detector would enable assessment of 
radiochemical identity and purity in the same device. 
In the long term, this device and other microfluidic QC tests could be combined in 
a unified lab-on-a-chip device for performing fully-automated QC testing of 
radiopharmaceuticals. In addition to alleviating the burden of performing and 
documenting QC tests, such a system would reduce the amount of sample consumed 
for analysis, reduce the radiation exposure to personnel, and potentially reduce the time 
needed to complete all QC tests.  
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4. Chapter 4: Novel volumetric method for highly repeatable injection in 
microchip electrophoresis  
Volumetric injection (bottom) provides reliable injections for CE and MCE using the same concept as an HPLC injection valve (top) 
 Overview 
We have previously explored the feasibility of using CE as a replacement for 
HPLC during quality control (QC) testing of batches of PET tracers. With CE, 
comparable separation performance and limit of detection could be achieved, while 
analysis times could be shortened in some cases. This is part of a larger effort to 
miniaturize all stages of tracer production to reduce costs of radiation shielding, 
equipment, and overall production, which could increase access to diverse PET tracers 
[23], [48], [193], [194]. 
 Motivation: Need of high injection repeatability in CE  
However, CE has often been considered to have inferior reproducibility 
compared to other separation techniques such as HPLC or gas chromatography (GC) 
due to sample injection bias, sample leakage and other factors inherently induced by 
current sample injection methods, and thus has not been as widely used in quantitative 
analysis [195]–[197]. Numerous advances have largely eliminated this concern in recent 
years [96], [156], though achieving the desired degree of reproducibility (e.g. peak area 
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RSD < 2% [182])  remains a challenge in many cases. In HPLC, highly repeatable 
sample volumes are achieved by using “injection valves”. In the “load” state of these 
specialized two-state valves, a “loop” of well-defined volume is filled with the sample, 
and, when switched to the “inject” state, this sample is injected directly into the 
separation pathway. Such method has not been directly applicable to CE due to the 
much smaller sample volume requirements of CE as well as issues arising from the use 
of high voltages. However, by developing an electrical decoupler, a similar approach 
has been shown in conventional, macroscale, CE systems [195], [198]. Sample was 
loaded into a nanoliter-scale injection valve, then pushed via a syringe pump through 
the electrical decoupler into the separation channel, after which the CE voltage can be 
applied. Combining this approach with low temperature operation, peak area RSD was 
reported to be 0.5 – 2.7%.  
In microchip electrophoresis (MCE), however, it is generally preferable that the 
injection method be integrated directly into the microfluidic chip rather than relying on 
external systems. Though a wide variety of methods have been explored to increase the 
reliability of sample injection in MCE [168], [199], [200], to the best of our knowledge, 
there has not been a fixed loop injector as in HPLC that allows the same quantity of 
sample to be introduced per injection [197]. Typically in MCE devices, injection of 
sample into a separation channel occurs at the intersection point between a sample 
channel and the separation channel. The intersection may be a “T”, a cross, a “double 
T”. With a T junction, the sample flows directly into the separation channel and control 
of timing or the sample flow determines the injection volume. With a cross or double-T 
injection, the sample flow crosses the separation channel and flows toward a (sample) 
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waste outlet; the detailed geometry of the junction and operation sequence/timing 
generally determines the injection volume. 
 Various sample injection methods in MCE 
A common way to induce the sample flow is by applying a potential between the 
sample and a waste well (electrokinetic injection). While very simple and offering the 
possibility to perform integrated sample concentration (i.e. stacking) [95], this method 
suffers from injection bias in which solutes with higher electrophoretic mobilities are 
preferentially introduced, resulting in a difference between the compositions of the 
original and injected samples  [167], [168]. The problem is exacerbated with repeated 
injections, though several groups have developed methods to replenish the sample to 
mitigate long-term changes in sample composition [201], [202]. The electrokinetic 
injection method is also sensitive to the voltage and to many properties of the sample 
(e.g. conductivity, pH, possibility of complex formation, electrolysis) [168].  
To overcome these drawbacks, pressure-driven injection is becoming more 
widely used [168]. It is often performed in a cross or double-T geometry by applying a 
pressure difference between two points to drive sample into the separation channel, and 
then separation voltage is applied. The resulting sample plug is free of injection bias 
(thus representative of the original sample). The sample can be driven by hydrostatic 
pressure [203], with a syringe pump [204], or by applying positive or negative pressure 
to the sample well [192], [205]. A variety of other “plug shaping” techniques have been 
developed to reduce the sample volume and/or avoid sample “leakage” [188], [204], or 
to improve control of the sample volume [206], but they tend to add complexity and 
sometimes introduce injection biases. 
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Despite the advantages of these pressure-driven injection methods, injection 
reproducibility remains too low in many cases. Rather than rely on geometry to control 
the injection volume, several methods rely on internal pumps and valves to exert more 
precise control over the amount of sample injected. One approach is to use microvalve-
based chips [207], typically made from poly(dimethylsiloxane) (PDMS). The basic 
concept is to apply constant pressure to the sample and use a computer-controlled 
microvalve that can be momentarily opened to inject the sample into the separation 
channel [188], [205]. Such valve-based approaches exhibit repeatable sample injection, 
yielding RSD of the peak area in the range of 1.76 to 5% [169], [200], [208]. Though 
pressure-driven injection eliminates analyte-dependent electrokinetic bias, it could still 
suffer from other types of variations due to its dependence on flow rate of the sample 
and microvalve timing to determine the volume injected and could be influenced by the 
sample properties such as viscosity, which can vary significantly with temperature.  
In addition to timing-based valves, other approaches have been developed in an 
attempt to improve repeatability and reduce dependence on sample properties. Bowen 
and Martin reported controlling the actuation time and frequency of an on-chip peristaltic 
pump, rather than timing and pressure, to achieve consistent injection volume [103]. 
Karlinsey et al. reported a similar approach with a CV of peak area of ~5% [209]. There 
also has been an attempt to combine the on-chip pump with a valve-enclosed sample 
loading area; however, it would be challenging to achieve injection repeatability due to 
problems associated with the large dead volume [187]. Solignac and Gijs reported a 
different method in which an elastomeric membrane is actuated with an electromagnet 
to generate a pressure pulse to inject a controllable amount of sample [210]. Though 
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most of these reports did not include reproducibility data, it is expected that all of these 
methods would still depend on fluid properties similarly to hydrodynamic injection.  
 Our approach: Volumetric sample injection 
We have developed a valve-based microchip injection method that eliminates all 
of these biases and is similar in operation to an HPLC injection valve. Using PDMS 
microvalves placed around the separation channel, a well-defined fixed volume can be 
confined within the separation channel in a loading step [211]. Due to the volumetric 
metering approach, this method eliminates the injection bias found in electrokinetic 
injection and eliminates the influence of several variables in valve-based injection such 
as driving pressure, valve response times, or properties of the sample (e.g. viscosity). 
Furthermore, unlike previously reported methods to meter accurate volumes in an 
external injection loop, this method is directly integrated into the chip, avoids the need 
for an electrical decoupler, and avoids dispersion and mixing because the sample does 
not need to be moved before separation can begin. Thus substantially improved 
injection repeatability can be expected. We characterize the performance, compare to 
conventional hydrodynamic injection and electrokinetic injection, and demonstrate the 
independence from fluid properties such as viscosity.  
 Materials and methods 
 Reagents and solutions 
Sodium phosphate monobasic (NaH2PO4), sodium phosphate dibasic dihydrate 
(Na2HPO4), sodium dodecyl sulfate (SDS), sodium hydroxide (NaOH), 3’-deoxy-3’-
fluorothymidine (FLT), thymidine, 2′,3′-didehydro-3′-deoxythymidine (Stavudine) and 
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zidovudine impurity B (chloro-L-thymidine; CLT) were purchased from Sigma Aldrich 
(Milwaukee, WI, USA). Glycerol (AR® ACS) was purchased from Avantor Performance 
Materials, Inc. (Center Valley, PA, USA). All chemicals were of analytical grade and 
were used as received without further purification. Deionized water (18 MΩ) was 
obtained using a Milli-Q® Integral Water Purification system (EMD Millipore, Billerica, 
MA, USA).  
 Microfluidic chip design and fabrication 
The microfluidic injector chip and details of the channel design are shown in 
Figure 4-1. To achieve a well-controlled injection volume, sample is loaded into a fixed-
volume chamber within the chip. The chamber is formed from a segment of a 
microchannel bounded by closed microvalves. The geometry and positioning of the 
microvalves are designed to minimize the dead volume. Inlets and outlet are connected 
to the sides of the chamber via microvalves to enable sample loading and washing. 
Once the chamber has been filled, microvalves at the ends of the chamber are opened, 
allowing the contents to be injected into the separation channel. 
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Figure 4-1. 3D representation and detailed channel design of the PDMS 
microfluidic chip. 
Microfluidic injection chip connected to a capillary with (A) perpendicular junction geometry and 
(B) collinear junction geometry. Valve control channels are shown in orange and fluid handling 
channels are shown in blue. Micrograph of the collinear junction (blue dashed box) is shown in 
the inset in B. The injection chamber is outlined in a red dashed box. vx = valve control port. (C) 
Micrograph of the region in the black dashed box. 
 
The chip was fabricated in the UCLA Integrated Systems Nanofabrication 
Cleanroom (ISNC) from poly(dimethylsiloxane) (PDMS) using multilayer soft lithography 
[207]. The chip consisted of two layers of PDMS bonded to a bottom PDMS substrate 
layer. Integrated microvalves were formed via a “push-up” valve architecture [170], with 
valve control channels (15 µm deep x 75 µm wide) molded in the thin PDMS layer 
closest  to the substrate, and fluid-carrying (“flow”) channels (20 µm deep x 75 µm wide) 
molded in a thicker layer above. The flow channel layers had a rounded cross section to 
enable complete channel sealing when underlying control channels were actuated. To 
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minimize dead volumes, microvalves were placed as close as possible to the edge of 
the channel they were blocking. Details of the fabrication of molds and microfluidic chips 
are described previously [33]. 
Separation was performed in a 20 cm long, Teflon-coated fused silica capillary 
(75 µm I.D., 375 µm O.D; Polymicro, Phoenix, AZ, USA) connected to the PDMS chip. 
In initial experiments, the capillary was connected via a port perpendicular to the 
channel (“perpendicular junction”). While suitable for characterizing volume 
repeatability, the dead volume inherent in this design led to non-optimal separation. 
Thus, in later experiments, the capillary was connected by insertion directly into the 
microchannel through the side of the microfluidic chip (“collinear junction”) as mentioned 
in 3.5.3 (‘Separation of samples’). The two chip-to-capillary junctions are illustrated in 
Figure 4-15. For the chips with the capillary connected via the “collinear junction”, this 
port for the capillary was not punched. After three layers were assembled and 
completely cured, the chip was cut vertically from the top surface with a razor blade 
near the end of fluidic channel, such that the channel was accessible from the side of 
the chip. One end of the capillary was tapered by polishing with micro-grit sand papers 
(grit sizes of 600, 1200 and 2500 in sequence; 2 min each) on the spin-coater (Model 
PWM32, Headway Research, Inc., Garland, TX). At the end of this procedure, the 
capillary was tapered down to an outer diameter of close to 75 μm. With the aid of a 
stereomicroscope (Stemi SV 11, Zeiss, Oberkochen, Germany) and portable 
microscope (Dino-lite Plus AM311S, AnMo Electronics, Taipei), the tapered capillary 
was horizontally inserted about ~1mm deep into the exposed end of the fluidic channel. 
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To provide mechanical stabilization and provide an air-tight seal, additional PDMS pre-
polymer mixture was poured near the interface and cured in the oven at 80°C for 2 h. 
 Microchip and capillary conditioning 
The chip was hydrated prior to conditioning by filling the chip and capillary with 
water via the buffer inlet port. Water was loaded at 10 psi for 30 min to ensure all air 
was purged from the device. The chip was placed in a Petri dish containing a damp 
Kimwipe and wrapped with parafilm and the other end of the capillary was inserted into 
a septum-sealed vial containing DI water. Conditioning, to form hydroxyl groups [177] 
was performed by following this same procedure using 1M NaOH instead of water. Just 
prior to use, the NaOH was flushed first with water and then the separation buffer, i.e., 
30 mM sodium phosphate buffer with 100 mM SDS. 
 Capillary electrophoresis setup 
The overall setup to evaluate the PDMS injector chip is shown in Figure 4-2. The 
capillary extending out of the hybrid chip runs through a detection cell and the other end 
is placed in a PDMS waste well. The waste well is fabricated from two 1”x1/2” PDMS 
slabs (~5 mm thick). A well is created by punching a 4.75mm ID hole through the top 
slab prior to corona discharge bonding of the two slabs together.  
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Figure 4-2. Experimental setup for evaluation of micro-injector chip. 
 
The sample (~1 mL) was contained in a 2 mL septum-sealed vial (Fisherbrand™ 
2 mL screw thread autosampler vial, Thermo Fisher Scientific, Waltham, MA, USA). 
Pressurized nitrogen gas was supplied to the vial through an electronic pressure 
regulator (ITV0010-3BL, SMC Corporation of America, Noblesville, IN, USA) set to a 
pressure of 1.5 psi. The vial also contained an outlet tubing (#30 PTFE tubing) 
connected to the sample inlet port of the injector chip. The buffer was contained in an 
identical vial, supplied with 6.0 psi nitrogen pressure, and with the outlet tubing 
connected to the buffer inlet of the injector chip. On-chip microvalves were each 
controlled by the common port of an external solenoid valve (S070B-5DG, SMC 
Corporation), connected to the chip via #30 PTFE tubing. The solenoid valves switched 
between two states: (i) supplying pressurized nitrogen (35 psi) to close the on-chip 
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microvalve, and (ii) venting to atmosphere to allow the on-chip microvalve to open via 
elastic restoration of the PDMS. To avoid the generation of air bubbles inside the 
sample-containing channels of the chip, the valve control channels were filled with 
water. To achieve this, the end of each PTFE tubing was immersed in DI water and a 
~1” water plug aspirated into the tubing prior to connection to the chip. By then 
supplying 35 psi pressure to each tubing for a few minutes, the small amount of air 
trapped in the corresponding channel was eliminated prior to operation.  
Injected samples were separated via micellular electrokinetic chromatography 
(MEKC). The separation voltage was provided by a 0-30 kV high voltage DC power 
supply (HV350, Information Unlimited, Amherst, NH, USA). The tip of the high voltage 
electrode wire was submerged in the separation buffer well of the injector chip and that 
of the ground electrode wire was submerged in the PDMS waste well. Electrodes were 
held in place by electrically-insulated clamps mounted on a retort stand. 4kV was 
supplied to achieve a field of 190 V/cm across the separation channel (~1 cm long 
channel in chip plus 20 cm long capillary). CE voltage was turned on or off using a solid-
state relay in series with the high-voltage side of the circuit. During operation, DC 
current was monitored in real-time via a digital multimeter (Model 2831E, BK precision, 
Yorba Linda, CA, USA) to detect any abnormal behavior of the chip such as air bubble 
formation followed by electrical arcing. The typical current was ~0.6 mA. If arcing 
occurred, the high voltage was immediately interrupted and the channel and capillary 
were flushed with buffer for 2 min to purge any bubbles and re-equilibrate the inner 
surfaces. 
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The detection cell was located 16 cm from the inlet of the capillary, i.e. 17 cm 
from the point of injection. It consisted of a 4-way junction (PEEK Cross, P-729, Idex 
Health & Science, Oak Harbor, WA, USA) for aligning the illumination and detection 
optical fibers with the capillary to perform UV absorbance measurements. Illumination 
was provided by a deuterium continuous light source (DH2000-DUV, Ocean Optics, Inc, 
Dunedin, FL, USA) and detection was performed via a spectrometer (USB4000, Ocean 
Optics, Inc, Dunedin, FL, USA). UV absorbance was measured at 262 nm, 
corresponding to the wavelength of maximum absorbance for the model compounds 
used (Figure 4-3). 
The solenoid valves, digital pressure regulator and spectrometer were connected 
to a digital acquisition (DAQ) module (USB 6211, National Instruments Corporation, 
Austin, TX, USA). A custom-written LabVIEW program (National Instruments 
Corporation, Austin, TX, USA) was used to coordinate the timing of all functions. 
 
 
Figure 4-3. Absorbance of thymidine, stavudine, FLT and CLT as a function of 
wavelength. 
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 UV absorbance measurements 
Spectrometer output was recorded at a rate of 10 samples/s since the time of 
injection to create an electropherogram. The transmitted light intensity across the buffer-
filled capillary, IB, was measured by the spectrometer prior to sample injection and used 
as a reference. Then, the absorbance of the sample (AS) was calculated as AS = log10(IS 
/ IB), where IS is the transmitted light intensity across the capillary containing the sample 
as measured by the spectrometer. 
 
 Chip operation 
4.2.6.1 Volumetric injection 
The detailed steps involved in operation of the chip to perform volumetric 
injection are shown in Figure 4-4. The basic approach is to prefill a fixed chamber (to 
volumetrically measure the sample), then open valves to fluidically connect this 
chamber to the separation channel, and finally apply the electric potential.  
The chamber was a channel of length 4 mm (75 µm wide, 20 µm deep). Due to 
the rounded profile the nominal volume is approximately 4 nL. In our chip design, a 
valve (v7) was also included in the middle of this chamber, enabling switching to a 
chamber of only half the volume (i.e. ~2 nL). This valve is not shown in Figure 4-4A, but 
is shown in Figure 4-6. Valve v4 was not used and was kept closed at all times. Before 
operation, the chip was first primed with buffer (Step 1) to ensure that the tubing from 
the buffer vial and all channels are filled with buffer. This was accomplished by 
pressurizing the buffer vial (6 psi) and opening valves v1, v3, and v6 until the entire 
channel and capillary were filled with buffer, and the buffer started flowing out of all the 
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ports and buffer well. Next (Step 2), the sample inlet was primed to ensure that the 
tubing from the sample vial as well as the sample inlet channel were completely filled 
with sample. This could be accomplished in two ways. In the first method (shown in the 
Figure 4-4), the sample vial could be temporarily pressurized to a higher pressure (e.g. 
~10 psi) causing the air ahead of the sample to permeate out through the PDMS until 
the sample inlet was completely filled with sample up to the valve v5 (blind filling).  A 
faster method is to purge the air by applying the normal sample pressure and opening 
both v2 and v5 until all of the air has passed through v5, the sample chamber, and past 
v2. 
After priming, the sample chamber is loaded by pressurizing the sample to 1.5 
psi and opening valves v2 and v5 (Step 3). Once the sample has started exiting the 
chamber through the waste, v5 is closed first, followed by closure of v2 after a ~2s delay 
(Step 4). The delay is included so that the sample pressure (1.5 psi) is not “trapped” in 
the sample chamber, which could distort the PDMS and change its volume [212]. The 
sample is then injected by opening valves v1 and v6 (Step 5), allowing a brief delay 
(150 ms) to ensure the valves are fully open, then then applying the electrophoretic 
potential (Step 6). 
Though completion of chamber loading was monitored by observing liquid 
emerging out of the waste port, which could consume a relatively large amount of 
sample, it is conceivable to use other means such as on-chip peristaltic pumping for a 
certain number of cycles [103] to minimize sample consumption associated with each 
injection. 
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Figure 4-4. Schematic view of injector chip operation for volumetric injection (A) 
and timed injection (B).  
Solid red boxes indicate closed microvalves and hollow red boxes indicate open microvalves. 
Arrows indicate direction of fluid flow. Channels filled with buffer are shown in blue while those 
filled with sample are shown in green. The capillary and waste well are connected for all steps 
but for clarity are only depicted in the final step when the separation voltage is applied. Diagrams 
not to scale. 
 
4.2.6.2 Timed hydrodynamic injection 
Using the same chip, it is also possible to perform conventional hydrodynamic 
sample injection, providing an ideal benchmark for comparison of the performance of 
the two injection methods. Basically, the sample is pressurized and a microvalve is 
momentarily opened to admit a small amount of sample into the separation channel. 
The detailed operation of the chip to perform “timed injection” is shown in Figure 4-4B. 
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Before use, the chip is first primed with buffer (Step 1) by pressurizing the buffer vial 
and opening valves v1, v3, and v6 until buffer started flow out of all the ports and buffer 
well. Next, the sample inlet is primed (Step 2) using either of the two methods described 
in the previous section. If the “purging” method is used, it it necessary to flush the 
sample out of the separation channel by flowing buffer through v3 and v2.  
To load the sample, valve v1 is opened, and then valve v5 is momentarily 
opened for a fixed time to allow sample to fill part of the main channel in the chip (Steps 
3-4). The opening time (600 ms) was chosen to achieve a comparable injection volume 
as the volumetric injection method (see Figure 4-5). The peak area resulting from 
volumetric injection was measured to be 3.5 AU-sec and 6.3 AU-sec for the timed 
injection.To inject the sample, v1 and v6 were opened (Step 5), followed by a brief delay 
(150 ms), and then electrophoretic potential was applied (Step 6). 
It should be noted that in many reports of timed injection, there is no valve 
interrupting the separation channel. Since the sample flow is less constrained in that 
case (i.e. it flows both upstream and downstream into the separation channel), we 
believe such form of timed injection would have comparable or inferior performance to 
that reported here. 
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Figure 4-5. Determination of valve actuation time for hydrodynamic injection 
Peak height of the timed injection as a function of valve opening time (n=1), and comparison to 
volumetric injection. Injected sample was 50mM FLT. 
 
4.2.6.3 Controlling the injected volume: “Half” volume injection 
We included a microvalve in the middle of the sample chamber to allow loading 
of two different sample volumes, i.e. a full chamber volume (~4 nL) or a half chamber 
volume (~2 nL). Chip operation to inject the full volume is shown in Figure 4-4. Figure 
4-6 shows the procedure to load a half chamber volume. 
 
Figure 4-6. Sequence of operations to perform injection of a half chamber volume 
(2 nL). 
 The microfluidic chip used in this work contained an additional valve and waste port in the middle 
of the sample chamber that can be used to subdivide the sample chamber and thus provide some 
control over the sample volume. A full volume (4 nL) can be injected by keeping v7 open and v8 
closed and performing the steps in Figure 4-4. 
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 Injection performance characterization 
Using the same chip design, comparisons were made among volumetric injection 
and timed hydrodynamic injection, as well as electrokinetic injection (see 4.2.8). 
Injections were performed with single compounds initially, and then mixtures of 
multiple compounds. The single-compound samples comprised thymidine in DI water or 
FLT in 95:5 water:acetonitrile (v/v). The mixture sample contained thymidine, stavudine, 
FLT, and CLT in water. These represent the product and structurally-similar side 
products in the synthesis of the positron emission tomography (PET) tracer [18F]FLT 
[102], [179]. Each injection resulted in an electropherogram. The detected UV 
absorbance peaks (at 262 nm) were fit to a Gaussian profile to determine the peak area 
and migration time (tm; peak center) from each injection. Injection repeatability was 
measured by performing multiple injections in the same chip and calculating the RSD of 
peak areas. Sets of injections were performed in different chips to determine 
consistency. 
Since peak symmetry can affect the resolution for mixture samples, we also 
characterized the peak symmetry by computing the U.S. Pharmacopeia (USP) tailing 
factor for each peak: Tf = wac / 2wab, where wac is the peak width at 5% of the peak 
height, and wab is the front half-width measured from the leading edge to a 
perpendicular dropped from the peak apex at 5% of the peak height. Tailing factor close 
to 1 is desired. The number of theoretical plates was also calculated for each peak: 
N=16 x (tm/W)2, where tm is the migration time and W is the baseline peak width 
determined via the tangent method (Figure 4-7). For mixture samples, the peak 
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resolution between pairs of neighboring peaks was calculated: R= (tm2-tm1)/0.5*(W1+W2), 
where tmi is migration time and Wi is the peak width at baseline (tangent method) for 
each peak (i = 1,2). 
To avoid effects of buffer depletion, which can affect the migration speed and 
hence the peak area, the fluidic channels were flushed with fresh buffer solution after 
each individual injection. In addition, the buffer well and waste well were replenished 
with ~120 µL each of fresh buffer solution. It may be possible to avoid the need for 
manual buffer exchange by implmenting wells for buffer and waste that have larger 
volume. Alternatively, a more sophisticated microfluidic chip could be designed that 
includes additional valves and pumps to perform automated buffer exchange. 
 
Figure 4-7. Method for determination of peak width 
Baseline peak widths were measured using the tangent methods. Tangents were drawn from the 
inflection points on each side of the peak and intersection with the baseline determined. The 
distance between these intersection points was the peak width 
 Method of Electrokinetic injection 
Electrokinetic injection (EK) was performed using the same chip to avoid the 
introduction of additional variables. Injection was performed by the series of steps in 
Figure 4-8. The chip is first filled with buffer (Step 1). During the sample loading step, 
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v5 remains closed and sample reservoir is filled with the sample solution (Step 2). For 
sample injection, the same field strength as separation, 200 V/cm, was applied between 
sample reservoir and sample waste. Because the distance was 1.5 cm, a potential of 
300 V was applied. Potential was applied for 3.0 s to inject sample in the sample 
reservoir toward sample waste (Step 3). This time was chosen to achieve a similar 
injection amount to the other approaches. Finally, the sample was injected into the 
capillary by applying separation voltage between the buffer well and waste well (Step 
4). The injection electrodes submerged in the sample inlet and sample waste were 
physically removed from the wells 1 s prior to applying separation voltage to avoid any 
backflow or other undesired fluid movement. The channel was flushed with fresh buffer 
solution between injections with v5 closed to avoid any change in sample composition 
during the rinsing step. 
 To verify the comparable injection volume in EK injection and volumetric 
injection, we compared the peak area of each peak in multiple-compound 
electropherograms. For 20 mM thymidine, the peak area for volumetric injection was 
1.21±0.01 AU-sec (n=4) and that for EK injection was 1.26±0.06 AU-sec (n=3). For 13.6 
mM Stavudine, the peak areas of both volumetric and EK injections were 0.91 AU-sec 
(n=4 and 3, respectively). 
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Figure 4-8. Schematic view of injector chip operation for EK injection.  
Solid red boxes indicate closed microvalves and hollow red boxes indicate open microvalves. 
Arrows indicate direction of fluid flow. Channels filled with buffer are shown in blue while those 
filled with sample are shown in green. The capillary and waste well are connected for all steps 
but for clarity are only depicted in the final step when the separation voltage is applied. The 
same field strength (200 V/cm) was used for both sample injection (HV1) and sample separation 
(HV2). 
 
 Measurement of microvalve response times 
To explore possible sources of variation in injected volumes for the timed 
injection method, we explored the consistency of response times of the on-chip 
microvalves. The experimental setup is shown in Figure 4-2. The positive terminal of a 
5 VDC power supply was connected to the buffer well, and the ground terminal was 
connected to a series resistor, Rm = 8 MΩ, which was connected to the waste well. The 
potential causes a current to flow through the separation channel and capillary and 
through Rm. The voltage across this resistor, Vm, was measured over time while 
momentarily opening (for 600 ms) a microvalve positioned along the separation 
channel. When the valve was open, current could flow and Vm had a non-zero value. 
When the valve was closed, current could not flow and Vm was 0. The time period that 
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the valve was open was determined from graphs of voltage versus time. Consistency of 
the total open time was compared for different valves on the same chip, different chips, 
and valves with different amount of hydraulic fluid (water) in the valve control lines. 
 
Figure 4-9. Experimental setup for electronically measuring the response time of 
microvalves.  
(A)Experimental setup. Vm is recorded as a function of time by a computer as a valve is 
momentarily opened. The resulting plots are analyzed to determine the total time that the valve is 
open (i.e. non-zero Vm due to non-zero current through the fluidic circuit). (B) Illustration of current 
flow when microvalve is open. (C) Current is blocked when microvalve is closed. 
 
 Results and Discussion 
 Comparison of injection performance 
In volumetric mode, the microfluidic chip with perpendicular chip-to-capillary 
junction was used to inject successive ~4 nL samples of single compounds. For each 
run, the electropherogram showed a flat baseline with a sharp single peak (Figure 
4-10A,B). The migration time for thymidine was 207±2 s (n=11), and that for FLT was 
221±6 s (n=11). Examples of the UV absorbance peaks from 11 successive injections in 
the same chip are shown in Figure 4-10C for 50 mM thymidine, and Figure 4-10D for 
50 mM FLT. Table 4-1 compares the peak area RSD values. As summarized in Table 
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4-1, the peak area RSD values for 3 trials (of 11 injections each) were 1.34%, 1.04%, 
and 1.47% for thymidine, and 1.79%, 1.55%, and 1.74% for FLT. 
The small RSD values are comparable to or better than literature reports. To the 
best of our knowledge, the best reported peak area RSD was 1.77% (n=15) using a 
PDMS chip with integrated microvalves for timed hydrodynamic injection [169]. Since 
there are many factors of the setup that could affect the apparent consistency of the 
results (e.g., optical setup, light source stability, detector performance), our results likely 
cannot be directly compared to those of Li et al.  
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To better gauge the enhanced performance of volumetric injection, we also 
performed timed hydrodynamic injection in the same chip to eliminate potential 
Figure 4-10. Electropherogram of single analyte injection. 
(A) Example electropherogram of single injection of 50 mM thymidine using the microfluidic 
volumetric injector chip. (B) Example electropherogram for sample of 50 mM FLT. (C) 
Assembled electropherograms of successive injections (n=11) for 50 mM thymidine. Peak area 
RSD was 1.04%. There is a gap between peaks because the wells were replenished between 
runs to avoid effects of buffer depletion. (D) Assembled electropherograms for 50 mM FLT. Peak 
area RSD was 1.55%. 
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variables. As expected, operation in time-dependent injection mode resulted in higher 
peak area RSD compared to volumetric injection. For thymidine, we observed peak 
area RSD values of 2.04%, 3.37% and 4.59% in three chips (11 injections per chip), 
and for FLT we observed values of 1.86%, 3.65% and 7.16%. Clearly, using the same 
chip and CE setup, volumetric injection shows significantly improved performance over 
timed injection.  
 
Table 4-1. Summary of RSD values. 
RSD values for single-compound injections using volumetric injection and timed injection in the 
same PDMS chip design. Each RSD value is computed from n=11 individual injections. A fresh 
microfluidic chip was used for each trial and for each compound. 
Injection method 
Injection 
parameters 
Trial 
Peak area RSD (%) 
thymidine FLT 
Volumetric injection 
Sample volume 
= 4 nL 
1 1.34 1.79 
2 1.04 1.55 
3 1.47 1.74 
Timed injection 
Injection time 
= 600 ms 
1 3.37 7.16 
2 4.59 1.86 
3 2.04 3.65 
 
 Sources of variation in timed injection 
We investigated some factors that affect only the timed injection method to see if 
they could potentially explain the different performance (peak area RSD) between the 
two injection methods. 
One consideration is the stability and repeatability of the pressure source. The 
flow rate of the sample would be expected to change linearly with any pressure 
changes. Some reports have controlled pressure via fluid height (hydrostatic pressure) 
[203], [213], [214] or external syringe pump [204], [215], while we used an electronic 
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pressure regulator. The regulator is reported to have a stability of ±0.2% of full-scale 
value (i.e. ±0.06 psi). Since the sample pressure was nominally 1.5 psi, it is possible 
that pressure fluctuations could be responsible for at least some of the observed 
variation. 
 Measurement of microvalve response times 
Another consideration is the consistency of microvalve operation: any variation in 
the opening or closing time could potentially affect the total amount of time the sample 
is flowing into the separation channel, and thus the volume that is loaded. The actual 
time the microvalve is open is the programmed opening time minus the opening 
response time plus the closing response time. The response times depend on several 
parameters: (i) the pressure of the gas used to control the valves (which may be subject 
to some fluctuation), (ii) the electromechanical response time of the external solenoid 
valve that switches between pressurized and vented state, (iii) the fluidic delay due to 
movement of pneumatic/hydraulic fluid within the valve control channel and valve 
control line (which would vary based on the amount of hydraulic fluid in the lines), and 
(iv) the mechanical deflection of the microvalve membrane (which would vary 
depending on the thickness of the micromachined valve membrane and the elastic 
properties of the PDMS). By monitoring the electrical current through a microchannel, 
we found in some cases significant variation (up to several %) in the total open time for 
a single valve (Figure 4-11) or for different valves (Figure 4-12) in the same chip. 
Variations in amount of hydraulic fluid in the valve control lines seem to have negligible 
effect on the total open time of the valves (Figure 4-13). 
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Volumetric injection, on the other hand, provides a way to use similar technology 
for injection (i.e. microvalves), but eliminate the effect of any variability in driving 
pressure, valve response times, etc. 
 
 
Figure 4-11. Repeatability of response time of the same microvalve in the same 
chip.  
Graphs show normalized measurement of Vm, which is proportional to electrical current through 
the channel, as the valve was momentarily opened for 600 ms. (A) Valve in Chip 1, (B) Valve in 
Chip 2, (C) Valve in Chip 3. The same legend applies to all graphs. In chip 1, the valve had an 
open time RSD of 5.3% (n=3 runs), potentially contributing significant variation in injected volume 
and thus peak area. In chips 2 and 3, the valves had open time RSDs of 2.6% (n=3 runs) and 
0.6% (n=3 runs), respectively. 
 
 107 
 
Figure 4-12. Repeatability of response time of different microvalves within the same 
chip.  
Graphs show normalized measurement of Vm, which is proportional to electrical current through 
the channel, as the valves were momentarily opened for 600 ms. (A) Chip 1, (B) Chip 2, (C) Chip 
3, and (D) Chip 4. The same legend applies to all graphs. The RSDs of the total open time were 
7.9% (n=3 valves), 5.8 (n=3 valves), 1.8 (n=3 valves), and 0.9 (n=3 valves), respectively, for Chips 
1-4. 
 
 
 
Figure 4-13. Effect of the amount of hydraulic fluid on the microvalve response time.  
(A) Schematic showing the tubing connecting the solenoid valves to the control channel inlet ports 
on the microfluidic chip. The distal portion of the tubing (i.e. closest to the chip) is typically filled 
with hydraulic fluid (e.g., water) to avoid injection of pressurized gas into the other device channels 
by permeation through PDMS. (B) Normalized voltage profile of a single valve actuation with 
varying amounts of hydraulic fluid (water). 
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 Effect of sample viscosity on injection repeatability 
The volumetric flow rate, 𝑄 = ∆𝑝/𝑅 , can be affected by the stability of the driving 
pressure ∆𝑝 or by the fluid resistance, R, which is highly dependent on the geometry of 
the channel as well as fluid properties (i.e., proportional to sample viscosity). A higher 
viscosity sample will flow more slowly than a low one, so any inconsistencies in sample 
concentrations, sample buffer composition, or temperature (e.g. Joule heating over 
time) can lead to poor reproducibility. The latter can be a significant issue as viscosity of 
aqueous solutions can exhibit significant temperature dependence (e.g., at room 
temperature, the viscosity of water or saline solution can vary ~2%/°C [216], [217]). One 
of the expected advantages of volumetric injection is that the loaded volume should be 
independent of the fluid properties. We compared the effect of viscosity on the quantity 
of sample injected for the two injection methods (Figure 4-14). Samples consisted of 50 
mM thymidine dissolved in DI water or dissolved in 30% glycerol/water (v/v), with 
expected dynamic viscosities of 0.893 mPa-s and 2.57 mPa-s, respectively, at room 
temperature [218], [219].  
For timed injection, the higher viscosity sample showed significantly lower peak 
area compared to non-viscous sample (p = 8x10-8 << 0.05, two-tailed T-test). The peak 
area was 3.58±0.10 AU-sec (n=6) for the low viscosity sample and 2.84±0.09 AU-sec 
(n=6) for the high viscosity sample. Based on the Hagen-Poiseuille equation, the flow 
rate is expected to be inversely related to the dynamic viscosity, and so a nearly 3-fold 
reduction in injected volume would be expected based on the viscosity differences (for 
the same driving pressure and valve opening time). A smaller reduction was seen, 
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perhaps due in part to the elastic nature of the PDMS which may expand slightly and 
tend to reduce the fluidic resistance, counteracting the effect of increased viscosity. 
In contrast, with volumetric injection, the peak areas of the low and higher 
viscosity samples were not significantly different (p = 0.20). The lower viscosity sample 
had peak area of 3.05±0.08 AU-sec (n=6), while the higher viscosity sample had peak 
area of 3.10±0.05 AU-sec (n=6). Thus the volumetric injection technique is expected to 
prevent differences in injection amounts for different samples, or for the same sample at 
different temperatures. This could enhance quantitative performance in situations where 
a variety of different samples (or sample buffers) may be injected in sequence. 
 
 
Figure 4-14. Effect of sample viscosity. 
(A) Representative electropherograms of thymidine samples with different viscosities injected 
via timed injection (hydrodynamic injection) and volumetric injection. Note that the small 
negative peak in the eletropherograms for the higher viscosity samples likely represents the 
glycerol that is present in these samples. (B) Averaged peak area (n=6 each) observed at 
detector after separation voltage applied. The use of timed injection results in variation in peak 
area (i.e. amount injected) depending on viscosity. For volumetric injection, the peak area is 
independent of viscosity. 
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 Other comparisons between injection methods 
An advantage of timed injection is that different injection volumes can easily be 
achieved via control of the valve opening time. This flexibility can be used to 
accommodate different length capillaries or other variations in CE method that might 
require different sample amounts. In the volumetric approach, the volume too can be 
adjusted, but requires redesign of the chip to implement a chamber of different volume.  
Alternatively, modest changes in volume could be achieved by filling the chamber under 
pressurized conditions, which leads to a predictable expansion of the chamber volume 
[212]. (The loading process would need to be slightly modified to ensure that the sample 
chamber is closed while still under pressurized conditions.) Another possible approach 
to add volume flexibility is to introduce several microvalves along the sample chamber 
to allow the length of the chamber to be dynamically adjusted (in discrete steps) [220], 
as was done in the chip designed in this study (i.e. either ~2 or ~4 nL injection volume). 
Another difference between the two injection methods is the flow profile. The 
hydrodynamic flow associated with timed injection has a parabolic velocity profile (i.e. 
faster flow in middle of channel compared to flow near the walls), which could lead to a 
small amount of dispersion in the sample plug as it is loaded from the inlet into the 
separation channel. In contrast, in volumetric injection, the injection chamber is part of 
the separation pathway and the sample does not undergo this dispersive flow prior to 
experiencing the separation potential.   
 Improvement of peak symmetry via colinear junction configuration 
It was evident from the electropherograms (e.g. Figure 4-10) that there was 
significant peak tailing for both the volumetric and timed injection approaches. For 
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samples of 50 mM FLT, the tailing factors were 1.78±0.2 (n=8; volumetric injection) and 
1.80±0.19 (n=8; timed injection), and for 50 mM thymidine, the tailing factors were 
1.62±0.14 (n=8; volumetric injection) and 1.85±0.05 (n=8; timed injection). 
We suspected the tailing was largely due to the chip-to-capillary junction. The 
“perpendicular” junction used in initial studies has significant dead volume (Figure 
4-15), which is known to be a cause of dispersion and potentially peak asymmetry as 
the sample plug is flowing through that region [184], [185]. To attempt to resolve the 
issue of peak shape, we implemented an improved chip-to-capillary junction with 
minimal dead volume.  Indeed, when switching to a “collinear” junction geometry, we 
observed that absorbance peaks were significantly narrower and more symmetric 
(Figure 4-16). For samples of 50 mM thymidine, the tailing factor was within the 
acceptable range (i.e., 1.15±0.01, n=8) with the collinear junction compared to 
1.62±0.14 (n=8) with the perpendicular junction and this was comparable to the tailing 
factor of electrokinetic injection with the collinear junction, 1.18±0.21 (n=8). 
In addition, the number of theoretical plates increased from 7770±730 (n=8) to 
9130±710 (n=8) with use of the collinear junction compared to the perpendicular 
junction. For a trial of successive injections, the peak area RSD was found to be 1.56% 
(n=10), which is in the same range as results with the perpendicular junction chips.  
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Figure 4-15. Schematic of chip-to-capillary junction geometry. 
(A) Perpendicular junction; (B) collinear junction. Diagrams not to scale. 
 
 
Figure 4-16. Peak symmetry comparison between two junction configurations.  
Electropherograms of injected via the volumetric injector chip with the perpendicular chip-to-
capillary junction (A) and the collinear junction (B). Inset shows zoomed in peak shape in the 
region of red box. 
 
 Separation of 4-compound mixtures 
We then examined the ability to separate multiple compounds, and compared 
results of volumetric injection (with two different junction geometries) as well as the 
widely-used approach of electrokinetic injection. To avoid introducing additional 
variables, similar injection volume was used in all three different injection modes. 
Baseline separation of a mixture of 4 compounds was achieved using the microfluidic 
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volumetric injector chip with the collinear junction (Figure 4-17). Separation using the 
perpendicular junction is shown in the , and separation using electrokinetic injection is 
shown in the Figure 4-19.  
 
 
 
Figure 4-17. CE electropherogram showing baseline separation of a mixture of 4 
compounds. 
Using the microfluidic volumetric injector chip and 20 cm capillary connected via collinear 
junction. Injected sample contained: 20 mM thymidine (peak 1), 13.6mM Stavudine (peak 2), 
16mM FLT (peak 3) and 14mM CLT (peak 4). 
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Figure 4-18. Electropherogram of four compound mixture injected via the volumetric 
injector chip with the perpendicular junction geometry 
The sample contained: 20mM thymidine (peak 1), 14mM Stavudine (peak 2), 16mM FLT (peak 
3) and 6mM CLT (peak 4). 
 
Figure 4-19. Electropherogram of four compound mixture injected electrokinetically in 
the volumetric injector chip with the collinear chip-to-capillary geometry 
 The sample contained: 20mM thymidine (peak 1), 13.6mM Stavudine (peak 2), 17mM FLT (peak 
3) and 4mM CLT (peak 4). 
 
Peak area RSD values for the 4 compounds and various injection methods are 
summarized in Table 4-2. It implies that the capillary-to-chip junction geometry does not 
significantly affect the sample injection repeatability. This is expected because the 
injected sample amount is physically metered within the injection chamber before even 
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seeing the junction. For volumetric injection, the peak area RSD was always < 2.0% and 
values as low as 0.55% were observed. When electrokinetic injection was performed in 
the same chip with the same injection volume (as verified by comparing peak areas), 
the peak area RSD was found to be substantially higher, indicating less consistent 
sample injection. From these results and the comparison of volumetric and timed 
injection presented earlier, it appears that sample injection repeatability is mainly 
influenced by the injection method. 
 
Table 4-2. Summary of peak area RSD (%) for mixture samples. 
  
Volumetric injection Electrokinetic injection 
Perpendicular junction 
(n=4) 
Collinear junction 
(n=3) 
Collinear junction 
(n=3) 
thymidine 0.40 0.55 7.13 
stavudine 1.59 1.70 7.86 
FLT 1.78 0.65 7.79 
CLT 1.93 1.69 5.78 
 
The number of theoretical plates, N, was also calculated for each peak for each 
junction geometry (Table 4-3). As expected, we observed N to be significantly higher for 
all compounds for injection using the collinear junction compared to the perpendicular 
junction (p<0.05). In addition, N was significantly higher using volumetric injection than 
electrokinetic injection in the same chip (p<0.05). The peak resolution, R, was also 
calculated between pairs of adjacent peaks (Table 4-3). Peak resolution between the 
thymidine and Stavudine peaks was significantly higher for volumetric injection using 
the collinear capillary-to-chip junction compared to the perpendicular junction; however, 
the difference in resolution for Stavudine and FLT peaks, and for FLT and CLT peaks, 
was not statistically significant. Interestingly, R was significantly higher for volumetric 
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injection than for electrokinetic injection in the same chip.  These results illustrate that 
the improved injection repeatability does not come at the expense of sacrificed 
performance elsewhere. 
Table 4-3. Summary of the number of theoretical plates and the peak resolution 
for mixture samples. 
  Peak(s) 
Volumetric injection Electrokinetic injection 
Perpendicular 
junction 
(n=4) 
Collinear 
junction 
(n=3) 
Collinear 
junction 
(n=3) 
Number of 
theoretical 
plates, N 
thymidine 12090 ± 1600  21910 ± 1100 12440 ± 860 
Stavudine 12130 ± 660 18190 ± 550 10720 ± 940 
FLT 10190 ± 750 15390 ± 770 8800 ± 1400 
CLT 14400 ± 1300  17570 ± 1030 8040 ± 530 
Peak 
resolution, R 
thymidine-Stavudine 3.18 ± 0.22 3.60 ± 0.19 2.65 ± 0.10 
Stavudine-FLT 2.28 ± 0.09 2.34 ± 0.07 1.77 ± 0.12 
FTL-CLT 7.77 ± 0.44 8.10 ± 0.19 5.32 ± 0.30 
 
 Conclusions 
A novel type of volumetric microfluidic injector for CE was developed to eliminate 
variations in injection volume and thereby increase repeatability for quantitative 
analysis. With this injection method, substantially improved repeatability of sample 
injection was achieved compared to hydrodynamic injection.  Volumetric injection 
showed relative standard deviation (RSD) of peak area as low as 1.04% (n=11) for 
single-compound injections and as low as 0.40% (n=4) for multiple compound 
injections, both of which are lower than the best RSD values reported in the literature for 
hydrodynamic microvalve-based injection. Furthermore, in contrast to hydrodynamic 
injection, volumetric injection was found not to depend on sample viscosity, which might 
be beneficial in situations where diverse samples are studied, or where sample 
temperature is not well controlled. 
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As a demonstration of the performance of the volumetric injection approach, we 
showed successful baseline separation of a 4-compound mixture with high injection 
repeatability. The set of compounds represents a positron emission tomography tracer 
and synthesis byproducts, illustrating how rapid CE analysis could be used in the QC 
testing process of radiopharmaceuticals to ensure that levels of impurities are below 
acceptable limits. In previous work we showed that adequate limit of detection could be 
achieved for this application [102]. 
We also made comparisons of injection repeatability, peak symmetry, and 
separation efficiency for different chip-to-capillary junction geometries between the 
PDMS injection chip and separation capillary. Injection repeatability was not influenced 
by the junction geometry, but number of theoretical plates and peak symmetry were all 
higher in the collinear junction (with very small dead volume) compared to the 
perpendicular junction (with significant dead volume). Compared to electrokinetic 
injection (performed in the same chip to avoid introducing additional variables), we 
found volumetric injection to have significantly higher separation efficiency, resolution, 
and injection repeatability. 
The injector is straightforward to implement with standard PDMS microfluidic 
fabrication techniques. To increase volume flexibility, valve-based approaches where 
the volume or length of the chamber is dynamically adjusted can be readily incorporated 
[212], [220]. The separation channel can be incorporated in a hybrid fashion as was 
done here (i.e. with capillary), or could be integrated directly into the microfluidic chip. 
This injector would be useful in a wide range of applications where an accurate and/or 
consistent injection amount is needed. 
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5. Chapter 5: Integration of high-resolution radiation detector for microchip 
electrophoresis 
 Introduction 
Capillary electrophoresis (CE) has been used in a variety of fields such as 
separation of biomolecules [92], [93], [147], environmental monitoring [150], [151], food 
analysis [152], [221], and explosive forensics [222]. Typically compounds are detected 
via UV absorbance [REF], and additional modes of detection can be implemented such 
as pulsed amperometric detection [103], capacitively coupled contactless conductivity 
detection (C4D) [104]–[106], refractive index detection [107], or mass spectrometry [108], 
[109]. Using a radiation detector, CE has also been used for separation of radioactive 
compounds, in applications such as assessing the purity of radiotracers labeled with 
positron-emitting isotopes for positron emission tomography (PET) or labeled with 
gamma-emitting isotopes for single photon emission computed tomography (SPECT) 
[99], [101], as well as the analysis of radioisotopes in nuclear fuel development [223], 
[224]. 
Analysis of radiopharmaceuticals is performed to satisfy quality control (QC) 
testing requirements after preparation of each batch of these compounds to ensure 
safety prior to use in patients [34], [36], [225]. Unlike ordinary pharmaceuticals, the short 
lifetime of radiopharmaceuticals due to radioactive decay requires fast analysis before 
injection. In addition, it requires high separation power to accurately determine the 
radiochemical purity and high sensitivity to quantify a variety of potential non-radioactive 
impurities. Though the analysis is typically performed with HPLC, the requirements align 
well with the general capabilities CE including rapid, high-resolution separation, 
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sensitive detection, and small sample volume. In fact, these features of CE can be 
further improved by miniaturization of CE, i.e. microchip electrophoresis (MCE), which 
reduces reagent and sample consumption, reduces separation time, improves 
repeatability and can lower the overall cost via miniaturization and automation [88], 
[165]. An MCE setup is expected to have similar separating power as HPLC, but 
significantly smaller footprint – an important criteria in radiochemistry applications where 
radiation-shielded laboratory space is at a premium. 
MCE has not yet been used for radiochemical analysis of radiopharmaceuticals, 
but we have previously demonstrated, using a “hybrid” MCE device, the successful 
separation and detection of non-radioactive impurities that arise during the synthesis of 
the PET tracer  3’-deoxy-3’-[18F]fluorothymidine ([18F]FLT) [33], [94]. To perform 
radiochemical analysis, it would be necessary to add a radiation detector to this system. 
Radiation detection is challenging in MCE in general due to the tiny (nanoliter range) 
sample volume, which contains very little radioactivity and therefore requires a high-
sensitivity detector to ensure individual analytes can be reliably detected with high 
temporal resolution. Furthermore, the spatial resolution of the radiation detector must be 
high to distinguish among closely spaced radioactive analytes. So far, most works 
involving radiation detection in radio-CE have used a scintillator combined with 
photomultiplier tube (PMT) as the detection method, which has reasonable sensitivity 
[99], [223], [224], [226]–[228]. However, these systems are bulky, and will require 
significant radiation shielding for the scintillator if not detecting specifically for positrons.  
Measuring radioactivity, particularly for PET, in a microscale environment is 
tricky, since there are both the gamma rays (from positron-electron annihilation can 
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come from further distance leading to a poor spatial resolution) and the positrons which 
only travel shorter distances (i.e., a few mm).  A few groups have reported the 
microscale radiation detection methods for non-CE applications. When evaluating each 
of these approaches for potential use in our MCE device, it is important to note that 
radiation detection method must have both high sensitivity as well as high spatial 
resolution [229]. Taggart et al. used an array of silicon photomultipliers (SiPM) to 
measure radioactivity in a microchip for PET and SPECT tracers. However, gamma ray 
detection and the SiPM’s intrinsic high background noise as well as low signal response 
led to low sensitivity [125].  They also required an entire array of detectors to gain high 
spatial resolution and account for gamma rays from other areas of their chip. Cho et al. 
described a system using a plastic scintillator and CCD camera to image a microchip 
used in PET tracer synthesis, though their spatial resolution and sensitivity come at the 
cost of long imaging times, and it requires complete dark conditions to reduce noise and 
sample to be stationary [129]. Dooraghi et al. also developed an imaging device for 
microchips, but using an avalanche photodiode (APD) as the radiation detector which 
shows near perfect sensitivity to the positrons and very low sensitivity to the gamma 
rays, with the limit of detection in the nano-Curie levels [133].  The analog signal 
response and internal gain makes the detector a good choice, though imaging requires 
a larger detector and long acquisition time that is too slow for a flowing sample. Tarn et 
al. was one of the few groups to demonstrate single-point detection, using a machined 
plastic scintillator microcell as a microscale HPLC radiation detector. Even though they 
showed excellent spatial resolution, the sensitivity was compromised due to its use of 
SiPM as mentioned above [230]. Use of an SiPM in this context would require either 
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collimation, which increases the size of detector and reduces the sensitivity, or 
scintillation, which reduces spatial resolution and requires more comprehensive optical 
shielding. 
The ideal low-activity radiation detector for MCE would be a positron/charged-
particle-focused detector, since they interact strongly over a small range and therefore 
allow for a miniaturized sensitive device.  From this information, the APD was chosen as 
the radiation detection method for our MCE system based on the inherent sensitivity of 
the device to charged particles, as well as the relative ease of integration into a 
microfluidic environment due to its small size. The typical radioactivity concentration in 
an injectable PET tracer ranges from 37 - 370 MBq/mL (1-10 mCi/mL), which leads to 
very low signal available due to small sample volume used in microfluidic devices.  
Since the APD can detect nearly all of the potential positron events, it can work in the 
low-activity regimes, and focusing on positrons can substantially improve the separation 
resolution.  Since the positrons from most PET-relevant isotopes travel in the mm range 
before annihilating, this is particularly important [231], [232, p. 68], [233]. With its very 
low sensitivity to far-reaching gamma rays along with fast acquisition time, the APD is 
the ideal radiation detector for the MCE device.  
Based on this approach, we develop here the first, to our knowledge, MCE 
system with integrated radiation detector. Into a microfluidic detection chip containing a 
Z-shaped cell for UV absorbance detection, we added a radiation detection region 
comprising a thin-walled segment of a microchannel against which a small APD could 
be mounted. The detection chip was coupled to a fused-silica capillary and PDMS 
injection chip in a “hybrid” radio-MCE device. We present a detailed characterization of 
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this system and a demonstration of the ability to simultaneously perform chemical purity 
analysis and radiochemical identity analysis using the PET tracer [18F]FLT as a model 
compound.  
 Materials and methods 
 Reagents 
Sodium phosphate monobasic (NaH2PO4), sodium phosphate dibasic dihydrate 
(Na2HPO4,  ≥99.0%), sodium dodecyl sulfate (SDS, ≥98.5), potassium phosphate 
monobasic (KH2PO4, ≥99.0%),), sodium hydroxide (NaOH), thymidine (≥99%), 2′,3′-
didehydro-3′-deoxythymidine (stavudine, ≥98%), and nosyl chloride (97%) were 
purchased from Sigma–Aldrich (Milwaukee, WI, USA). Zidovudine impurity B 
(chlorothymidine, CLT, European Pharmacopoeia (EP) reference standard) was 
purchased from LGC Standards (Wesel, Germany). 3′-deoxy-3′-fluorothymidine (FLT 
reference standard, >95%), was purchased from ABX (Radeberg, Germany). SDS (100 
mM) in 30 mM phosphate buffer was prepared by dissolving SDS in 30 mM PB. All 
samples were prepared with 18 MΩ deionized water using a Milli-Q® Integral Water 
Purification system (EMD Millipore, Billerica, MA, USA). All chemicals were of analytical 
grade and were used as received without further purification. 
 Preparation of radioactive sample, [18F]FLT  
The synthesis of [18F]FLT was performed using an automated radiosynthesizer 
(ELIXYS, Sofie, Culver City, CA, USA) as previously described [234], with slight 
modification to reduce impurities. The synthesis scheme with all potential impurities is 
described in Figure 5-1. 
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Figure 5-1. Synthesis of [18F]FLT showing both product and side. 
 
5.2.2.1 Reagents for [18F]FLT synthesis 
Anhydrous-grade acetonitrile (MeCN), ethanol, 2,3-dimethyl-2-butanol (thexyl 
alcohol), hydrochloric acid (HCl), sodium hydroxide (NaOH), were purchased from 
Sigma–Aldrich (Milwaukee, WI, USA). Kryptofix 2.2.2 (K222), 3-N-Boc-5′-O-
dimethoxytrityl-3′-O-nosyl-thymidine (FLT precursor) were purchased from ABX 
(Radeburg, Germany). No-carrier-added [18F]fluoride was produced by the 18O(p,n)18F 
reaction of [18O]H2O (84% isotopic purity, Zevacor Pharma, Noblesville, IN, USA) in an 
RDS-112 cyclotron (Siemens; Knoxville, TN, USA) at 11 MeV using a 1 mL tantalum 
target with havar foil. Unless otherwise specified, all reagents were analytical grade and 
used as received. 
  
5.2.2.2 [18F]FLT Synthesis details 
The one-pot synthesis of [18F]FLT was adapted from literature [235] and 
performed on the ELIXYS radiosynthesiszer (Sofie, Inc., Culver City, CA, USA). Briefly, 
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[18F]fluoride in [18O]H2O (14.8 GBq [400 mCi]) was trapped on a pre-conditioned QMA 
cartridge and eluted with 1.38 mL of a 32% v/v H2O:MeCN mixture containing 0.59 mg 
K2CO3 and 15 mg K222 into the reaction vial. This solution was then dried at 110°C 
under nitrogen (8 psi) and vacuum. The cartridge was eluted twice more with 1 mL 
MeCN each and then further evaporated to dryness. 5 mg FLT precursor dissolved in 
700 mL thexyl alcohol and 300mL H2O was added to the vial and reacted at 115°C for 
15 min.  After cooling, the solution was evaporated at 105°C until dryness, and then 2 
mL 1N HCl was added to the vial and reacted at 135°C for 10 min. After cooling the 
vessel, the solution was neutralized with 1 mL of 2M NaOH, and then diluted with 2 mL 
of HPLC mobile phase (8% v/v EtOH in 20 mM phosphate buffer). 
The sample was purified via reversed-phase semi-preparative HPLC with a 
WellChrom K-501 HPLC pump (Knauer; Berlin, Germany), C18 Luna column (250 x 10 
mm, 5 µm particle size; Phenomenex, Torrance, CA, USA), WellChrom K250 
spectrophotometer UV absorbance detector (254 nm; Knauer) and B-FC-3300 and B-
FC-1000 radiation detector and counter (Bioscan Inc., Washington, DC, USA). At a flow 
rate of 4.0 mL/min, the retention time of FLT was 19-21 min. Since the mobile phase is 
suitable for injection, no additional formulation was performed. Identity and purity of the 
sample collected were confirmed via analytical radio-HPLC. The Smartline HPLC 
system (Knauer, Berlin, Germany) was equipped with a pump (Model 1000), degasser 
(Model 5050), UV detector (Model 2500) and a radiometric detector (B-FC-4000, 
Bioscan Inc., Washington DC, USA). Separation was performed using a C18 column 
(Luna, 250 mm x 4.6 mm, 5 µm particle size; Phenomenex, Torrance, CA, USA) with 10 
 125 
% (v/v) EtOH in 20 mM phosphate buffer mobile phase at 1.5 mL/min. Retention time of 
FLT was 5.5 min. 
To test the system at a range of radioactivity concentration, some collected 
[18F]FLT samples were concentrated by evaporation at 95 °C with a nitrogen stream (3-
5 psi) to reduce the typical ~7 mL collected volume to <1 mL. After concentration, 
radioactivity concentration of 0.74 – 3.7 GBq/mL [20 – 100 mCi/mL] could be achieved. 
 Hybrid MCE device  
The hybrid MCE device (Figure 5-2) comprised a PDMS sample injection chip, a 
20 cm fused-silica capillary, and a PDMS detection chip. The two PDMS chips have 
been slightly modified from previous designs [94], [236].  
 
 
Figure 5-2. Schematic of the microchip design.   
A) A 3D rendering of the injection and detection chips, capillary, and optical fibers. B) A top-view 
of the detection chip geometry, showing both UV and radiation detection systems. The sensitive 
region is all areas up to 1mm beyond detector edge. C) A side-view of the same geometry, 
showing the detector and substrate “tower.”  Side-view, top-view, and capillary are not to scale. 
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5.2.3.1 Injection chip 
The injection chip was fabricated as reported previously [94] with several 
modifications of the channel design as shown in Figure 5-3. First, the number of 
inlets/outlets connected to the main separation channel to perform loading of buffer, 
loading of sample, and cleaning was reduced from 5 to 2. 
Second, on these connections, we implemented “triple” microvalves instead of 
single microvalves to improve electrical isolation when activating the separation voltage. 
With a single microvalve to separate the side channels from the main channel, 
breakdown occurred frequently when operating at +12 kV (for separation in 60 cm 
capillary) and occasionally when operating at +4 kV (for separation in 20 cm capillary). 
We suspect that buffer, sample, or waste reservoirs fluidically connected to the chip act 
as local grounds, causing a large potential drop across the closed valve. Each valve 
provides only 30 μm (=2 x 15 μm) of PDMS as electrical insulation, where 15 μm is the 
thickness of the microvalve membrane. With typical breakdown strength in the range 19 
- 133 V/ μm [237], the valve can withstand 0.6 – 4.0 kV, which is insufficient to prevent 
dielectric breakdown. In contrast, the triple valves can withstand 1.8 – 12 kV. 
In all respects besides the simplification of the design, sample injection and valve 
actuation were performed in the same manner as previous work.[33] 
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Figure 5-3. Volumetric injection chip channel design.  
Fluidic layer is shown in blue. Valve control layer is shown in orange for control of flow using the 
microvalves. Tri-leaflet (“triple”) valves are added near the side channel to avoid undesired current 
leakage from the main separation channel towards the side channels. Chip is cut vertically to 
expose the flow channel for interface with glass capillary.  
 
 
5.2.3.2 Detection chip 
The previous design of the PDMS detection chip [33] was modified to improve 
the performance in several ways. 
The optical path length of the Z-shaped UV absorbance detection cell [33] was 
extended from 0.5 to 2.0 mm to enhance absorption sensitivity. The height of channels 
was 125 µm to enable inclusion of alignment channels to ensure optical fibers (125 µm 
outer diameter; ThorLabs, Newton, NJ, USA) were well aligned with the optical path of 
the cell. The optical fibers were connected to a light source and spectrophotometer as 
previously described [33]. In the initial version of the detection chip, the width of all 
channels, include the optical path, was 125 µm. However, to improve separation 
 128 
resolution, we explored a design with decreased volume of the UV absorbance cell, 
achieved by shrinking the channel width within the optical path from 125 to 45 µm while 
maintaining the same channel height (Figure 5-4). This change reduces the mismatch 
in cross-sectional area between the capillary and the rest of the chip that can lead to 
dispersion and increased peak widths (due to the lower flow velocity in the chip 
compared to the capillary) as described in Figure 5-5.  
The UV signal was collected as previously described [33]. 
In addition, a radiation detector was integrated into the detection chip. 
Downstream of the UV absorbance cell, the detection channel crosses over a region 
with thin substrate (100 μm) where the 2 mm x 2 mm radiation detector is mounted, 
before terminating in the waste well. Fabrication of the detection chip was described 
previously [33], except that the bottom PDMS was created with a 3 mm x 3 mm square 
cavity that was aligned with the radiation detection region such that the sample was 
separated from the detector by only a 100 μm PDMS membrane. To create this 
substrate, a mold was machined from acrylic having a 25 mm square cavity with 1.01 
cm depth and a 1.0 cm tall, 3 mm x 3 mm square pillar in the middle. After filling with 
degassed PDMS (10:1 mass ratio A:B, RTV615, Momentive, New Smyrna Beach, FL, 
USA), a final flat piece of acrylic was pressed on top of the mold and the PDMS cured at 
80°C for at least 2 h. The layers were bonded by exposing each piece to air plasma for 
2 min (Dyne-a-Mite LM4816; Enercon Industries Corp., Menomonee Falls, WV, USA), 
and then carefully aligning and pressing together and baking at 80°C for 10 min. The 1 
cm thickness provides mechanical stability while the cavity allows the radiation detector 
to be positioned only 100 μm below the channel. 
 129 
Finally, to improve separation resolution, the capillary-to-chip junction dead 
volume was reduced by implementing a collinear junction [94], [184], [185] as used in 
the injection chip, by tapering the capillary and inserting into end the detection channel 
via the side of the chip. To stabilize the connection, freshly-prepared and degassed 
liquid PDMS (10: 1 mass ratio A:B, RTV615, Momentive, New Smyrna Beach, FL, USA) 
was added and then cured at 80°C for at least 1 h. Prior to this step, the chip was filled 
with water to avoid clogging of channels by the liquid PDMS.  
 
Figure 5-4. Detection chip channel design  
Gradual tapering of fluidic channel from 125um to 45um, and narrower channel (45um wide) near 
the OPL to improve separation efficiency. The channel height is 125um everywhere. Chip is cut 
vertically to expose the flow channel for interface with glass capillary.  
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Figure 5-5. The influence of UB absorbance detector volume on separation 
resolution 
Time sequence of multiple-analyte detection in the chip with (A) 125 µm wide detection region 
and (B) 45 µm wide detection region. The lower volume cell reduces the likelihood that adjacent 
peaks will overlap. 
 
 Radiation detector 
Radiation detection was performed using an avalanche photodiode (APD; 
Radiation Monitoring Devices Inc., Watertown, MA, USA) with a 2 mm x 2 mm active 
area biased at 1750 V using a high-voltage power supply (TC952; Tennelec, Oak 
Ridge, TN, USA).  
A thin opaque coating was deposited on the detector to prevent optical photons 
from triggering the detector while minimizing attenuation of positrons. The device was 
first coated with 2 µm of parylene C (Specialty Coating Systems Inc., Indianapolis, IN, 
USA) using a parylene deposition machine (PDS 2010, Specialty Coating Systems 
Inc.), followed by 350 nm of gold deposited by sputtering (Desk V, Denton Vacuum, 
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Moorestown, NJ, USA), and finally followed by an additional 2 µm of parylene C. The 
gold layer also served as a Faraday cage, providing electrical shielding of the detector. 
A thin nichrome wire was attached to the detector substrate via silver epoxy (MG 
Chemicals, Burlington, Ontario, Canada) before the gold coating, and later soldered to 
circuit ground.  
To discriminate electronic and heat-related noise and fluctuations from positron 
events, it is necessary to amplify and “shape” the signal, as the noise pulses have much 
lower amplitude than the desired signal. The current change in the APD when energy 
was deposited was too low to be directly measured, and is therefore passed through a 
trans-impedance amplifier, capacitively coupled to the detector to protect from the high 
bias voltage, as described by Dooraghi et al. [238]. This signal is then further processed 
by a pair of two passive filters, a CR filter of time constant 100 ns and a RC filter of time 
constant 200 ns, to shape the pulses to a sharp peak with a 200 ns width.  Each filter is 
followed by a non-inverting amplifier to both increase the signal and stop each filter from 
interfering with the others.  Once filtered and amplified, the signals were compared 
against an empirically-chosen threshold, and those above the threshold were counted 
as digital pulses by a data acquisition (DAQ) module (USB-6501, National Instruments, 
Austin TX, USA).  A program written in LabVIEW (National Instruments, Austin, TX, 
USA) records the number of counts every 0.5 s, and the value is multiplied by 2.0 to 
determine an instantaneous value in units of cps. A detailed schematic of the process 
can be seen in Figure 5-6. 
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Figure 5-6. Schematic diagram of the signal shaping process.  
 The preamplifier, a transimpedance amplifier, changed the small current into a voltage peak.  The 
high-pass filters create a sharp leading edge on the peaks, for temporal resolution, and the low-
pass filters smooth out any noise in the peaks. The asymmetry in the filter times was chosen as 
reducing noise/lengthening peaks was more beneficial to us than increasing peak shape-related 
SNR.  The comparator is set to reject all peaks that fall below a certain value, which is all electronic 
noise-caused peaks. 
 
 Characterization of radiation detector 
The dark noise of the radiation detector was measured by collecting data for 6 h, 
and then calculating the average and standard deviation of the data. During this time, 
the chip was empty, and no radioactive sources were located near the detector (i.e. 
exposed only to natural radiation background). The limit of detection (LOD) and limit of 
quantitation (LOQ) were computed as 3x and 10x the standard deviation, respectively. 
The average value of the dark noise, which was recalculated for each experiment, was 
subtracted from all data, and the standard deviation of the noise was used to determine 
the limits of detection for the day of experiment. 
To investigate the linear range, a detection chip was filled with known 
concentrations of aqueous [18F]fluoride (11-1600 MBq/mL [0.3-42 mCi/mL]) and the 
resulting APD signal measured over 5 min for each sample. All measurements were 
performed with a single chip on a single day. Between each run, the chip was cleaned 
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with DI water (1.0 mL) and dried with compressed nitrogen. Additionally, the dark noise 
was re-measured before each run to enable accurate subtraction of any background 
radioactivity that might be present due to contamination of the chip from the previous 
run. The 600 datapoints collected over each 5 min interval were averaged and plotted 
as a function of the radioactivity concentration. To estimate the LOD and LOQ for this 
setup (detection chip only), the dark noise from the lowest-concentration sample was 
used, and LOD and LOQ were computed as mentioned above. 
5.2.5.1 Simulations of radiation detector 
To estimate the size of the sensitive region of the detector, Monte Carlo 
simulations (PET specific extension of the Geant4 Monte Carlo environment) were 
performed to ascertain the total number of particles interacting with the detector, or 
events, by filling a channel of varying widths and heights with homogenous radioactivity 
concentration for 60s (see Figure 5-7).   
We modeled a microfluidic channel over a radiation detector to determine the 
number of particles hitting detector. The channel was filled with a uniform distribution of 
fluorine-18 solution (37 MBq/mL [1 mCi/mL]) embedded within a PDMS slab. The 
channel had a length of 2 cm (well beyond the expected sensitive area of the detector). 
The detector was modeled as a 200 µm thick piece of silicon. And different channel 
widths (100 – 2000 µm) and heights (100 – 2000 µm) were explored. 
Both the width response (shown as total counts over 60s in Figure 5-7) and the 
height response (not shown) increase with size, up to 1mm away from the edge of the 
detector, where it drops off to almost flat.  From this data, we observed that a channel 
width of 4 mm results in >95% of the maximum count rate value (for a channel much 
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wider than the radiation detector, 2 mm), suggesting that the sensitive region can be 
considered to be a 4 mm segment of the channel for all experiments. 
 
Figure 5-7. A graphical representation of the increasing signal with respect to 
channel width(centered on detector) for varying channel heights.  
Each point was simulated using 37MBq/mL (1mCi/mL) radioactivity concentration, over a 
detection period of 1 minute.  The data are grouped into lines based on the channel height (100 
µm to 5mm).  A distinct plateau can be seen in each line after the 4mm mark, with slowing before 
that, suggesting that no benefit is gained from activity beyond 1mm from the detector edge. 
 
 Performing microchip electrophoresis (MCE)  
The detection and separation of samples was performed on the MCE chip via 
micellar electrokinetic chromatography (MEKC) as described previously [33], [94]. The 
buffer consists of 30 mM sodium phosphate buffer and 100 mM SDS in DI water. The 
sample was loaded into the injection chamber (~4 nL) inside the PDMS volumetric 
injection chip, and then injected into the separation channel (capillary) by applying ~4 
kV between the buffer well in the injection chip and the waste well of the detection chip 
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(field strength 200V/cm). For all radioactivity measurements, the bias voltage of the 
APD was turned on for 1 hour before injection to allow it to stabilize. 
To demonstrate the utility for assessment of chemical purity, samples of purified 
PET tracer ([18F]FLT) were injected. Demonstration of radiochemical identity testing was 
performed by co-injection of purified [18F]FLT with FLT reference standard. To compare 
the MCE results to HPLC,  samples were analyzed using the analytical HPLC conditions 
mentioned in ‘[18F]FLT Synthesis details’. 
In order to better align the UV and radiation peaks, the time signal of the 
radiation detection data was shifted by a calculated factor based on the geometry of the 
device and the migration time of the UV peak. 
To estimate the sensitivity to radioactivity of the overall system, samples with 
different concentrations of [18F]FLT (59 - 500 MBq/mL [=1.6 -1 3 mCi/mL] at time of 
injection) were injected. Radiation background was also measured for 5 min at the 
beginning of the experiment, and the average and standard deviation were calculated 
for use in limits of detection estimation. Data was collected for at least 30 s beyond the 
visual end of the radioactive peak, and resulting peaks analyzed to determine the peak 
area. The results were plotted against initial radioactivity concentration. All 
concentrations were tested using the same chip on a single day. 
To estimate the LOD for this experimental setup, we ran a CE run with no sample 
injected as a blank. As no radioactive materials were present, no peak was available to 
measure. To determine an equivalent peak area for this blank, the LOD and LOQ 
values from the noise based on the peak height (standard deviation x3 and x10 
respectively) were multiplied by the average FWHM of our samples after analysis.  
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 Data Analysis 
5.2.7.1 UV absorbance signal  
Each UV electropherogram was analyzed as described previously [33], [94] to 
determine peak migration times (tm, taken at peak center), peak widths (WFWHM; full 
width at half maximum), number of theoretical plate (N), theoretical plate height (H), 
peak area (Gaussian fit), and  separation resolution. Briefly, for each peak in the 
resulting electropherogram, the number of theoretical plates, N, was calculated as N = 
5.54 x (tm / WFWHM)2. The plate height, H, was calculated as H = L / N, where L is the 
effective separation length (21 cm). For mixture samples, the peak resolution, R, 
between pairs of peaks was computed as R = 1.18 x (tm2 - tm1) / (WFWHM,1 – WFWHM,2), 
where tm1 and tm2 are the migration times of the two peaks and WFWHM,1 and WFWHM,2 are 
the peak widths (FWHM). 
Peaks were identified based on migration times determined by injecting 
reference standards for each compound individually. 
5.2.7.2 Radiation detector signal 
After subtracting the average dark noise (measured on the day of the 
experiment), electropherograms were analyzed in a similar manner.  
Because the migration time can vary from run to run and because the migration 
speed affects the apparent peak area, a time-correction is needed for any quantitative 
peak analysis. The differences might arise from inconsistency or deterioration in surface 
chemistry from run to run that could affect the magnitude of the electroosmotic flow, or 
from small temperature differences due to heating. This might be affected more 
severely in the PDMS channel as previously known [239] compared to glass capillary 
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[240]. Co-injection with non-radioactive reference standard was performed to confirm 
peak identity. In addition, the co-injection could be used to determine, and correct, the 
delay between UV absorbance and radiation detector signals provided the 
radiochemical identity was first verified with an independent method (e.g. radio-HPLC). 
 
 Results  
 Separation efficiency  
The modified MCE setup included several improvements (lower dead volume 
chip-to-capillary junctions, and increased optical path length) to address limitations in 
separation efficiency and UV detection sensitivity observed in our previous work [33]. To 
assess the separation performance of the modified setup, non-radioactive samples 
were injected into the MCE device. For a 20 cm capillary length, the separation of a 
mixture of 4 compounds using the 125 µm wide optical flow cell is shown in Figure 
5-8A. It is apparent that numerous peaks are overlapping and baseline separation has 
not been achieved. We performed the separation of a similar mixture with 5 compounds 
in a device with a modified UV detection cell (45 µm width instead of 125 µm to reduce 
the volume of the optical flow cell while maintaining the same optical path length) and 
achieved baseline separation of all species (Figure 5-8B). A more detailed comparison 
is included in Table 5-1. Notably, with the improved flow cell design, the resolution 
between the FLT and the closest impurity (stavudine) improved from 0.68 to 1.85 ± 
0.17. 
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Figure 5-8. Separation of multiple compounds. 
(A) Separation of 4 compound-mixture in 125 µm wide optical cell: thymidine 100 µM; stavudine 
100 µM; FLT 100 µM; CLT 95 µM in DI water (B) Successful separation of FLT from 5 known 
impurities in 45 µm wide optical cell. Non-radioactive sample was used for this measurement: 
thymidine 250 µM; stavudine 250 µM; FLT 250 µM; CLT 237.5 µM; nosyl acid 250 µM in DI water. 
Non-radioactive samples were used. 
 
 
Table 5-1. Summary of peaks observed after MCE separation of mixtures of non-
radioactive compounds.  
Peak area, migration time (tm), peak full width at half maximum (w1/2), number of theoretical 
plates (N), plate height (H), peak resolution (R) are shown for each. Peak resolutions between 
FLT and its nearest peak (stavudine) were calculated. 
 
125 µm optical detection cell (n=1) 45 µm optical detection cell (n=3) 
Thymidine Stavudine FLT CLT Thymidine Stavudine FLT CLT 
Nosyl 
acid 
Peak rea (AU*s) 2.17 1.83 3.10 2.26 0.42 ± 0.01 0.36 ± 0.01 
0.80 ± 
0.03 
0.56 ± 
0.02 
0.74 ± 
0.02 
Migration time (s) 225.9 248.7 263.8 321.0 221.3 ± 12.9 243 ± 14.8 
258.7 ± 
16.3 
315.2 ± 
21.9 
382.1 ± 
28.5 
FWHM (s) 12.6 13.7 12.5 16.5 4.5 ± 0 4.7 ± 0.1 5.1 ± 0.1 
7.2 ± 
0.1 
7.7 ± 
0.2 
Number of 
theoretical plates, N 
1783 1815 2474 2106 
13482 ± 
1277 
14953 ± 
1524 
14116 ± 
1471 
10539 
± 1137 
13488 
± 1165 
Theoretical plate 
height (µm) 
117.8 115.7 84.9 99.7 15.67 ± 1.45 
14.14 ± 
1.43 
14.98 ± 
1.51 
20.07 ± 
2.07 
15.65 ± 
1.33 
Peak resolution 
(Stavudine-FLT) 
0.68 1.85 ± 0.17 
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 Characterization of radiation detector  
The dark noise (measured over 6 h), was found to be 0.01 ± 0.16 counts/s (cps). 
This corresponds to a LOD count rate of 0.48 cps, and a LOQ count rate of 1.6 cps. 
Repeat measurements showed that the noise level and thus ideal detection limits were 
consistent from day to day. 
To investigate the linear range, a detection chip was filled with known 
concentrations of aqueous [18F]fluoride (11-1600 MBq/mL [0.3-42 mCi/mL]) and the 
resulting APD signal measured over 5 min for each sample. Figure 5-9 shows the 
signal as a function of radioactivity concentration. The resulting data is strongly linear 
(R2=0.994) and  To estimate the limit of detection for this setup, the dark noise from the 
lowest-concentration sample led to LOD and LOQ count rate values of 3.7 and 12 cps, 
which corresponded to radioactivity concentrations of 592 kBq/mL and 2.0 MBq/mL (16 
µCi/mL and 54 µCi/ml) respectively, which is very low by QC standards.  However, 
since this data is from a fully filled 62.5 nL channel as opposed to a typical 4 nL 
injection, all it can tell us is that the data is linear over a wider range than the 37-370 
MBq/mL (1-10 mCi/mL) range expected. 
Next, we used the whole MCE setup and performed injections of different 
radioactivity concentrations of [18F]FLT. Samples of 7 different radioactivity 
concentrations were injected. The radiation detector signal was plotted versus total 
injected activity in Figure 5-10. Additionally, detailed peak analysis including the 
number or theoretical plates and the theoretical plate height can be found in Table 5-2. 
Analysis of the peak shapes for the radioactivity measurements showed that the 
theoretical number of plates was around 5000, which was approximately half of the 
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number of plates for the UV detection. This suggests that the radiation peaks are wider 
than the UV, and would have worse separation efficiency. 
 
Figure 5-9. Radiation detector signal when detection channel is uniformly filled 
with aqueous [18F]fluoride solution of different concentrations. 
The dark noise has been subtracted from all values. Error bars represent the standard deviation 
of the 600 detector readings over the entire 5 min acquisition. The dashed line represents a linear 
fit with intercept of zero (R2 = 0.997). 
 
 
Figure 5-10. Calibration of radiation detector signal: peak area (CPS*s) vs [18F]FLT 
concentration.  
Peak area was computed based on a Gaussian fit to peak. Dashed line shows a linear least 
square fit (y= 147x – 59; R² = 0.994). 
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Table 5-2. Analysis of electropherogram of [18F]FLT peak.  
Summary of figures of merit for analysis of various concentration of [18F]FLT. Migration time (tm), 
peak full width at half maximum (FWHM), number of theoretical plates (N), plate height (H), are 
shown for each concentration. 
Activity Conc. 
(mCi/ml) 
Peak Area 
(CPS*s) 
Migration time 
(s) 
FWHM 
(s) 
 Number of 
theoretical plates, N 
Theoretical plate 
height (µm) 
13.5 1884.8 208.5 7.71 4057 51.8 
12.6 1828.1 207.1 7.77 3935 53.4 
9.1 1214.5 198.1 7.25 4137 50.8 
7.2 1019.6 210.0 7.60 4228 49.7 
6.6 1005.7 211.2 7.99 3869 54.3 
1.6 139.5 204.3 7.01 4703 44.7 
1.5 152.4 199.5 7.22 4232 49.6 
 
 
 Demonstration of radio-MCE 
A sample of purified and formulated [18F]FLT was analyzed. With a concentration 
of 703 MBq/mL (19 mCi/mL), the total injected radioactivity in the 4 nL sample plug is 
estimated to be 2.8 kBq (76 nCi). A single peak was observed in the radioactivity 
electropherogram (Figure 5-11A), and a corresponding small peak was observed in the 
UV electropherogram. There were no UV impurity peaks observed at the expected 
relative migration times. To verify radiochemical identity, the same [18F]FLT sample was 
spiked with the FLT reference standard (~500 uM final concentration) leading to a 
radioactivity concentration of 630 MBq/ml (17 mCi/mL). Once more, a single peak was 
observed in the radioactivity electropherogram Figure 5-11B, and a single large peak 
was observed in the UV electropherogram. To corroborate this result, 25 µL of the same 
sample was injected into analytical HPLC, and a similar single UV and radiation peak 
was observed at a retention time of 5.5 minutes, with the co-injection strengthening the 
same UV peak.  From this, we know that the single radiation peak is indeed the 
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[18F]FLT.  After determining the peak identity, the radiation peak data was shifted in time 
by the difference between the UV and radiation peak centers for visual clarity.  
 
 
Figure 5-11. Example dual-modality electropherogram of radioactive sample  
(A) purified/formulated [18F]FLT, and (B) the same sample co-injected with 500 µM FLT 
(reference standard). UV absorbance signal is shown in blue, and radiation detector signal is 
shown in black. The migration times of the radiation peaks were corrected according to the 
estimated delay between the two detectors. 
Additionally, a “mock crude” sample was prepared by adding impurities into the 
[18F]FLT sample. The concentrations of the impurities were 250 µM thymidine, 250 µM 
stavudine, 450 µM FLT, 238 µM CLT, and 300 µM nosyl acid. As seen in Figure 5-13, 
all 5 peaks were discernable though baseline resolution was not quite achieved for 
thymidine, stavudine, and FLT.  
A sample of crude [18F]FLT (before purification) was also analyzed (Figure 5-13). 
From the UV electropherogram, the major side products stavudine, thymidine, and CLT 
could be observed, as well as a significant peak not described in previous literature 
[179]. This impurity has been observed by other investigators but not identified [235]. 
Here we observe that the impurity appears to coincide with the migration time of nosyl 
acid, the by-product resulting from removal of the leaving group when the precursor is 
 143 
fluorinated. During purification, we collected the fraction corresponding to this peak and 
also confirmed its identity via analytical HPLC. The retention of the unknown impurity 
matched that of nosyl chloride (dissolved in DI water), and the peak size was confirmed 
to increase when the unknown impurity was coinjected with nosyl chloride.  
 
 
Figure 5-12. Separation of [18F]FLT from 4 added impurities.  
Radiation peak (in black) and UV absorbance peaks of added 4 known impurities (in blue). The 
concentrations of added impurities are estimated to be thymidine 250 µM; stavudine 250 µM; FLT 
450 µM; CLT 237.5 µM; nosyl acid 300 µM. Note that migration time of radiation peak was shifted 
according to the estimated delay between two detectors. 
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Figure 5-13. Superimposed electropherograms of crude [18F]FLT product (non-
purified sample).  
Detection with a 125 µm wide optical flow cell was used. Note that migration time of radiation 
peak was corrected according to the estimated delay between two detectors. 
 
 UV absorbance peak calibration: Conc vs peak area  
The calibration curve of UV absorbance peak area versus sample concentration 
was generated (Figure 5-14). The tested concentration ranges from 10 – 400 µM, and 
the linear relationship was observed with the R2 value of 0.9987. And it becomes non-
linear for the concentration higher than 700 µM and gradually plateaued. The typical 
concentration of PET tracer (including [18F]FLT) lies within this range. 
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Figure 5-14. Calibration of UV absorbance peak area (AU*s) vs FLT concentration.  
Each concentration of FLT reference standard was analyzed in the MCE device, and the peak 
area was computed. Error bar shows the standard deviation of 3 repeats. Linear fit: y = 0.0035x, 
R2= 0.9997.  
 
 
 Discussion 
The use of the triple valve structure, shown in Figure 5-3 was significant in a 
number of ways. First, from our previous work [33], we found that on some chips, 
particularly those utilizing longer (60cm) capillaries and therefore higher voltages, the 
sample vial and buffer vial, along with their side-channels would often form bubbles if 
not physically disconnected before applying the high voltage.  We suspected this was 
from the stray current, and therefore requires a larger amount of PDMS blocking the 
channel to electrically isolate the wells from the CE supply. With the new triple valve 
structure, we have yet to see a single failure of this type, or any suspected bubbling in 
side-channels. The second benefit is the increase in the fluidic isolation of the side-
channels from the main channel. This reduces the chances for a poor localized sealing 
of the channel that can lead to sample leakage into the channel during CE.   
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The APD had very low noise, with the all remaining noise pulses suspected as 
cosmic rays striking the device [133], or strong current changes from the APD itself 
which we have not investigated at this time. Small improvements could be made to the 
device by reducing distances between various components and reducing any detector 
movement with respect to the preamp circuit, though it is likely that the remaining noise 
is inherent to the fabrication method of our devices and will not be easily removed.  
For the linearity testing, it was shown that the response of the device is linear 
with regards to radioactivity within the sensitive area well beyond the radioactivity range 
we would encounter from a QC sample with current injection volume (4 nL), 1.5 GBq/mL 
(40 mCi/mL) compared to the typical maximum 370 MBq/mL (10 mCi/mL). The 
calibration curve generated from actual injection resulted in a good curve, though this 
curve was not tested against an unknown concentration in this work. This would be an 
important next step, as it would be necessary to measure the precise amount of the 
analyte in unknown sample. 
We have noticed a chip-to-chip variation of migration time for FLT. We believe 
the major culprit for this is variation in the capillary length caused during fabrication; a 
longer capillary leads to a longer migration time for the same field. Also, the alignment 
of chip-to-capillary junctions, temperature inside the chips, and the stability of the 
channel surface chemistry as well as the stability of power supply (separation voltage) 
could contribute to this variation. To resolve this, each chip could be referenced to 
previous data where the other chip was used, likely by a single injection of a known 
concentration standard before the main run. Also, improved fabrication consistency  
reduces the variation. 
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The sensitivity of the radiation detector is expected to vary for other isotopes, 
depending on the positron branching ratio and the positron range (related to the 
positron energy). Furthermore, the APD is expected to be sensitive to electrons (beta 
particles) and thus this approach could also be used for analysis of molecules 
containing beta-emitting therapeutic radioisotopes (e.g. Lu-177). For isotopes that emit 
predominantly gamma rays, another method of radiation detection may be needed as 
the APD has low sensitivity to gamma rays due to its thin dimensions.  It may be 
possible to detect alpha  particles, though the thickness of PDMS between the liquid in 
the channel and the detector would likely need to be reduced as alpha particle range is 
typically <100-200 μm. 
Focusing on 18F-labeled tracers, the typical concentration of the formulated tracer 
is in the range 37-370 MBq/mL (1-10 mCi/mL).  Though we were able to obtain clear 
peaks for samples with concentration in this range, it would be challenging to detect 
low-abundance impurities.  Typically, the passing criteria for the radiochemical purity 
test of a radiopharmaceutical is that the compound is >95% radiochemically pure. Thus, 
at minimum, the sensitivity should be able to quantify the amount of an impurity down to 
5% abundance, or 1.85-18.5 MBq/mL (0.05-0.5 mCi/mL) radioactivity concentration in 
the original sample. 
We can consider several potential approaches to improve sensitivity.  One 
approach would be to add a second radiation detector on the other side of the channel, 
increasing the effective signal by nearly 100%; however, implementing such a 
configuration would be extremely challenging from a microfabrication point of view as 
well as developing appropriately shielded electronics. Reduction of the thickness of 
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material between the liquid sample and detector would also increase the sensitivity. 
Dooraghi et al. [133] measured the effect of different thicknesses of low-density 
polyethylene (LDPE) material thicknesses on the signal detected from a Tl-204 sources 
(beta-emitter with beta energies only slightly higher than the positron decays from F-18). 
A 200 μm LDPE layer resulted in 60% signal attenuation and 100 μm resulted in 38% 
reduction. 100 μm of PDMS would be expected to have a similar attenuation as LDPE. 
Reduction in layer thickness is possible, but if the layer becomes too thin, it may suffer 
dielectric breakdown between the local separation voltage within the channel and the 
ground of the APD.  Given that PDMS manufacturers quote the dielectric strength of 
PDMS as 10-15 V/µm, and the potential in the channel at the radiation detector would 
be around 200V (1cm away from the waste well), at least 40µm of PDMS would be 
required to protect the detector from breakdown.  
Another approach to increase the signal would be to increase the sample 
volume, but this would likely require an increase in separation length (and thus 
separation time) to achieve the same resolution. Alternatively, signal can be increased 
by slowing down the sample such that it spends more time within the detection region. 
Though reducing the separation voltage is not desirable as it would slow down the 
analysis and reduce resolution, increased interaction between the sample and detector 
could be accomplished using a serpentine channel pattern above the radiation detector.  
We have shown that the narrower optical flow cell (inside detection chip) 
substantially improves the separation efficiency even with the presence of two chip-to-
capillary junctions. Further decrease in cross-sectional area of entire detection chip 
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channel would further enhance the separation power of our system, though it would 
lead to reduced optical absorption signal unless smaller size optical fibers are utilized.  
Additionally, longer separation channel (e.g., longer capillary) would help 
improving the separation efficiency as we have observed a better separation when the 
60cm capillary was used [33]. However, when the longer capillary is utilized, in addition 
to the longer analysis time, a higher voltage is needed to maintain the same separation 
field strength.  These higher voltages are more dangerous and difficult to work with, and 
the increase in voltage could result in the higher chance of breakdown of microvalves. 
Longer capillaries also lead to higher temperatures at steady state in both the capillary 
as well as the PDMS chips. 
Currently our MCE system can be used for radiochemical identity analysis as 
well as chemical purity and identity tests, and could be used as a PET tracer QC device 
once able to perform radiochemical purity analysis. On top of that, our microfluidic 
radiation detection system could potentially be applied to applications other than MCE 
that involve radiolabeled compounds or radiolabeled cells, where high-sensitivity and 
relatively fine spatial resolution would be needed, particularly those involving real-time 
detection[130], [241]. With reductions in membrane thickness, the system could easily 
be used for QC of beta-emitting compounds (e.g. 177Lu) and even alpha emitting 
compounds. Changes in the detection circuitry could even allow for online energy 
spectrum analysis, which would perhaps be beneficial for alpha isotopes that can have 
many side-particles. 
 150 
  Conclusions 
A novel MCE device with a miniaturized positron detector (“radio-MCE”) was 
developed to analyze radioactive compounds following electrophoretic separation. The 
radioactive PET tracer [18F]FLT of clinical concentration was successfully detected by 
the positron detector along with the UV absorbance detector. We demonstrated a 
successful separation of [18F]FLT from all added impurities. 
The detection system is capable of detecting radioactivity concentrations at the 
lowest end of PET tracer QC testing levels, though our quantitation limits are not low 
enough yet. We have shown that this system is capable of quantifying radioactivity 
concentrations down to 7 mCi/mL, though quantitating impurity peaks is currently limited 
to 20% or higher. These detection limits could be further lowered by improving 
electronics or reducing the distance between sample and detector, though the former 
has diminishing returns and the latter could become hazardous to the detector from the 
CE current. 
The fast acquisition time of our system allows for a real-time detection method, 
which can identify and quantify radioactive compounds without compromising 
separation efficiency. In fact, the radioactivity peak was the stronger indicator of 
identifying FLT in our samples than the UV peak when the sample concentration was in 
the sub-nanomolar range. 
Though further development and optimization is needed, the successful 
separation of FLT from its impurities and successful determination of radiochemical 
identity suggests that MCE has the potential to perform QC tests traditionally performed 
using HPLC. The sensitivity of the radiation detector was found to be sufficiently high for 
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the expected clinical sample concentrations that would be analyzed by this system. We 
are investigating whether a similar device could be used to determine radiochemical 
purity, molar activity and half-life in a short timeframe. 
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6. Chapter 6: Microscale radiolabeling of Biomolecules 
Summary 
Radiolabeled peptides and antibody fragments provide a means to image 
disease-specific targets with extremely high specificity. However, many proteins 
including antibodies and antibody fragments can usually not be labeled directly with 
[18F]fluoride due to required harsh reaction conditions like elevated temperatures and 
the use of organic solvents and incompatible pH conditions [242]. Thus, to preserve the 
function of proteins, the radioisotope fluorine-18 can initially be incorporated into an 18F-
labeled prosthetic group which is then conjugated to the biomolecule under mild 
conditions. However, these mild conditions often lead to slow rates of conjugation 
reaction, unless a large excess of the biomolecule is used. Typically, 100-500 μg of 
peptide or protein is used in conventional “macroscale” approaches [243]. To reduce the 
high cost of labeling, efficient techniques with lower biomolecule consumption are 
necessary. Previously, using a droplet-based microfluidic chip, it has been shown that 
reagent consumption for small-molecule tracers can be reduced 2-3 orders of 
magnitude compared to conventional approaches [27]. Here, the feasibility of using this 
microfluidic chip approach to reduce precursor consumption in radiolabeling of 
biomolecules is investigated. As an example, a thiol-containing RGD peptide was 
labeled with fluorine-18 in a site-specific manner via the maleimide-based prosthetic 
group, N-2-(4-[18F]fluorobenzamido)ethylmaleimide ([18F]FBEM). Furthermore, the site-
specific labeling method was extended to the radiolabeling of antibody fragments (cys-
diabodies).   
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 Biomolecules as PET probes 
 Over the past few decades, radiolabeled biomolecular agents have evolved from 
large proteins (e.g. intact polyclonal antibodies with low specificity) to monoclonal 
antibodies and fragments with relatively higher specificity, to even smaller molecular 
recognition units such as single-chain antigen-binding domain fragments, and finally to 
receptor-specific peptides [244], [245]. Biomolecular PET imaging probes such as 
radiolabeled peptides, proteins and antibodies provide a means to target specific 
biological targets with exceptional specificity, such as tumor-specific targets in cancer 
diagnostics. These probes also play an increasing role in drug discovery to test the 
efficacy of a new drug by imaging before and after treatment [246].  
Various methods have been reported for radiolabeling of biomolecules including 
indirect radiolabeling that generally employs a bifunctional linker containing a 
radionuclide or chelating group for attachment of radiometals and a reactive group that 
can react with functional groups on biomolecules [247], [248]. This chelation approach 
typically requires use of radionuclides (radiometals) with long half-life, such as the 
positron-emitting radionuclides iodine-124 (100.2 hr) and zirconium-89 (78.4 hr), 
copper-64 (12.7 hr) and yttrium-86 (14.7 hr). Even though theses half-lives match well 
with the long biological half-life of intact antibodies, different radionuclides are desired 
for smaller antibody fragments that have much shorter biological half-life, e.g. a few 
hours at most [246]. 
It would be ideal to match the physical half-life of the radionuclide with the 
biological half-life of the antibody or fragments. Fluorine-18 is of great interest for same-
day imaging due to its wide availability and favorable short half-life (109.8 min), which 
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matches the fast clearance of smaller antibody fragments such as scFvs, nanobodies,  
affibodies, and diabodies [249], [250].  Furthermore, fluorine-18 has almost ideal 
imaging properties, with a high positron yield (97%), low mean positron range (0.5 mm) 
and no simultaneous gamma ray emission that would increase background. 
 
 Conventional approaches for protein/peptide radiolabeling with fluorine-18  
An ideal radiofluorination method for biomolecules requires (1) a short reaction 
time with high RCY and specific activity (2) reaction conditions (i.e., room temperature, 
pH 7, and aqueous medium) to prevent the denaturation of the biomolecules [251]. 
Peptides and other biomolecules can usually not be labeled directly with [18F]fluoride 
due to required harsh reaction conditions like elevated temperatures and the use of 
organic solvents and incompatible pH conditions. Therefore, the synthesis of 18F-labeled 
peptides and proteins often requires first synthesizing 18F-containing “prosthetic 
groups”, small intermediate molecules which can be subsequently conjugated to 
biomolecules (Figure 6-1). 
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Figure 6-1. Fluorine-18 labeling of biomolecules.  
Typical radiofluorination of biomolecules requires synthesis of intermediate molecule, “prosthetic 
group”, to gently introduce fluorine19 onto biomolecules.  
 
Among many prosthetic groups, N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) 
is the most widely used [252], [253]. The active ester group in [18F]SFB can react with 
amine groups of protein and peptide Figure 6-2. However, [18F]SFB is labile in the basic 
aqueous conditions generally required for efficient amino reactions, providing limited 
yield. Furthermore, [18F]SFB often impairs the biological activity of the resulting 
conjugate which may result from the non-specific modification of amino groups near the 
binding region. Cai et al. reported that 18F-labeled anti-carcinoembryonic agent (CEA) 
diabody was produced with compromised immunoreactivity (57%) when labeled with  
[18F]SFB compared to other reported site-specific prosthetic groups such as [18F]FBEM 
and [18F]FPEGMA [254]–[256]. Labeling with [18F]SFB often requires fairly large 
amounts of peptide or protein to achieve sufficient radiochemical yield. [18F]FDG also 
has been used as a prosthetic group via oxime formation between aminooxy-
functionalized peptide and [18F]FDG [257]. The major limitations of FDG for protein 
labeling are the relatively high reaction temperature (100 °C or higher) and acidic pH 
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required. High temperature and acidic pH are tolerated for many small unprotected 
peptides but might not be suitable for larger peptides and proteins [258].  
 
Figure 6-2. Examples of amine-reactive 18F-labelled prosthetic groups used in 
protein labeling. 
Adapted with permission from [247] Copyright © 2010 Elsevier. 
 
 Desired conditions for radiolabeling of biomolecules 
Direct or indirect conjugation chemistries that react with random surface amino 
acid residues on biomolecules can compromise the binding affinity of antibodies and 
derivatives, especially those with critical tyrosine or lysine residues in the 
complementarity determining regions [246].  
The ideal prosthetic group reacts at physiological pH and room temperature in 
less than 30 min. And the reaction does not require any organic solvent. More 
importantly, the conjugation occurs in a site-specific manner where the exact site of 
labeling can be predicted (Figure 6-3).  A number of site-specific indirect conjugation 
methods have been reported that can specifically target cysteine residues in antibodies 
and antibody fragments after reduction of disulfide bridges [255], [259]. Conjugation and 
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radiolabeling using thiol-reactive chemistries targeting reduced cysteines (either native 
or introduced via protein engineering) reduce the probability of adversely affecting the 
immunoreactivity of the antibody [246]. 
 
 
Figure 6-3. Types of radiofluorination of biomolecules. 
(A) Non site-specific (random) labeling; (B) Site-specific labeling. 
 
Michael-addition of a thiol (of cysteine) to a maleimide is commonly used for 
bioconjugation of drugs to macromolecules. The free thiol functional group is not very 
common in most peptides and proteins and is only present in cysteine residues. Thiol-
reactive agents have therefore been used to modify peptides and proteins at specific 
sites. Several 18F labeled thiol-reactive reagents have been reported in the literature 
including 1-(4-18F-fluorophenyl) pyrrole-2,5-dione ([18F]FPPD), 1-[3-(2-(18F-fluoropyridin-
3-yloxy)propyl]pyrrole-2,5-dione ([18F]FPyME), N-[4-[(4-18F-fluorobenzylidene) 
aminooxyl] butyl]maleimide ([18F]FBABM) and N-[2-(4-18F- 
fluorobenzamido)ethyl]maleimide ([18F]FBEM) [260] (Figure 6-4, Table 6-1).  More 
recently, “click” chemistry-based prosthetic groups have been introduced. In particular, 
the Cu(I)-catalyzed variant of the Huisgen 1,3-dipolar cycloaddition of terminal alkynes 
and azides offers a very powerful reaction with high specificity and excellent yields 
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under mild conditions for 18F-labeling of small molecules and peptides [251], [261], 
[262].  
 
Figure 6-4. Thiol-reactive 18F-labelled prosthetic groups used in protein labeling. 
Adapted with permission from [247] Copyright © 2010 Elsevier.   
 
 
Table 6-1. Examples of thiol-reactive maleimide-containing prosthetic groups. 
Prosthetic group 
Labelled Peptides/Proteins 
Radiolabeling 
condition 
Coupling 
yield (%) 
Ref. 
Type 
Radiochemical yield 
(%) 
Synthesis time (min) / 
#steps 
[18F]FNEM 4  
75 min from EOB/ 
2 steps in 1 pot 
GLP-1 analogue:[Cys40]-
exendin-4 
30min, RT, pH 7.4 36 - 48  [263] 
[18F]FBOM 19 
80 min / 
2 steps 
LDL apoB-100 20min, RT, pH7.2 5  [257] 
[18F]FBABM 23 
92min / 
2 steps in 1 pot 
Annexin V-128 
15min, RT, pH 
7.4, periodic 
gentle agitation 
37  [264] 
[18F]FDG-MHO 45-69  
45 min / 
3 steps 
Annexin A5 
30min, RT, pH 
7.4(Tris-HCL), 
FDG-MHO in 
ethanol 
44-58  [265] 
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[18F]FBAM 29  
69 min / 
2 steps 
LDL apoB-100 20min, RT, pH7.2 20 [266] 
[18F]FBEM 13 -44 
100-150 min / 
3 steps in 2 pots 
RGD-SH 20 min, RT, pH 7.4 96 [260] 
[18F]FPyMe 34 – 4- 110min / 3 steps 
Hexapeptide & Proteins (c-
AFIM-0 & c-STxB) 
15-30 min, RT, pH 
8, 10% DMSO 
33 - 85 [244] 
[18F]FPPD & 
[18F]DDPFB 
15 ( FPPD),10 
(DDPFB) 
FPPD: 100 min / 
4 steps; 
DDPFB: 70 min / 
3 steps 
Fab' from rabbit IgG Not described 50 [267] 
 
 
 Application of Microfluidic Technology for 18F-Labeling of Peptides 
Biomolecules are usually labeled with a 18F-labeled prosthetic group under mild 
conditions. These mild conditions often lead to slow rates of the conjugation reaction 
and therefore a large excess of the biomolecule precursor is often needed to promote 
efficient labeling. Typically, 100-500 µg of peptide or protein is used for radiolabeling 
[243]. Furthermore, the production of custom engineered antibody and antibody 
fragments is a very time-consuming process taking weeks to produce small amount of 
proteins. 18F-labeling of peptides using novel techniques such as microfluidic technology 
offers several advantages over conventional radiolabeling methods, including shorter 
reaction times, more efficient radiochemistry and more economical use of starting 
material [268]. 
Microfluidic radio-synthesizers are emerging as useful platforms for PET probe 
synthesis due to their rapid reaction kinetics and exquisite reaction selectivity. Batch 
microfluidic platforms, in contrast to flow-through platforms, provide additional 
advantages such as the ability to work at extremely low volumes (nL–µL), thus having 
the potential to increase the fluorination kinetics by achieving higher concentration of 
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[18F]fluoride ions or 18F-labeled prosthetic groups in a batch reaction. Similarly, although 
yet to be investigated, the reduced reagent consumption in batch microdevices has the 
potential to reduce cost, to simplify the downstream purification process, and to produce 
PET probes with higher specific activity [269].  
Biomolecules are often labeled by hand (manual pipetting) as commercial 
radiosynthesizers are not designed to operate at the small reagent volumes (e.g. 10-
100 μL) that radiochemists prefer in order to minimize reagent consumption. Droplet 
microreactors, with typical work volume of 1 - 20 μL are ideally suited to automate this 
labeling, with potential for further reduction in reagent consumption.  
Several microfluidic platforms have been explored to harness the advantages of 
droplet reactions in radiochemistry. Keng et al. demonstrated the successful 
radiosynthesis of several 18F-labeled compound using an electrowetting-on-dielectric 
chip, droplet-based digital microfluidic chip. The electrowetting-on-dielectric (EWOD) 
system, a promising digital microfluidic device, uses electric potentials to manipulate 
liquids without mechanical valves, pumps, or channels. It has shown that reagent 
consumption for small-molecule tracers can be reduced 2-3 orders of magnitude 
compared to conventional approaches [20]. Despite the widespread use of EWOD-
based systems, there have been many challenges due to the high cost of prototype 
chips, frequent failure of the dielectric coating and the operating complexity. To address 
these issues, Wang et al. recently reported a simpler microfluidic device based on 
passive droplet transport using based on passive droplet transport using patterned 
wettability for multi-step radiochemical reactions and demonstrated production of 
[18F]fallypride and [18F]FDG [22]. Microfluidic radiosynthesis can significantly reduce the 
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amount of radiation shielding necessary for safety and the amount of precursor and 
other reagents needed for the synthesis. Furthermore, significant improvements in the 
molar activity of the tracers have been observed. 
Based on these recent successful and promising results of radiosynthesis in 
microfluidic platforms [22], [270], [271], we expect the same advantages to be applied to 
the production of biomolecular PET probes, where the cost of starting material is 
particularly high.  
 
 Microfluidic radiolabeling of peptide 
Here, the feasibility of using this microfluidic chip approach to reduce precursor 
(biomolecule) consumption in radiolabeling is investigated. As an example, a thiol-
containing RGD peptide was labeled with fluorine-18 in a site-specific manner via the 
maleimide-based prosthetic group, N-2-(4-[18F]fluorobenzamido)ethylmaleimide 
([18F]FBEM) (see Figure 6-5). 
 
 
Figure 6-5. Site-specific radiolabeling of peptide. 
As an example, c(RGDfC) peptide was labeled with [18F]FBEM.  
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 Selection of prosthetic group: [18F]FBEM 
Among several thiol-reactive maleimide prosthetic groups (shown in Table 6-1), 
[18F]FBEM was chosen for this study since it has been reported in multiple studies with 
relatively high radiochemical yield  (RCY), and successful preclinical imaging has been 
demonstrated [272], [273]. Additionally, [18F]FBEM reacts with biomolecules very quickly 
in a site-specific manner at physiological pH without requiring organic solvents. 
Furthermore, the precursor for this prosthetic groups is commercially available.  
A cysteine-containing RGD peptide was selected as model for the microscale 
radiolabeling. The RGD peptide targets integrin αvβ3 that plays a key role in tumor 
angiogenesis and metastasis [260].  
 
Table 6-2. Examples of [18F]FBEM-labeled biomolecules  
Year 
Biomolecules (proteins or peptides) Prosthetic group: [18F]FBEM 
Radiolabeling 
yield (%) 
Ref. 
Type 
 Size 
(kDa) 
Amount 
(µg) 
Solvent 
Molar 
activity 
(Ci/µmol) 
Radioche
mical 
yield (%) 
Amount 
(mCi) 
Solvent 
2006 c(RGDyK) & 
E[c(RGDyK)
]2 
> 620  200 50 µl 
DMSO, 1mg 
TCEPHCL 
in 100µl 
Water 
4 - 5.4 5 (non-
corrected)  
5 (non-
corrected) 
600 µl  
MeCN 
80% non-
corrected based 
on starting 
[18F]FBEM 
[26
0] 
2008 Affibodies 
(ZHER2:239
5-cys & 
ZHER2:342-
cys) 
7 & 8 100 250µl PBS NA 22.4 (non-
corrected) 
2.7 - 10 10 µl 
MeCN 
10 .5 & 11.6 
(decay non-
corrected) 
[27
4] 
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2011 Glucagon-
like peptide-
1 (GLP-1) 
> 3.3-4 115 - 
135 
100 µl of 
DMF:DMS:P
BS(=10:45:4
5) 
3-Feb 24.8 (non-
corrected) 
1.9 - 3 10 µl 
EtOH 
24.9 (decay 
non-corrected) 
[27
5]  
2012 Single-chain 
(sc)-VEGF 
with a Cys-
tag  
28 100-200 100µl PBS 1.58 20.6 (non-
corrected) 
15-37  10µl 
EtOH 
20.6 (decay 
non-corrected) 
based on 
starting 
[18F]FBEM  
[27
6] 
2014 Glutathione 
(GSH) 
0.31 1000  1mL of PBS 
buffer 
1.2-1.8 15-20  20 NA 99 (decay 
corrected) 
[27
7] 
2015 Wild-type 
annexin V 
36 100 100 µl PBS NA NA 5.4 Dried 
FBEM 
4 ± 2 % (n = 5) 
based on 
starting 
[18F]FBEM) 
(decay 
corrected) 
[27
8] 
2015 Cys-
Annexin V 
with a 
cysteine-tag  
36 50-100 100µl PBS 4 5.4 11.5 10µl 
EtOH 
 71.5% ± 2.0% 
(decay non-
corrected) 
[27
2]  
 
 
 Materials and Methods 
6.2.2.1 Synthesis of N‐[2‐(4‐[18F]fluorobenzamido)ethyl]maleimide, [18F]FBEM 
[18F]FBEM was synthesized on an automated radiochemistry synthesizer 
(ELIXYS, Sofie Biosicences, Inc.) in high radiochemical yield (35±8% (n=7), decay-
corrected) in 100 min following a previously reported method [234]. 
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The automated synthesis of [18F]FBEM was adapted from Kiesewetter et al. [256] 
and Ackermann et al. [277] with slight modifications. The fluorobenzoic acid precursor 
used for FBEM synthesis (5 mg in 0.5 mL MeCN) was added to the activated 
[18F]fluoride residue in reaction vessel 1. The contents of the vessel were heated for 10 
min at 120 °C. Following the reaction, diethyl ether (2 mL) was added and the contents 
were transferred directly through a silica cartridge and delivered into reaction vessel 2. 
The ether was completely evaporated using 4psi of N2 pressure at 35°C. Additional 
ether (2 mL) was added to reactor 1, and then transferred through the silica cartridge to 
reaction vessel 2, followed by evaporation at 35°C. Next, TFA (300 μL) was added to 
the vessel and heated for 2 min at 30°C. The TFA was then evaporated slowly at 30°C 
for 6 min. 
After TFA was removed, the FBEM maleimide precursor (2.3mg in 300μL of 
MeCN, mixed with 5.8mg of DCNP in 300μL of MeCN), was added to the reactor. A 
solution of DIEA (30 μL) in MeCN (300 μL) was also added. The mixture was heated for 
7 min at 75°C. Following the reaction, the solvent was evaporated at 75°C to dryness 
(~2 min). A solution of 5% MeCN in 50mM NH4OAc (2 mL) was then added and the 
diluted crude mixture was transferred to the HPLC injection loop for semipreparative 
HPLC purification. The purified [18F]FBEM was formulated manually using an Oasis 
Plus WCX cartridge preconditioned with 5mL of EtOH and 10mL of water. The collected 
HPLC fraction was diluted with water (30 mL), and then pushed through the cartridge to 
trap the product. After trapping, the cartridge was rinsed with water (5 mL) and then 
dried with a stream of nitrogen. The product was then eluted from the cartridge with 
DCM (2 mL). Finally, the solution was concentrated by evaporating the solvent with a 
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gentle stream of nitrogen at room temperature and subsequently used in the labeling of 
thiolated peptides and proteins. 
 
6.2.2.2 Microfluidic chip fabrication    
To fabricate the Teflon-coated glass chip (Figure 6-6A), a glass slide was cleaned 
thoroughly with MeOH and acetone, 5 min each in an ultrasonic cleaner, followed by 
Piranha cleaning (3:1 H2SO4:H2O2, 20 min at 120°C). After rinsing with DI water, the 
clean glass slide was treated with trichloro(1H,1H,2H,2H-perfluorooctyl)silane (97% 
purity, Sigma-Aldrich, Milwaukee, WI, USA) as an adhesion promoter inside a 
desiccator overnight. It was then spin-coated at 1000 rpm for 30 s with a 1% solution of 
Teflon AF 2400 (Chemours, Wilmington, Delaware, USA) to create a 100 nm thick 
hydrophobic surface. The teflon-coated glass chip was heated at 160°C for 10 min and 
at 245°C for 10 min. It was further annealed at 340°C for 3.5 hr in the Carbolite oven to 
achieve smooth surface. 
 
Figure 6-6. On-chip radiolabeling of biomolecules 
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(A) Schematic representation of Teflon-coated glass chip (top view). Reaction site marker is on 
the back side of the chip. (B) Step-by-step process for on-chip peptide labeling with [18F]FBEM. 
Note that the amount of [18F]FBEM radioactivity can be increased by repeating the first 3 steps 
more than once. DCM=dichloromethane, MeCN=acetonitrile (C) Cerenkov image confirms the 
successful concentration of [18F]FBEM at the reaction region. 
 
6.2.2.3 Microscale site-specific labeling of RGD peptide 
Firstly, to perform the microscale labeling (Figure 6-6B), a 20 µl droplet of 
[18F]FBEM dissolved in  dichloromethane (DCM) was concentrated (by rapidly 
evaporating solvent) onto a small part of the reaction site of the chip, and the 
distribution of radioactivity on chip was visualized via Cerenkov imaging (Figure 6-6C). 
This concentration step was repeated a few times to achieve desired radioactivity 
concentration (e.g., ~ 1mCi = 37 MBq). Dried FBEM was re-dissolved by adding a 2 µl 
droplet of MeCN and waiting for 1min. Then, 20 μL peptide solution (in PBS, pH 7.4) 
was added for the room temperature conjugation reaction.  After 30min reaction, 50 µl 
PBS was added to quench the reaction. The crude product was extracted from the chip 
an analyzed via analytical HPLC.  The effect of peptide concentration was explored by 
using peptide solution droplets containing different amounts of peptide (0.2 to 100 μg).  
 
6.2.2.4 Data analysis (Estimation of radiolabeling efficiency) 
   The crude reaction product was collected for analysis via analytical HPLC 
(Smartline HPLC system, Knauer, Berlin, Germany). Analytical HPLC employed a C18 
Luna reverse phase column (4.6 mm × 250 mm, 5 µm; Phenomenex, Torrance, CA, 
USA) and a gradient eluant of 5% A, 80% B from 0 - 2 min  to 35% A, 75% B from 2- 32 
min, then 95% A, 75% B from 32 – 40 min . Solvent A was 0.1% TFA in acetonitrile. 
Solvent B was 0.1% TFA in DI water. The flow rate was 1mL/min.  
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The radiochemical conversion was estimated based on the area under curve 
(AUC) of radio HPLC peak of the conjugate, [18F]FBEM-c(RGDfC), relative to the sum of 
all AUCs detected (Figure 6-7). The sample collection efficiency (%) was calculated by 
measuring the remaining radioactivity on chip after sample was collected, then 
comparing it to the radioactivity on chip before the collection (after reaction is 
completed). The crude radiolabeling yield (an estimate of isolated yield) was estimated 
by multiplying the conjugation efficiency by the sample collection efficiency to estimate 
the expected amount of product if it was purified (“crude RCY”).    
 
 Results 
Labeling efficiency was investigated as a function of the amount of peptide 
precursor participating in the reaction. On-chip [18F]FBEM conjugation of c(RGDfC) 
resulted in high labeling efficiency: 96.7, 94.8, 84.7% for 100, 20 and 6.7 μg of peptide 
precursor, respectively (Figure 6-8A). Even with 2 μg peptide, it exhibited practical 
conjugation efficiency (26.6%). The collection efficiency of sample from the chip was 
Figure 6-7. Preparative HPLC chromatogram  
(A) “cold” (non-radioactive reaction for peak identification purpose) and (B) “hot” (radioactive) 
crude reaction mixture. Performed on analytical-scale HPLC. 
 168 
over 90%. The crude radiochemical yield was found be very high: 84.1, 83.9, 70.2% for 
100, 20 and 6.7 μg peptide, respectively (Figure 6-8B).  
 
 
 Conclusion 
We have demonstrated that microscale radiolabeling of peptides using low 
amount of peptide is feasible using droplet microfluidics. Peptide consumption was 
reduced 50-250 times compared to conventional methods where  100 - 500 µg of 
peptide is typically required. Although the current study used ~1mCi of [18F]FBEM per 
experiment, the activity could be easily scaled up for clinical & pre-clinical imaging by 
repeated  [18F]FBEM loading, or by pre-concentrating [18F]FBEM using a method like 
microfluidic membrane distillation as our group demonstrated previously [43].  
We envision that this small volume reaction approach could potentially be applied 
to the development of antibody-based imaging probes and radiotherapeutics with 
Figure 6-8. Labeling efficiency as a function of peptide mass 
(A) Conjugation efficiency of [18F]FBEM to labeled peptide based on the percent peak area 
corresponding to conjugate in the HPLC chromatogram. (B) Estimate of radiolabeling yield. 
Crude radiolabeling yield corresponds to the conjugation efficiency multiplied by the collection 
efficiency from the chip.  Note that efficient conjugation is possible on chip with as little as a few 
µg of peptide. 
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reduced precursor consumption and could possibly increase the effective molar activity 
(radioactivity per protein mass).  
 
 Radiolabeling of protein: Labeling engineered antibody fragments 
 Introduction 
To extend our findings from peptide labeling to protein labeling, we explored the 
radiolabeling of engineered antibody fragment (cys-diabody) used in immunoPET. 
ImmunoPET, utilizing the specificity of antibodies, could provide additional phenotypic 
information regarding the presence or modulation of a lymphocyte-specific target, and 
has the potential to improve diagnosis, therapy selection, and patient stratification [279]. 
CD20 antigen expression on B-cell malignancies is an important  biomarker and 
therapy target, as evidenced by the clinical success of anti-CD20 monoclonal antibodies 
(mAbs) such as rituximab and obinutuzumab [280]. While radiolabeled full-length 
antibodies have been successfully used for PET imaging, their long plasma half-life and 
their therapeutic activity are disadvantageous for both prompt and repeated imaging. 
Zettlitz et al. previously developed CD20-specific immunoPET tracers using 
obinutuzumab (GA101) based antibody fragments radiolabeled with zirconium-89 (89Zr) 
or iodine-124 (124I) and showed antigen specific targeting of malignant and endogenous 
B cells in vivo [19].  
The smallest bivalent fragment, the cys-diabody (GAcDb, 55 kDa), presents a 
suitable compromise between tumor uptake (peak uptake 1-2 hr) and blood clearance 
(t1/2 = 2-5 hr) that aligns with the half-life of fluorine-18. 18F-radiolabeling of GAcDb could 
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enable same-day imaging and lower the patient’s radiation exposure compared with the 
longer-lived 124I and 89Zr. Here, we are exploring the site-specific conjugation of 
[18F]FBEM to GAcDb.  
 Site-specific radio-fluorination of diabody (GAcDb) with [18F]FBEM  
For site-specific radiolabeling, [18F]FBEM (330 MBq in 30 μL PBS) was incubated 
with reduced (10-fold TCEP, 2 h, 22°C) GAcDb (100 μg in 30 μL PBS) for 15 min at 
22°C. Excess prosthetic groups were separated from the conjugate using Micro Bio-
Spin size exclusion columns (Bio-Rad) pre-blocked with PBS, 1%FBS. Labelling 
efficiency and radiochemical purity were analyzed using ITLC strips (for monoclonal 
antibody preparation, Biodex Medical Systems) with saline as solvent (Wizard 3’ 1480 
Automatic Gamma Counter, Perkin Elmer).  
 
Figure 6-9. Schematic of site-specific conjugation using [18F]FBEM to the 
Cterminal cysteine residues (after mild reduction using TCEP) resulting in 
[18F]FBEM-GAcDb. 
 
SDS-PAGE analysis shows the unconjugated GAcDb migrating with an apparent 
molecular weight of approximately 55 kDa corresponding to the covalent homodimer 
(Figure 6-10, lane 1). Incubation with TCEP results in complete reduction of the solvent 
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exposed C-terminal disulfide bond and the visible band corresponds to the scFv 
monomer (MW 27.3 kDa) (Figure 6-10, lane 2). After TCEP removal (by size exclusion 
spin column) the GAcDb reoxidizes to its dimeric conformation within 24 hr (Figure 
6-10, lane 3). Incubation of the reduced GAcDb with [18F]FBEM and with TCEP present 
or with TCEP removed, leads to site-specific conjugation, blocks reoxidation of the cys-
tag and [18F]FBEM-GAcDb migrates as a monomer (Figure 6-10, lane 4, 5). 
 
 
Figure 6-10. SDS-PAGE analysis of site-specific conjugation (non-reducing 
conditions).  
GAcDb (lane 1), with TCEP (lane 2), reoxidized after TCEP removal (lane 3), conjugated with 
[18F]FBEM in the presence of TCEP (lane 4) or after TCEP removal (lane 5). 
 
 Microscale radiolabeling of diabody with [18F]FBEM 
As a proof-of-concept, microscale labeling of diabody was performed on the chip 
as shown earlier in Figure 6-6 with minor modification. First, [18F]FBEM was 
concentrated on the chip. Then, dried [18F]FBEM was re-dissolved by adding a 2 µl 
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droplet of PBS (1x, pH 7.4) and incubating for 1min. Then, 10 μL diabody solution (20 
μg in 10 μL, reduced with TCEP) was added for the room temperature conjugation.  
After 30min reaction, 50 µl PBS was added to quench the reaction. The crude product 
was extracted from the chip an analyzed via iTLC. Detailed reaction conditions and 
results are summarized in Table 6-3. From the iTLC results, we confirmed that 
successful conjugation occurs in the on-chip reaction as observed in conventional scale 
method where 100 µg diabody was used. However, large variation between chips was 
observed.  
In the future, we will systematically characterize this microscale radiolabeling, 
and potentially optimize the reaction conditions (e.g., reaction time, reaction volume, 
molar ratio of prosthetic group to protein, mixing parameters) to achieve higher and 
more repeatable labeling yield. 
 
Table 6-3. On-chip radiolabeling of GAcDb 
Chip Starting 
activity of 
[18F]FBEM 
(mCi) 
Protein 
volume 
(µl) 
Absolute 
protein amount 
(µg)  
Sample collection efficiency 
(% recovery from chip to 
collection vial) 
Crude labeling yield 
(%, based on iTLC) 
1 1.30 
10 
20 
(0.37nmol) 
84.07 5.47 
2 0.87 75.12 17.11 
3 0.16 
84.79 12.28 
100.00 37.75 
4 0.17 
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 Preclinical imaging: ImmunoPET/CT imaging, ROI analysis and 
biodistribution 
To investigate properties of this new diabody-based probe,  PET imaging 
(Inveon, Siemens) was performed under 2% isoflurane anaesthesia followed by a CT 
scan (MicroCAT, Siemens). For immunoPET imaging, mice were injected with 15 to 20 
μg (3.7-7.4 MBq) of [18F]FBEM-GAcDb. 1-2 hour dynamic PET acquisitions were 
followed by ten minute static scans at 2, 4 and 6 h post injection (p.i.). PET images were 
reconstructed using maximum a posteriori (OSEM MAP) algorithm and PET and CT 
images are presented as maximum intensity projection (MIP) overlays. As a 
comparison, the diabody conjugated to the most common prosthetic group, [18F]SFB, to 
form [18F]FB-GAcDB, was injected for imaging. 
For quantitation of the PET signal in specific organs, 3D regions of interest (ROI) 
were drawn and the mean voxel value was converted to %ID/cc ROI using the decay 
corrected injected dose and an empirically determined cylinder factor for F-18.  
[18F]FBEM-GAcDb (Figure 6-11) showed earlier (5 min p.i.) and higher target specific 
accumulation in the spleen peaking at 30 min p.i. followed by a steady decrease of the 
radioactivity signal compared to [18F]FB-GAcDB. The signal in the heart (estimating the 
activity in the blood pool) decreased visibly from 10 min p.i. on, indicating a more rapid 
blood clearance compared with [18F]FB-GAcDb. Similar to [18F]FB-GAcDb, the site-
specifically conjugated [18F]FBEM-GAcDb showed primarily renal clearance with activity 
visible in the kidneys after 10 min and in the bladder at 30 min p.i. (Figure 6-12). 
Approximately 60 min p.i. activity started to become visible in the gastrointestinal (GI) 
tract and 2 hr p.i. accumulation of radiometabolites in the gall bladder (GB) suggest a 
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secondary hepatobiliary clearance route. It indicates that the [18F]FBEM-GAcDb is not 
fully stable in vivo and its metabolites have distinctive excretion route.  
 
Figure 6-11. ImmunoPET imaging of hCD20 transgenic mice shows antigen 
specific retention in the spleen 
 [18F]FBEM-GAcDb immunoPET, 4.3 MBq/12 μg. Primarily renal clearance (kidneys, K) and 
excretion into urine (bladder, B) is visible. Increased gallbladder (GB) and GI tract activity 
suggests secondary excretion of radiometabolites through the hepatobiliary system. 
 
 
Anti-CD20 immunoPET tracer, [18F]FBEM-GAcDb, successfully visualized the 
normal tissue distribution of hCD20 in spleen and lymph nodes (rescaled images in 
Figure 6-12). Notably, the smallest (popliteal) lymph nodes visible in the immunoPET 
scans, are only about 1 mm3 in size. Although the signal in the spleen at 4 hr p.i. is 
comparable between the two tracers, the remaining activity in the intestines for 
[18F]FBEM-GAcDb obstructs the view of the abdominal area.  
In conclusion, we have confirmed that [18F]FBEM-GAcDb shows specific 
targeting of hCD20 B cells and optimized pharmacokinetics to enable same-day 
imaging. 
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Figure 6-12. ImmunoPET imaging using [18F]FBGAcDb and [18F]FBEM-GAcDb, 4 h 
p.i.  
Specific spleen and lymph node uptake are visible. The secondary secretion route of 
radiometabolites through the hepatobiliary system is indicated by the high signal in the gallbladder 
(GB) and the intestines (GI) and excretion of radioactivity with feces. Scans are depicted as 
microPET/CT overlay, whole body MIP. Black arrows indicate the location of the 2 mm transverse 
section shown in the lower panel. 
 
 Future directions 
As we successfully demonstrated the site-specific radiolabeling of a peptide and 
a protein, we can now explore the use of microscale reactions to minimize the precursor 
(biomolecule) consumption while also maximizing labeling yield.   
Additionally, we will investigate the effective molar activity of labeled proteins in 
microscale radiolabeling. As the isolation of labelled protein molecules from the non-
labeled proteins is usually not feasible due to the chemical similarity of the labeled and 
non-labeled proteins, the effective molar activity is defined as the ratio of the mass (or 
molar quantity) of a single species radiotracer to the total of the radiotracer and non-
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radioactive compound that have similar biochemical properties. It is expected that the 
effective molar activity of labeled proteins would increase in our microfluidic approach if 
the amount of protein can be reduced compared to conventional methods. Radiolabeled 
protein probes with higher effective molar activity are expected to show better 
visualization of targets in vivo, especially for saturable binding sites. 
 One potential problem of on-chip conjugation that might be encountered is 
adhesion of proteins to the chip surface that could make the protein unavailable for 
reaction, or could make it difficult to remove labeled proteins from the surface. If 
needed, surface passivation techniques, or alternative surface materials will be 
considered. 
In the future, in addition to the thiol-maleimide site-specific reaction, we will 
explore other bio-orthogonal labeling methods such as “Click” chemistry for on-chip 
radiolabeling. One potential candidate is an aromatic 18F -PEG-Azide compound. 
Sachine et al. have explored the copper-free strain-promoted alkyne azide cycloaddition 
(SPAAC) click reaction and shown highly efficient labeling yield of RGD peptide, 92% 
(decay-corrected), and the reaction was performed in aqueous solvent for 20 min 
reaction at room temperature [281]. Furthermore, more recently introduced sydnone 
cycloadditions can also be explored [282], [283].   
If a robust radiolabeling platform is established, the next step is to automate the 
system. A fully automated microfluidic radiolabeling system for biomolecules would 
significantly lower the radiation exposure to operators, lower the degree of skill needed 
to perform labeling, and substantially lower the labeling cost making it more accessible 
to investigators. 
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7. Chapter 7: Electrodewetting microfluidic droplet manipulation 
Summary:  
The ability to manipulate liquid droplets on substrate with only electric signals 
[284]gave birth to digital microfluidics, which has found applications from optical [285], 
[286] and biomedical [270], [287] to thermal [288] and electronic [289], including 
commercial [290]–[292].  For many such electrical actuations, especially electrowetting-
on-dielectric (EWOD)[293], [294], a liquid drop is attracted towards and spread on a 
conductive substrate covered with a dielectric layer and a hydrophobic topcoat. While 
credited to make electrowetting practical, these added layers are responsible for the 
relatively high actuation voltage (20-200 V) and reliability issues such as dielectric 
breakdown [295], electric charging [296], and biofouling [297]. Here we report “electro-
dewetting” that acts in an opposite manner to electrowetting, i.e., electrically repels a 
droplet on substrate effectively enough to support digital microfluidics. This surfactant-
mediated mechanism uses a hydrophilic surface, eliminating the issues originating from 
the added layers. This study investigates the underlying mechanism and operating 
characteristics of nd to manipulate droplets on substrate in air. Using only ±2.5 V and a 
few µA, electrodewetting is demonstrated to generate, move, split, and merge water 
droplets on silicon in open air. The compatibility is further validated with a variety of 
liquids, including common buffers and organic solvents. Despite the required use of 
surfactant, electrodewetting shows a great promise for microscale liquid handling 
platform that is extremely simple and highly reliable.  
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 Introduction: Electrowetting and EWOD vs. Electro-dewetting  
As an elegantly simple platform technology for microfluidics, electrowetting (more 
specifically electrowetting-on-dielectric (EWOD) [293], [294]) has enjoyed exponential 
advancement during the past 15 years and has culminated in many commercial 
applications [290]–[292]. Despite the success, however, EWOD devices are well known 
to suffer from reliability problems, which are predominantly associated with the dielectric 
layer and hydrophobic topcoat [295]–[297]. First, since the electric double layer (EDL) 
can sustain only a small voltage (e.g., < ~1V) between the liquid and substrate and the 
electrowetting force generated by the small voltage is too weak for most applications, a 
dielectric layer is added on the substrate (hence the term EWOD [294], [298], [299]). 
Since the voltage applicable on a given dielectric material is proportional to the 
thickness and the electrowetting force is proportional to the voltage squared [294], 
[299], one would prefer a reasonably thick dielectric to make the EWOD devices more 
robust (especially important for commercial product) despite a relatively high voltage 
required. However, since deposition of a defect-free thin film is challenging, especially 
across the relatively large area of some devices, the dielectric layer often experiences 
electric leakage or even breakdown [295], resulting in the notoriously well-known device 
failure by electrolysis27. Second, the top surface needs to be hydrophobic so that a 
droplet is naturally dewetted on it and has a sufficient room for significant induced 
wetting by electrowetting. However, since most materials, including the added dielectric 
layer, are hydrophilic, a low-energy material is coated on top to render the final surface 
hydrophobic. Unfortunately, this hydrophobic topcoat, e.g., polytetrafluoroethylene 
(PTFE), is susceptible to charging under electric field[296] and prone to protein 
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fouling[297], not to mention its material and deposition costs. Despite the associated 
problems, the dielectric layer and hydrophobic topcoat (i.e., EWOD) were the critical 
advances that made the once-obscure concept of electrowetting practical for 
applications, leading to the digital microfluidics of today.  
Here, we expect electrodewetting to be a mirror opposite of the well-known 
electrowetting with comparable effectiveness. While most of the electrically-induced 
dewetting phenomena were not effective for common microfluidics because they are 
based on irreversible processes [300], [301] or special conditions [302], studies involving 
surfactants have shown that reversibility may be possible. For example, electrically-
initiated dewetting of an aqueous film on derivatized gold electrodes has been 
demonstrated using redox-active surfactants [303]. Recently, by using ionic surfactants, 
the coefficient of a lubricated friction was switched in a solid-liquid-solid configuration 
[304], and boiling bubble nucleation was modulated in a liquid-vapor-solid system [305]. 
Furthermore, an organic droplet was translated on a conjugated polymer electrode in an 
aqueous electrolyte [306]. However, they have not led to a microfluidic platform 
technology, which would require an electric actuation that is reversible, repeatable, 
strong, and easily applicable to a liquid-fluid-solid system [298]. In fact, we could not 
obtain electrodewetting with aqueous droplets containing ionic surfactants on either bare 
metal electrodes [304], [305] or the dielectric-coated conductive substrate of EWOD.  
Instead, we have discovered that a bare silicon wafer does the trick by letting its 
native oxide resistively pass the electric current as well as providing a very hydrophilic 
surface. An expected consequence for this electrodewetting is that, with neither the added 
dielectric layer nor the hydrophobic topcoat, the reliability problems of EWOD can be 
avoided, not to mention the device simplification and cost reduction. 
 
 Electrodewetting: Novel droplet actuation 
The electrodewetting mechanism would be impactful for microfluidic applications 
only if the wetting and dewetting states have a significant difference to induce a strong 
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actuation, the transition between the two states is reversible, and the mechanism is 
realized in a simple device configuration. The electrodewetting was found to induce the 
contact angle difference between the two states that is large enough (e.g., > 20°, the 
contact angle hysteresis on common materials) to incite strong-enough fluidic 
actuations; reversibly switches over 10,000 cycles with no apparent degradation; and 
demonstrated in an extremely simple configuration.  
When an electrodewetting test similar to this study was tried with water on a gold 
surface, we did not observe the appreciable contact angle change found on the silicon 
surface. We believe water, which has 60-65° of contact angle on gold surface [307] is 
not hydrophilic enough for effective electrodewetting. As matter of fact, gold was used 
as a hydrophobic metal when electrowetting was explored for microfluidics before 
EWOD took its place [299]. After testing many surfaces, our experience indicated that a 
hydrophilic surface with contact angle < 25° is desired to perform effective 
electrodewetting on. This is a stark contrast to electrowetting and EWOD, which 
requires a hydrophobic surface with contact angle typically > ~100°. While 
electrodewetting uses an electric field formed inside a droplet to manipulate the 
adsorption of ionic surfactant molecules on the solid surface, electrowetting (i.e., 
EWOC) and EWOD use an electric field formed across EDL and the dielectric layer, 
respectively.  
Some other approaches: There have been interesting advances in recent years 
to achieve effective electrowetting without the dielectric and hydrophobic layer. One 
approach is to use special surfaces (e.g., the basal plane of highly oriented pyrolytic 
graphite) with an extremely low contact-angle hysteresis. One can achieve a large 
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contact-angle change on such a pinning-free surface using the conventional 
electrowetting [308]. Often called electrowetting-on-electrode (EWOC) to distinguish it 
from EWOD, this approach is attractive for its use of low voltages (~1 V). However, the 
actual electrowetting force is likely too small to overcome disturbances, such as gravity, 
vibration, and imperfections, which are bound to be encountered in realistic conditions. 
Another approach is to immerse the droplet in a second liquid and thus dramatically 
reduce the contact-angle hysteresis. Applicable to both EWOC and EWOD, this 
approach uses a much voltage than EWOD in air. With this two-liquids approach, one 
can further utilize surfactants to decrease the contact angle of the filler liquid, thus 
increasing the contact angle of the droplet and enhancing electrowetting effect35 and 
facilitate specific applications[309]. A related approach is to replace the dielectric 
coating with the native oxide of a liquid-metal electrode [310], making the device robust 
both for fabrication and usage. However, this approach also works in a two-liquid 
system, as it needs a low hysteresis and the help of oil-based surfactant. It is to be seen 
if any of the new approaches will show the level of effectiveness EWOD has enjoyed 
despite the reliability issues. 
 Mechanism of electrodewetting  
To study the electrodewetting mechanism and characterize its behavior, we 
adopted the configuration popular for electrowetting studies, as shown in Figure 7-1. An 
elaborate setup was developed for accurate experimentation, as detailed in Figure 7-3. 
The droplet contains an ionic surfactant, which consists of a charged hydrophilic “head” 
group and a neutral hydrophobic “tail” region. Depending on the polarity applied and the 
type of surfactant, the electric field inside the conductive (resistive) liquid drives the ionic 
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surfactant molecules towards or away from the liquid-solid interface, making the drop 
dewet the surface (Figure 7-1a) or wet it again (Figure 7-1b). An exemplary result 
shown Figure 7-1c&d used a decyltrimethylammonium bromide (DTAB) solution on a 
highly doped (i.e., conductive) silicon wafer, chosen for its smooth surface and native 
oxide (2-10 Å thick) that is highly hydrophilic (water contact angle < 10°). To assess the 
proposed mechanism, we have performed a separate experiment using a droplet 
containing a fluorescent cationic surfactant, as detailed in 7.5.3. The fluorescent 
intensity on two surface regions – region I (always inside droplet) and region II (outside 
droplet during electrodewetting but inside during wetting) – are overlaid on Figure 7-1c 
&d.  The higher fluorescent level on I.C than I.D supports the illustration of Figure 
7-1a&b for region I. For region II, the much higher fluorescent level on II.C than II.D 
confirms that the retraction of the contact line by electrodewetting leaves a significant 
amount of surfactant on the substrate right outside the droplet. It also shows that these 
adsorbed surfactant molecules are removed from the surface as the contact line 
advances during wetting, further corroborating the proposed mechanism and explaining 
its reversibility.  
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Figure 7-1. The surfactant-mediated electrodewetting mechanism proposed and 
studied with a wire-inserted sessile drop on a conductive, hydrophilic substrate. 
a, For electrodewetting, the electric field inside the liquid between the substrate and wire, 
established by the small current across a thin oxide (purple line) and through the liquid 
(blue), draws the ionic surfactant molecules (cationic surfactant is shown) onto the liquid-
solid interface, making the droplet dewet (bead up on) the substrate. b, For wetting by 
active recovery, the opposite electric field by the reverse current removes the ionic 
surfactant away from the surface, making the droplet wet (spread on) the substrate. For 
most cases, wetting is also possible by passive recovery, i.e., simply removing the electric 
signal. c, d, Electrodewetting experiment corresponding to (a) and (b), respectively, with 
a DTAB-containing aqueous droplet (~3 µL, pH ~7) on bare silicon (with native oxide) 
using ±3 V with ±3 µA. The surfactant concentrations on two different regions (I, II) of the 
substrate surface, obtained in a similar but separate test using a fluorescent cationic 
surfactant, corroborate the proposed mechanism.  
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Figure 7-2. Switching between electrodewetting, neutral, and actively-recovered 
wetting state experimentally confirmed for droplets containing DTAB (cationic 
surfactant) and SDS (anionic surfactant) on a bare silicon wafer.  
The working mechanisms are proposed by schematically illustrating surfactant molecules and 
surface charges. 
 
Based on our current finding, current is essential and electrodewetting depends 
on the current. We reason that ionic surfactant requires electric field across the droplet 
to be migrated onto the surface and the migration of charged particles results in current. 
If we assume 3 µA of current, which would consume 1.12x10-7 mole electrons per hour, 
it would take ~150 hours to consume 10% of a 3 µL droplet. Considering EWOD 
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actuation duration in typical tasks take less than an hour in most microfluidic 
applications, we expect the Faradaic reaction to be negligible for most cases. We have 
performed experiment using thicker (100 nm, thermally grown) oxide. 0-100 V were 
applied while monitoring the current. We did not observe electrodewetting effect before 
the 100 nm oxide broke down at ~100 V but observed electrodewetting after the break 
down. This result experimentally supports the currently understood mechanism.  
 
 Methods 
 Silicon wafer preparation 
For the electrodewetting characterization in this study, we prepared bare silicon 
wafer in the following manner: piranha clean with 3 parts of 98% sulfuric acid and 1 part 
of 30% hydrogen peroxide at 110 °C for over 10 min; DI water rinse for 10 min; spin dry; 
bake on a hot plate at ~450 °C for 15 min to remove excess water and OH- groups40 
for a consistent hydrophilicity. This process was used for all wafers including new 
wafers, i.e., directly out of a factory-sealed package, to ensure all characterization 
experiments are done on bare silicon of an identical surface condition. 
 Contact angle measurement  
 The test setup with the accuracy and repeatability needed to study and 
characterize electrodewetting is schematically shown in Figure 7-3. To induce 
electrodewetting, a platinum (to avoid oxidation and reduction) wire (100 μm diameter) 
was inserted vertically into a sessile drop on a conductive (p++, resistivity < 0.005 ohm-
cm) silicon wafer (4 inch diameter). Two cameras (Point Grey FL3-U3-13Y3M-C CCD 
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with GO® Edmund VZM™ 200i Zoom Imaging Lens), each mounted on an independent 
XYZ stage, were used to record the droplet side views, from which contact angles were 
obtained using ImageJ with DropSnake plugin38 or an in-house code to assist 
measuring very low contact angles (< 10). The wafer was placed on an XY stage, and 
the wire was attached to a separate Z stage.  Before each test, the wire was rinsed in DI 
water to remove the surfactant left from the previous test. After pipetting a droplet (~3 
μL) of surfactant solution onto a fresh wafer, we adjusted the XY stage to center the 
droplet right below the wire. We then lowered the Z stage to insert the wire into the 
droplet until the tip of the wire was ~85 μm above the substrate for all tests. The 
orthogonal views of the droplet by the two cameras were used to assist the user 
positioning the droplet and wire and later measuring the contact angles. A source 
measure unit (Keithley 2425 SourceMeter®) was used to apply voltage and monitor the 
current between the wire and substrate. All the stages were fixed on a vibration-isolation 
plate to obtain stable images, and all experiments were performed in a Class 1000 
modular cleanroom (Terra Universal 12’x8’ Class 1000 Modular Clean Room) to 
minimize contamination of the fresh silicon surface by the ambient air.  
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Figure 7-3. Contact angle measurement setup with a wire-droplet system for the 
current study.  
The silicon substrate sits on an XY positioning stage; the wire electrode is attached to a Z 
positioning stage; and two cameras, each mounted on their own XYZ stage, view two orthogonal 
sides of the droplet. Drawn not to scale for clarity. All the stages are fixed on a vibration-isolation 
plate inside a Class 1000 modular clean room. 
 
 Characterization 
 Avoiding the autophobing effect   
The degree of observed electrodewetting may be complicated by the 
“autophobing” effect [311], which refers to the spontaneous dewetting of a sessile 
droplet as a result of electrostatic attraction of ionic surfactant to the intrinsic surface 
charge [312]. Studies showed that adsorption of ionic surfactants on solids can be 
altered by controlling pH [312]–[314]. On the bare silica surface, increasing pH leads to 
deprotonation of silanol groups and increase negative surface charge. Under these 
conditions, cationic surfactants (e.g. CTAB) are increasingly attracted to the surface the 
higher the pH, resulting in increased amount of autophobing. To reduce autophobing to 
enable study of the electrodewetting effect in isolation, the pH can be lowered. There is 
little surface charge below pH ~6, and negligible charge below pH 2. For anionic 
 188 
surfactants, e.g. SDS, there can be some intrinsic adsorption due to hydrophobic 
interactions, but this can be minimized via increase in pH which leads to electrostatic 
repulsion. Autophobing was absent at pH 2.3, and the contact-angle change (purely by 
electrodewetting actuation) at pH 2.3 was smaller than those at pH 11.2 and 6.5, where 
autophobing effect exists. The use of a low-pH solution enabled us to study 
electrodewetting with minimal interference by autophobing. 
 Electrodewetting of various liquids  
The above fundamental study and microfluidics demonstration were performed 
using well-controlled water (i.e., low salt concentration) solutions on identically-prepared 
bare silicon surfaces for scientific rigor. Next, we have explored the validity of 
electrodewetting for a variety of liquids: two buffer solutions widely used for biological 
applications – phosphate-buffered saline (PBS) and 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES); two common organic solvents used in chemistry 
applications –  acetonitrile and dimethyl sulfoxide (DMSO); and ethylene glycol. 
Although the degree of effectiveness varied as shown in Figure 7-4, electrodewetting 
was found to work for all the tested liquids. We adopted the working liquids in only their 
typically used conditions in order to assess the utility, leaving more complete 
characterization of each liquid for future studies. The successful results with these five 
additional liquids suggest the versatility of the proposed electrodewetting, opening the 
door for a wide range of application areas.        
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Figure 7-4. Electrodewetting confirmed for a variety of liquids on bare silicon.  
DI water (Fig. 1) is included as a reference. For PBS and HEPES, we added DTAB to a 
concentration of 0.15 mM and obtained ~9° and ~6° of contact-angle changes, respectively, using 
±5 V. In the cases of ethylene glycol, acetonitrile, and DMSO, we added DTAB to a concentration 
of 20 mM and obtained ~40°, ~15°, and ~60° of contact-angle changes, respectively, using ±3 V. 
 
 
 Better understanding of electrodewetting using fluorescent surfactant 
To visualize the proposed underlying mechanism of the electrodewetting in 
Figure 7-1, we have performed a separate experiment using a droplet containing a 
fluorescent cationic surfactant found to exhibit electrodewetting behavior similar to 
(albeit less controllably than) other cationic surfactants used in this study. By blowing 
the droplet away during dewetting and wetting states (equivalent to Figure 7-1c and d, 
respectively) and imaging the resulting dry surface with a fluorescence microscope, we 
were able to compare the level of surfactant adsorption onto the substrate surface 
during the two states. The level of surfactant adsorption is expressed as the fluorescent 
intensity, following the color bar on the right end of Figure 7-1. The fluorescent cationic 
surfactant solution was prepared by dissolving 10 mg of R18 (octadecyl rhodamine B 
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chloride, ThermoFisher Scientific, Waltham, MA, Figure 7-5) in 1 mL of dimethyl 
sulfoxide (DMSO, Sigma Aldrich) and further diluting with DI water to 0.2 mM. The result 
was an aqueous solution with ~1.5% DMSO v/v. The pH was adjusted to 2.3 by adding 
hydrochloric acid (37 wt%). 
 
Figure 7-5. Structure of fluorescent surfactant, octadecyl rhodamine B chloride 
(R18).  
Amphiphilic fatty acid contains hydrophobic “tail” and charged hydrophilic “head” with a 
fluorophore. Molecular formula: C46H67ClN2O3 (“R18”), Molecular weight: 731.5 
 
 
 A droplet containing R18 showed an apparent autophobing on the silicon 
surface: upon dispensing onto a fresh silicon substrate, the droplet moved around for a 
few seconds. To account for this, the wire was inserted into the droplet as soon as it 
stopped moving. For the color lines I.D and II.D in Figure 7-1d, we applied reverse 
electrodewetting (-5 V to the wire) for 10 seconds, and then the wetting droplet was 
physically blown away, using a compressed air duster, while the voltage was still on. 
The air flow was roughly horizontal on the substrate from the duster tip 
positioned ~1 cm away from the droplet center. Immediately after blowing the droplet 
away, fluorescent images of the substrate surface were taken where the droplet had 
been located. For the color lines I.C and II.C in Figure 7-1c, we applied 
electrodewetting (5 V to the wire) for 10 seconds after reverse electrodewetting (-5 V to 
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the wire) for 10 seconds and gently blew the dewetted droplet away while the 
electrodewetting (5 V to the wire) was on. We used an inverted fluorescent microscope 
(Zeiss Axio Observer Z1 with ORCA Flash 4.0 CCD camera, 20x magnification, 2 
second exposure, DSRED filter) to acquire the fluorescent images on the substrate 
surface. 
7.5.3.1 Reverse voltage for more repeatable and efficient actuation  
Electrodewetting tests with a fluorescent amphiphilic fatty acid surfactant R18 
(used in Figure 7-1) are elaborated to explain the surfactant clean-up process during a 
recovery-to-wetting step by reverse voltage after electrodewetting. Unlike a sessile 
droplet containing a regular ionic surfactant, a sessile droplet containing R18 
electrodewetted and recovered to wetting with poor axisymmetry and repeatability. The 
droplet moved around despite the wire, and the contact line did not recede (dewet) and 
advance (wet) around a fixed central position on the surface when repeated. Thus, in 
Figure 7-6 we show only three steps towards three states: reverse actuation (Step 1) 
actively recovered the droplet to a wetting state (State 1); electrodewetting actuation 
(Step 2) electrodewetted the droplet to a dewetting state (State 2); reverse actuation 
(Step 3) actively recovered the droplet to another wetting state (State 3). The droplet 
containing R18 exhibited severe autophobing compared with the droplets containing the 
other surfactants used in this study (DTAB, TTAB, CTAB, and SDS). The severe 
autophobing, which apparently caused the poor axisymmetry and repeatability above, 
might be explained by the high hydrophobicity and low solubility of R18, resulting from 
the hydrophobicity of both its hydrocarbon “tail” and the bulky fluorescent group near the 
“head” region. Therefore, even if there was not much electrostatic interaction between 
 192 
the substrate and the cationic “head” of R18 at pH 2.3, where autophobing was not 
found for the case of DTAB, there could be a tendency for excess R18 molecules at the 
interfaces (especially near the triple-contact line), “propelling” or pushing the droplet 
around. Despite the limitation, the fluorescent intensities shown at the bottom of Figure 
7-1 indicates the reverse actuation (Step 3) was effective in cleaning up the surfactant 
molecules left outside the droplet during the preceding dewetting (Step 2). Despite the 
poor electrodewetting performance with R18, this three-step exercise nevertheless 
helps explain how the reverse actuation assists returning an electrodewetted surface 
back to the natural, wetted state. 
 
Figure 7-6. Surfactant concentration on substrate surface during electrodewetting 
and reverse electrodewetting revealed by a blow-off test.  
A water droplet with ionic fluorescent surfactant was electrically actuated to wet, dewet, and wet 
the surface successively, as illustrated in the three sideview schematics (top portion of the figure). 
The top-view fluorescent image (bottom right) reveals the surfactant molecules left on the 
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substrate surface after the droplet was blown away while actuation was on. The fluorescent image 
is color-enhanced. The surface outside the droplet has a high concentration of surfactant due to 
autophobing after the droplet was initially placed on the fresh surface. Step 1 lets the droplet wet 
the surface, i.e., natural state, by applying reverse electrodewetting. The contact line advances 
to the black dashed line drawn in the sideview schematics, corresponding to the black arrow in 
the fluorescent image. Step 2 lets the droplet dewet the surface by applying electrodewetting. The 
contact line retreats to the green dashed line drawn in the sideview schematics, corresponding to 
the green arrow in the fluorescent image. Step 3 lets the droplet wet the surface again by applying 
reverse electrodewetting. The contact line advances to the red dashed line drawn in the sideview 
schematics, corresponding to the red arrow in the fluorescent image. 
 
7.5.3.2 Confocal imaging  
To better visualize the distribution of surfactant within the droplet under the 
influence of an applied electrical field, we also explored confocal fluorescence 
microscopy. 3 µl of 0.2 mM R18 (dissolved in DI water) was placed on Si wafer (Figure 
7-7A). Using a X-Z scanning mode (line scanning along z-axis, optical sectioning 
thickness: 0.992 µm), images of the droplet were recorded with an inverted confocal 
microscope (SP8-SMD, Leica, Wetzlar, Germany). When there is no voltage applied, 
the majority of R18 molecules (i.e. brightest area in the image) was observed near the 
droplet-air interface (Figure 7-7B).  When the voltage was applied, however, a higher 
intensity of fluorescent signal was observed near the droplet-substrate interface. This is 
consistent with the hypothesis that applied voltage leads to migration and adsorption of 
cationic surfactant to the surface, while removal or reversal of voltage allows the 
surfactant to diffuse away from the interface.  
We noticed that continuous vertical movements of the microscope stage during 
the X-Z scanning mode caused significant vibration of the droplet, potentially leading to 
mixing in the droplet. Further study using 3D confocal microscopy and confocal 
microscopy over a larger fraction of the droplet in the future could lead to additional 
insight and clarification about the distribution of the surfactant, especially if such 
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imaging could be performed in real-time as the droplet was actuated between wetting 
and dewetting states.   
 
Figure 7-7. Confocal imaging of fluorescent droplet 
(A) Chip setup for confocal imaging: 3 µL R18 droplet placed on Si wafer, (B) Snap shots of X-Z 
scanning (stacking) showing the distribution of surfactants with the presence of applied voltage.  
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 Demonstration of droplet manipulation on digital microfluidic chip 
7.6.1.1 To assess the potential for sophisticated digital microfluidic applications, we 
have developed an electrodewetting device. Using proper actuation sequences 
and 0.2 mM DTAB solution, we have achieved droplet generation, 
transportation, splitting, and merging. Although pH 2.3 solution was used for 
Figure 7-8, any pH level works for electrodewetting. Building blocks for more 
complex microfluidic protocols for applications, these basic droplet logic 
operations were successfully obtained in air, i.e., without the help of the 
commonly-used filler oil, on an open device, i.e., without using a cover plate. 
While in-air operations are more difficult than in-oil but still possible, open-
device operations of generating or splitting droplets is not possible with EWOD. 
Furthermore, the droplets were transported (Figure 7-8b) in a speed 
comparable to EWOD despite the 10-100 times slower actuation observed 
during sessile drop tests. This unique performance of electrodewetting suggests 
its microfluidic operation comparable to EWOD in addition to the inherent 
reliability.    
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Figure 7-8. Droplet generation, transportation, and splitting realized by 
electrodewetting. 
Water droplets are operated in air on a silicon device with no cover plate, using ±2.5 V (or 0 and 
5 V). Images were captured from Video 4 and enhanced by coloring the liquid portions. a, 
Sequential images of a small (~0.2 µL) droplet generated from a reservoir droplet (~3 µL). a-1, 
The added black lines indicate the large electrodes underneath the reservoir. a-2, Dewetting the 
third reservoir electrode from left results in necking of the reservoir droplet. a-3, A droplet is 
generated on the two small electrodes to the right of the reservoir. b, c, Four sequential images 
showing droplet transportation and splitting. Along with a and merging (not shown), they establish 
the basis for digital microfluidics.  
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